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This thesis documents research that investigated whether class switch recombination 
and somatic hypermutation occur locally in the nasal mucosa of allergic rhinitis 
patients. AnalysisOfVHregion sequences from the nasal mucosa demonstrated families 
of related IgE+ B cell clones, exhibiting identical signature region sequences and both 
shared and differing VH region mutations. VH region sequences from IgE' B cells 
isolated from adjacent pieces of allergic nasal mucosa demonstrated that members of an 
IgE' B cell clonal family present in, for example, one half of a nasal biopsy, could not 
be detected in the other half VH region sequences were also detected from IgA' B 
cells, related to an IgE' B cell clonal family. 
These observations, strengthened by the presence of mRNA encoding AID, support the 
concept of local class switch recombination, somatic hypermutation and clonal 
expansion in the allergic nasal mucosa. Furthermore, the VH5 class of genes was over- 
represented in sequences isolated from nasal mucosa. IgE' B cells. In combination with 
unusual non-intrinsic hotspots of mutation in the VH5 sequences, this was suggestive of 
local selection of some IgE_' B cells by aB cell superantigen in the allergic nasal 
mucosa. 
It is therefore suggested that in allergic rhinitis, the nasal mucosa is an organised 
microenvironment in which local class switch recombination, somatic hypermutation, 
clonal expansion and antigen selection occur, optimising the efficacy of the local 
allergic response. 
This thesis is dedicated to the memory of my father Peter Coker, who 
could not have given me more love and support. 
(1947- 2003) 
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1.1 An introduction to allergy. 
Allergic disease has become of increasing concern to developed countries, where the 
incidence of allergy can be so great that a quarter of children under fourteen suffer from 
asthma [Beasley, 1998]. While strictly an allergic reaction can result from several 
different mechanisms, the term 'allergy' usually refers to type I hypersensitivity, 
mediated by antibodies of the immunoglobulin E (IgE) isotype. It is this definition of 
allergy that will be used in this thesis. Allergy may manifest as a variety of diseases 
from which a patient may suffer with single or multiple forms, allergic rhinitis, allergic 
asthma and allergic dermatitis being the most common. In all allergic disease, IgE- 
mediated hypersensitivity is a consequence of the interaction of allergen with IgE. 
Allergens originate from a huge variety of different origins and cannot be identified by a 
single common property [Gould et al., 2003]. A patient may be allergic to single or 
multiple allergens. 
Allergy is a multifactorial disease, contributed to by both genetic and environmental 
factors. There are multiple genetic markers for allergy, including particular HLA-DR 
alleles, polymorphisms of FcsRI (the high affinity receptor for IgE) and polymorphisms 
in interleukin-4 (EL-4). The cumulative effects of the different genetic markers for 
allergy result in a less than 15% chance of a child with non-allergic parents developing 
atopy (a clinical predisposition to allergy), while if one parent is allergic there is nearly 
a 30% chance, and if both parents are allergic the likelihood is increased to more than 
50% [Roitt et al., 1996], 
Even if a subject has inherited a predisposition towards atopy, environmental factors 
may be important in determining if they develop clinical symptoms, i. e. if they are 
allergic. Environmental pollutants are thought to exacerbate allergic disease and diesel 
exhaust particles, for example, have been shown to increase production of IgE detected 
in nasal lavage fluid from human subjects [Diaz-Sanchez el al., 1994]. 
Exposure to both bacteria and allergens can also influence the development of atopy. A 
bias towards TH2 cells and away from the THI cell type necessary in the immune 
response against bacteria, is characteristic of allergy. The essential role of TH2 cells in 
allergy is described in greater detail in section 1.3, but it has been suggested that while 
it is usual for the foetus to exhibit a TH2 bias, after birth, exposure to bacterial antigens 
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results in the development of a TH I biased repertoire of cells. In Westernised countries 
it has therefore been hypothesized that the decreased exposure of neonates to bacteria 
results in the maintenance of the TH2 bias, particularly in children with atopic parents 
[reviewed by Kay, 2001]. Exposure to high levels of allergen, such as that from house 
dust mite, is also far more common in Westernised society [reviewed by Kay, 2001]. 
1.2 Allergic rhinitis. 
Allergic rhinitis is the manifestation of allergic disease in the nose. Patients suffer from 
sneezing, itching, rhinorrhea and nasal obstruction [reviewed by Kay, 2001b]. Rhinitis 
is not always allergic in origin and so, as with other allergic disease, is determined on 
the basis of both a positive skin-prick test and also elevated allergen-specific serum IgE 
(determined by radioallergosorbency test (RAST)) [Ying el al., 200 1 ], combined with a 
clinical history of rhinitis symptoms, for diagnosis. Only such conventional allergic 
rhinitis patients were included in the research presented in this thesis. However, some 
patients, while displaying classic symptoms of allergic rhinitis, exhibit both negative 
skin-prick test and RAST results. It has been suggested that these patients, known as 
non-atopic rhinitics (or intrinsic rhinitics), suffer either from an allergy towards an 
unidentified allergen, or that the allergic response is confined solely to the nasal mucosa 
[discussed by Kay, 2001b). 
Allergic rhinitis can occur as both a seasonal and / or perennial disease. In the 
temperate northern hemisphere, seasonal rhinitis is usually a consequence of either tree 
(in spring), or grass (in summer) pollen allergy. In contrast, perennial rhinitis patients 
are sensitive to allergens such as house dust mite or animal dander, present throughout 
the year. 
In the nose there are three nasal turbinates in each nostril, the inferior, middle and 
superior. These are situated on the opposite wall of the nose to the septum (Fig. 1.2.1). 
The nasal turbinates contain a high concentration of immune cells and as a consequence 
are often swollen, especially in perennial allergic rhinitis patients [Mygind el al., 1996). 
Research conducted into allergic rhinitis often relies on analysis of the nasal mucosa of 
the inferior turbinate (being the nearest to the entry point of aeroallergens to the nose). 
Samples of the inferior turbinate are most commonly obtained by nasal biopsy, although 
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when allergic rhinitis results in very severe nasal obstruction, surgical removal of the 
whole inferior turbinate is an extreme solution. 
ST 
MT 
Fhq. 1.2.1, The position of the inferior, middle and superior turbinates in the nasal ca 
[adapted from My-qind et A. 19961. The site of the inferior (IT), middle (MT) and superior (ST) 
turbinates on the opposite side of the nasal cavity to the septum are detailed. 
1.3 The mechanisms of IgE-mediated hypersensitivity. 
IgE is produced by plasma B cells and is known to occur locally in the nasal mucosa of 
allergic rhinitis patients [Smurthwaite et al., 2001 ]. Allergen-specific IgE is produced 
locally throughout the year, even in seasonal allergic rhinitis patients [Smurthwaite et 
al., 2001 ]. IgE has two receptors to which it can bind with either high (FcP_RI), or low 
affinity (FcF. RII, also known as CD23). CD23 is present both as a surface-bound and 
soluble molecule and is involved in complex feedback mechanisms controlling IgE 
synthesis [reviewed by Gould et al., 2003]. In contrast, the high affinity receptor FcCRI, 
has a direct role in mediating the symptoms of allergy. 
Allergen cross-links specific IgE, bound to the surface of mast cells by FcFRI in allergic 
tissue (and importantly for systemic anaphylaxis, also on basophils in the circulation), 
(Fig. 1.3.1). Crosslinking triggers mast cell degranulation to release histamine, 
cytokines, proteases, membrane-derived lipid mediators (leukotrienes and 
prostaglandins) and platelet-activating factor. These are responsible for the symptoms 
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of allergy and in combination with cytokines generated by TH2 cells, attract 
inflammatory cells including macrophages and eosinophils that help constitute the late- 
phase response of allergic inflammation. In contrast to immediate hypersensitivity that 
is initiated within minutes, this late phase response induces symptoms six-nine hours 
after exposure to allergen [Kay, 2001b], The degranulation of mast cells in the skin 
forms the basis of the skin-prick test. 
Activated mast cells produce IL-4. This perpetuates the bias towards TH2 cells present 
in allergic tissue, reinforced by the production of IIL-4 by TH2 cells themselves (Fig. 
1.3.1). TH2 production of IL-4, in combination with the expression of CD40L, up- 
regulated on the T cell surface in response to antigen, drives cells of other isotypes to 
switch to the production of IgE (see section 1.7). The importance of IL-4 in mediating 
the production of IgE has been illustrated by the identification of a polymorphism in the 
IL-4 receptor, associated with both hyper-IgE syndrome and atopy [Hershey el al., 
1997]. 
















Ra. 1.3.1. Interactions of Me immune cells in hcjE-mediated hvVersensitivitV. A simplified 
schematic demonstrates some of the important IgE mediated cellular interactions in the allergic 
response. B cells produce antibody that is displayed on the cell surface. The cognate 
interaction of allergen specific TH2 and B cells triggers a positive feedback loop in which T cell 
IL-4 production is increased. This IL-4 production combined with CD40L displayed on the T cell 
surface stimulated B cells to switch to the production of IgE (depicted in green). IgE is secreted 
and also present as a membrane protein on the surface of B cells. Cells including mast cells 
and antigen presenting cells (APC) display soluble IgE on their cell surface via the high affinity 
receptor (FccRI), (depicted in blue). The interaction of allergen (pink) with IgE on APC causes 
further stimulation of TH2 cells. In addition, the IL-4 that the T cells produce reinforces the bias 
towards TH2, perpetuating the allergic cycle. Crosslinking of allergen on mast cells results in 
their degranualtion, releasing the mediators of allergic symptoms. 
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B cells expressing membrane IgE themselves bind allergen, but the secretion of IgE, 
particularly by plasma B cells, ensures that the mast cells are continually primed. In 
addition, IgE bound to Fc&RI on the surface of antigen presenting cells, such as 
dendritic cells, stimulates further activation of antigen-specific B cells and importantly 
can also direct T cells towards TH2 [reviewed by Gould et al., 2003]. 
The allergic response is thought to have evolved to provide an immune response against 
parasitic worm infection [reviewed by Sutton and Gould, 1993]. Such a response is 
mainly redundant in the developed world, providing a unique opportunity for therapies 
to target IgE-mediated allergic disease, as the complete inhibition of IgE would be 
unlikely to be detrimental. Indeed, preliminary anti-IgE monoclonal antibody therapy 
has given promising results [MacGlashan el al., 1997]. The range of drugs currently 
available is, however, still relatively limited, being comprised mainly of anti-histamines 
and corticosteroids, while immunotherapy is only suitable for the treatment of some 
specific allergies. 
1.4 Antibody structure and function. 
There are five different antibody isotypes: IgM, IgD, IgG, IgA and IgE. Each B cell 
initially produces IgM and (by alternate splicing) IgD. IgE is the least abundant serum 
antibody isotype, with approximately 150 ng / ml of serum IgE compared to 10 mg / ml 
of serum IgG in normal subjects [Gould et al., 20031. Although atopic patients have 
elevated serum IgE in addition to IgE present in the local tissue, a relatively small 
amount of IgE is able to bring about a disproportionably strong immune response 
because of the unusually strong affinity of IgE for FccRI. This means that while serum 
IgE has a half life of only three days, compared to that of twenty days for serum IgG, 
IgE may remain bound to FceRI on mast cells for months [Roitt et al., 1996], [reviewed 
by Gould et al., 2003]. 
Class switch recombination (CSR), (described in detail in section 1.7) enables B cells 
activated by antigen to switch from IgM to the use, for example, of IgE. While IgE is 
most common in allergic tissues, IgG is mainly found in the circulation and IgA is most 
common in secretions. The structure of antibodies of different isotypes varies slightly, 
but all antibodies, regardless of isotype, have both an Fc and a Fab region (Fig. 1.4.1). 
The Fc region binds to its appropriate antibody receptor (such as Fc&Rl for IgE) and 
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includes most of the heavy chain constant region (CH) that specifies the antibody 
isotype. CSR enables an antibody to bind to a different class of receptor, mediating a 
different effect, depending on the type of cell displaying the particular FcR and its 
cellular location. Even after CSF, the variable region of the Fab encoded by each B cell 
remains the same, as it is the Fab (specifically the variable (V) region) that binds to 
antigen and endows each B cell with unique antigen specificity. 
All antibodies are comprised of both a heavy and light chain. The Fe region is only 
comprised of the heavy chain constant region, whereas the Fab comprises part of the 
heavy chains, the heavy chain variable region and both the constant and variable regions 
of the light chains (each heavy and each light chain being identical within an antibody). 
The interaction of antigen is generally with both the heavy (VH) and light (VO chain 
variable regions. The V regions therefore exhibit the greatest diversity between 
antibodies, enabling the widest possible range of antigens to be recognised by the 
immune system. Antibody diversity is introduced at three stages of B cell development, 
V(D)J recombination, class switch recombination and somatic hypermutation (discussed 
in sections 1.5,1.7 and 1.8). 
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Fa 
Fha. 1.4.1. The structure of IgE. IgE is comprised two identical heavy chains and two identical 
light chains. The different chains are held together by disulphide bonds. The heavy chain 
includes a variable region NO and a constant region (CF, ). The constant region of the IgE 
heavy chain contains four domains and specifies the effector function of the antibody. The light 
chain also contains both a variable region NO and a constant region (CL). In contrast however, 
CL is comprised of only one domain. VH and VL are encoded by different repertoires of genes 
(see Table 1.5.1). The Fab and Fe regions are indicated. 
1.5 The structure and recombination of the variable region. 
Antibody heavy and light chains both have aV region, at the tip of the Fab fragment 
(Fig. 1.4.1). TheVH and VL of each 'arm' of an antibody conventionally form an 
antigen binding site, such that theoretically each antibody could bind to two molecules 
of antigen. In order to generate a broad range of antibodies for a successful immune 
response, the V regions have a high level of diversity. Initially this is introduced by the 
recombination of different V, D (diversity) and J Ooining) genes in the bone marrow. 
Antibody V regions are encoded by the recombination of different V(D)J genes on 
human chromosome 14 (VH) and chromosomes 2 or 22 (VL). The VH region is 
comprised of three gene products, from a VH, aD and a JH gene, while the VL region is 
encoded by only two types of gene, VL and JL (Fig. 1.5.1). 
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Rcl. 1.5.1 The structure of the Zc af1d V re on. The VH and VL regions are encoded by 
either two (VL) or three (VH) genes that have been spired together. The V regions exhibit 
regions that are hypervariable, known as the complementarity-determining regions (CDRs). 
Regions that are relatively preserved are referred to as framework regions (FWRs). The CDRs 
conventionally have direct contact with antigen. A) VH is comprised of three gene products; a 
VH gene encodes FWR1,2 and 3, CIDR1 and 2, while aD gene encodes CIDR3. FWR4 is 
encoded by a JH gene. B) In contrast, VL is encoded by only two genes, a VL gene encodes 
FWR1,2 and 3, CIDR1 and 2, but there is no D gene. CIDR3 is encoded by the junction Of VL 
and JL. The JL genes also encode FWR4. 
Within the V regions, the complementarity determining regions (CDRs), conventionally 
have direct contact with antigen by forming loops at the tip of the antibody (Fig. 1.5.2). 
Of the CDR regions, CDRI and CDR2 are encoded by aV gene. CDR3 is encoded 
primarily by D in the heavy chain, but by the V-J junction in the light chain. In 
contrast, framework regions (FWRs) do not generally have a direct role in antigen 
binding, but are necessary for the structural stability of the antibody. However, the 
sequence of the FWRs can affect the conformation and position of the CDRs 
[Tramontano el al., 1990]. FWR 1,2 and 3 are encoded by the V gene, while FWR4 is 
encoded by the J gene. 
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Rcl. IA2, The CDR loops of the antibodv heavv and fight chain [courtesy of B. Suffonl. 
The Ca backbone of the heavy and light chain variable regions illustrates the CDR loops. On 
the left of the figure the position of CDR1,2 and 3 of the heavy chain is detailed (labelled in 
white). On the right of the figure the position of CDR1,2 and 3 of the light chain is detailed 
(labelled in orange). 
The V, D and J genes are taken from such a large repertoire that they can be divided 
into gene classes, in which the sequences have approximately 80% homology (Table 
1.5.1). The choice of which V (D) or J gene is recombined with the other is random. 
However, each gene has a recombination signal sequence (RSS) that includes either a 
12 or 23 bp spacer sequence. The '12 / 23 bp rule' dictates that genes are only able to 
recombine if their RSSs have different length spacers [reviewed by Lewin, 2000]. In 
the mouse, for example, the VH genes are each followed by a RSS that includes a 23 bp 
spacer. The D genes are both preceded and followed by 12 bp spacers, while each JH 
gene is preceded by a 23 bp spacer [Lewin, 20001. This ensures that a VH gene does not 
join directly to a JH gene. Breakage of the chromosome during recombination is 
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directed by the recombination-activating genes (RAG) I and 2 [McBIane et al., 1995]. 
Subsequent repair of the rearranged chromosome is thought to occur by non- 
homologous end-joining [reviewed by Grawunder and Harfst, 20011. 
Total number Numbers of V, D and J genes in each class 
ofgenes 
VH VO VH2 VH3 VH4 VH5 VH6 VH7 
51 11 3 22 11 2 1 1 
D D1 D2 D3 D4 D5 D6 D7 
Heavy 25 4 4 5 4 4 3 1 
- - - chain JH JH1 JH2 JH3 JH4 JH5 JH6 
6 1 1 11 1 1 11 
VK Výi Vý2 V,, 3 Vý4 V,, 5 V,, 6 7 
40 19 9 7 1 1 3 
JK 
. 1ý2 . 1ý3 J,, 4 J,, 5 
Light 5 1 1 1 1 1 
chain Vx V, 1 V,, 2 ý Vx3 Vx4 Vx5 Vx6 Vj Vx8 Vx9 Vx1 0 
31 5 5 9 3 3 1 2 1 1 





0 0 1 
-- -- 
Table 1.5.1 The repertoire of functional human V. D and J aenes [Adapted from VBasel- 
The diverse repertoire of V, D and J genes from which recombination to form the heavy chain 
variable region (VH-D-JH) and the light chain variable region (VL-JJ Occurs. The light chain 
variable region can consist either of kappa genes (VK and JK) or lambda genes (Vx and A). 
The genes are divided into classes on the basis of sequence similarities (with greater than 80% 
homology between the sequences in each class). Only the genes known to have an open- 
reading frame and therefore be functional are detailed. Those classes that have 0 members, 
are constituted solely of non-functional genes. 
in the pro-B cell the VH region is the first to be rearranged. Initially aD and JH gene are 
brought together, then rearrangement of a VH gene occurs such that VH, D and JH can 
encode a continuous mRNA transcript (Fig. 1.5.3). If the heavy chain VH-D-JH 
rearrangement enables the production of a functional protein, then the light chain is also 
subject to rearrangement. If the genes have been rearranged such that the reading frame 
is no longer in-frame, then heavy chain rearrangement on the second chromosome takes 
place. If this is also non-productive, the cell is subject to apoptosis [Janeway et al., 
20001. 
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Fhcj. 1. &3 The order of heavy chain VDJ rearrangement A simplified schematic 
demonstrates the order in which the V (variable), D (diversity) and J aoining) genes rearrange 
on chromosome 14. Initially one of the D genes is recombined with one of the JH genes. Then 
one of the VH genes is recombined with DJH. In the first instance Clt is proximal, resulting in the 
expression of IgM if rearrangement of the light chain is also productive. 
The light chain can either be kappa (K), or lambda (k) in origin, so that the light chain is 
comprised of either VK-JK-CK or VX-AXX. Initially in the pre-B cell, rearrangement 
of the kappa locus takes place on chromosome 2. If this is unproductive, then 
recombination of the kappa locus on the second chromosome takes place. The VK 
genes are clustered upstream of the JK genes. This means that on each kappa 
chromosome there are multiple opportunities for correct rearrangement. For example, if 
initially an unproductive out-of-frame rearrangement occurs between a 3' Vic gene and 
a 5' JK gene, it is possible for recombination to be attempted again on the same 
chromosome. In this instance a more 5' VK gene would recombine with a more 3' JK 
gene, excising the intervening out-of-frame VK-JK segment [reviewed in Lewin, 2000 
and Janeway el al., 2000]. As a consequence, in humans the majority of antibodies are 
kappa [Foster et al., 1997]. 
If all the opportunities for kappa rearrangement fail, rearrangement of the lambda locus 
occurs on first one and then if necessary, the other chromosome 22. However, in 
contrast to the kappa chromosome, multiple opportunities to rescue an unproductive 
lambda locus are not thought to arise. If rearrangement of both the kappa and then the 
lambda light chain are unsuccessful, the cell is subject to apoptosis. On both the heavy 
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and light chain chromosomes, allelic exclusion ensures that only one productive 
rearrangement occurs [reviewed by Janeway et al., 200 1] 
Even if the same V(D)J genes were recombined in two different B cells, antibody 
specificity would be likely to differ in each, as a consequence of the deletion and / or 
insertion of nucleotides at the recombination junctions. P nucleotides form palindromes 
with the germline-encoded nucleotides and are often inserted at the recombination 
junctions. N regions are also inserted across recombination junctions, mainly in the 
heavy chain, as a consequence of the activity of terminal deoxynucleotidyl transferase 
[Desiderio et al., 1984]. These also consist of non-germline encoded nucleotides, but 
are of random sequence. The insertions and deletions that are introduced across the VH- 
D-JH junction results in CDR3 having the greatest diversity of all the CDRs. CDR3 is 
therefore regarded as a 'signature region', unique to each B cell clone and provides a 
method by which descendents of the same progenitor cell can be identified. 
1.6 Sites of B cell maturation. 
After productive V(D)J recombination of aB cell in the bone marrow, IgM and (by 
alternate splicing) IgD are expressed. The B cell is considered to be mature, although 
naive, as it has not yet encountered antigen. When a mature, naive B cell is released 
from the bone marrow it enters the circulation and migrates towards a site of secondary 
lymphoid tissue. These include the spleen, lymph nodes, gut-associated lymphoid 
tissue and mucosal-associated lymphoid tissue. In this secondary lymphoid tissue, B 
cells encounter antigen. Antigen is usually presented by dendritic cells after acquisition 
at a peripheral site. B cell activation is triggered by exposure to antigen in the presence 
of an antigen specific T cell. 
Further maturation of aB cell is dependent upon successful class switch recombination 
(CSR) to change the isotype of the antibody, and somatic hypermutation (SHM), in 
which mutation of the V region sequences leads to increased affinity of the antibody for 
its antigen. CSR and SHM both require the expression of activation-induced cytidine 
deaminase (AID) [Muramatsu et al., 2000] and all three occur in germinal centres [Liu 
et al., 1996], [Jacob et al., 19911, [Kuppers el al., 1993], [Muramatsu el al., 1999]. 
Activated B cells migrate towards, or initiate, a germinal centre within the secondary 
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lymphoid tissue. Initially, an activated B cell enters the dark zone of a germinal centre 
(Fig. 1.6.1). SHM is triggered as B cells develop to become centroblasts [Pascual et 
al., 1994], both SHM and clonal expansion therefore occurring in the dark zone. 
Apical Light Zone 
Class switch recombination 
Differentiation 
qP -- I 




Centroblasts Clonal expansion 
Somatic hypermutation 
Adivated B Cell 
Ru. 1.6.1: A schematic demonstratina the miaradon of aB cell throwuh the (yenninal 
centre [adapted from Liu et A. 19961. Initially, an activated B Gell enters the dark zone of the 
germinal centre, becoming a larger centroblast. Centroblasts are subject to somatic 
hypermutation and clonal expansion. The B cells then migrate into the light zone, where they 
become centrocytes that display the mutated antibody on their surface. In the basal light zone 
these mutated antibodies are subject to antigen selection by antigen displayed on follicular 
denddtic cells. B cells of high affinity progress to the apical light zone and outer zone, where 
the presence of T cells is thought to trigger CSR and further clonal expansion. B cells then 
differentiate into either memory or plasma B cells. Alternatively, they may re-enter the germinal 
centre dark zone (hypothesised by [Kepler and Perelson, 1993] and not detailed in this figure). 
Chauter I Introduction 32 
After affinity maturation by SHM, clones progress to the light zone where they are 
exposed to antigen displayed by follicular dendritic cells (FDC's). Increased affinity for 
this antigen results in consequential competition between B cells [reviewed by Berek 
and Ziegner, 1993]. B cells that successfully compete for antigen because of increased 
antibody affinity may re-enter the dark zone to undergo further rounds of SHM. The 
cyclic re-entry of B cells with increased antigen affinity and their subsequent clonal 
expansion, results in the step-wise accumulation of somatic mutations among related B 
cell clones [reviewed by Kepler and Perelson, 1993]. 
Alternatively, B cells may differentiate to become memory or plasma cells [Berck and 
Ziegncr, 1993]. Memory cells enable a prompt high affinity immune response to 
subsequent antigen challenge, while plasma cells produce copious quantities of 
immunoglobulin. Memory B cells can also re-enter germinal centres, resulting in the 
capacity for a further increase in antigen affinity upon subsequent re-exposure to 
antigen. 
B cells that fail to acquire favourable somatic mutations and as a consequence are 
unable to compete successfully for the limited antigen are subject to apoptosis. Thus at 
the beginning of an immune response, germinal centres are composed of multiple 
unrelated clones, while antigen selection results in the eventual population of the 
germinal centre by only a few different B cell clones which have expanded and become 
heavily mutated [Kuppers et al., 1993]. Although CSR also occurs in germinal centres, 
B cells are only triggered to undergo CSR at the centrocyte stage, in the light zone and 
outer zone [Liu el al., 1996], where T cells are able to provide cytokines (e. g. IL-4) and 
also CD40L necessary to instigate C SR. 
Although CSR and SUM were conventionally assumed to be confined to the secondary 
lymphoid tissue, it has been demonstrated that when chronic antigen stimulation occurs, 
these processes may occur in other tissues. This has most frequently been demonstrated 
in autoimmune diseases. In ankylosing spondylitis, germinal centres have been shown 
to develop abnormally in the synovial membrane [Voswinkel el al., 2001 ] and have also 
been identified in the pancreas of the murine model of diabetes mellitus [Ludewig et al., 
1998]. 
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Research conducted on a murine model of autoirnmunity suggested that somatic 
hypermutation in the spleen was able to occur outside of germinal centres [William el 
al., 20021. However, the presence of local germinal centre-like structures in the 
synovial membranes of rheumatoid arthritis patients has been researched in greatest 
detail. Repeated analysis has suggested that these germinal centre-like structures 
contain B cells, T cells and FDC's [Randen et al., 1995], [reviewed by Berek and Kim, 
1997]. Although not occurring in lymphoid tissue, these B cells have been 
demonstrated to undergo SEM, CSR and clonal expansion as an apparent consequence 
of persistent local antigen [Schroder et al., 1996], [Williams el al., 1999]. 
Germinal centre formation was also stimulated to occur in the murine lung after antigen 
challenge [Chvatchko el al., 1996]. In contrast to rheumatoid arthritis, these germinal 
centres did occur within secondary lymphoid tissue (bronchial-associated lymphoid 
tissue, BALT). They generated antigen-specific IgE+ plasma cells. It was therefore 
suggested that the chronic antigen stimulation observed in human allergic asthma may 
also stimulate local germinal centre-like structures and therefore local production of 
IgE+ memory and plasma cells [Chvatchko et al., 19961. To date however, no such 
observations have been reported. 
1.7 The induction of IgE production by class switch recombination. 
In order for aB cell to be induced to switch isotype to IgE in the germinal centre, it 
must receive two signals, the first from IL-4 (or IL-13) and the second via the 
interaction of CD40 with its ligand [Jabara et al., 1990], [Zhang el al., 1991 ], [Shapira 
et al., 1992], [Armitage et al., 1993]. Both signals are provided by TH2 cells, but IL-4 is 
additionally produced by allergen stimulated mast cells (and basophils in the blood). 
IL-4 stimulates the induction ofF. germline transcription (IL-13 also has this ability and 
works via a similar mechanism to IL-4). 
The binding of IL-4 to its receptor (IL-4R), on the B cell surface, triggers a signalling 
cascade that ultimately stimulates e germline transcription (reviewed by [Nelms et al., 
1999], [Oettgen, 2000] and [Gould et al., 2000]). Interaction of IL-4 with IL-4R results 
in the activation of the JAK I and JAK3 kinases, these subsequently phosphorylate the 
transcription factor STAT-6. le, the F. germline promotor, includes a STAT-6 binding 
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site. In order for successful e germline gene transcription to be stimulated however, two 
other transcription factors, NFKB and BSAP, must also be present. 
Expression of both NFicB and BSAP are stimulated by the CD40-CD40L interaction 
[Gould et at., 20001, [Thienes el al., 19971. The CD40-CD40L interaction is also 
necessary for B cell expression of CD80 and B cell proliferation [reviewed by Gould el 
al., 2000]. The interaction of CD80 with CD28 (on T cells) forms a positive feedback 
loop whereby further synthesis of IL-4 is stimulated. 
Germline gene transcription is essential for CSF, because in order for a different heavy 
chain constant gene (CH) to be used, rearrangement and therefore chromosomal breaks 
must occur. In order for aB cell to switch from its initial production of Igm, to the 
production of IgE for example, both the ýt (IgM) and F. (IgE) locus must be actively 
transcribed. The heavy chain genes are arranged in tandem on chromosome 14 (Fig. 
1.7.1). The arrangement of chromosome 14 is such that everyCH gene (with the 
exception of IgD) is preceded by a promotor (1) and also a switch region (S). 
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Fic. 1.7-1. Class switch recombination fadmoted from Gould et al.. 2003L Class swftch 
recombination (CSR) enables the isotype that an antibody expresses to be changed by the 
repositioning of the heavy chain constant region (CH) genes encoded by chromosome 14. The 
CH genei'6rdered IgM (Cg), IgD (C8), IgG3 (Cy3), IgGl(Cyl), IgAl(CCCI), IgG2 (CY2), IgG4 
(Cy4), IgE (CF-), then finally IgA2(C(x2). In this figure, only CR, Cy4 and Qx2 are detailed. Each 
CH gene (except C8) is preceded by a promoter (1) and a switch region (S). Gene transcription 
occurs at both of the loci to be rearranged, producing a sterile germline transcript at the donor 
locus, from which the S region is excised (see text for details). CSR (in this instance from IgM 
to IgE) generates a switch circle of excised DNA that is transiently transcribed. Transcription of 
the rearranged heavy chain, leads to the expression of IgE. The position of the leader (L), 
variable (V), diversity (D) and joining (J) regions and enhancers (E) are also detailed. 
Germline gene transcription occurs across 1, S and CH. Therefore & germline transcripts 
are comprised IF. -SF. -Ce (Fig. 1.7.1). Splicing of the germline transcripts means that Se 
is removed, resulting in IF, -C6. The I exons contain a stop codon in each of the three 
reading frames. This means that all germline transcripts are sterile. Class switch 
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recombination is thought to rely on the excised S region enabling the formation of an R 





(excised from F, germline transcript) 
Fid-1.7-2: R looo lbrinatfon. The formation of an R loop takes place as a consequence of 
germline gene transcription of a CH locus on chromosome 14 and enables class switch 
recombination to take place. In an IgM to IgE switch, for example, trancripts are produced from 
both C4 and C&. The S region is excised from the transcripts. In the case of the Cc locus, the 
SE RNA remains paired to the Se DNA, forming an R loop of single stranded DNA. The DNA at 
both the Cp and CF, locus is then cleaved by an AID mediated mechanism, enabling CSR to 
take place as illustrated in Fig. 1.7.1. 
At both the S4 and Se sites actively undergoing transcription, the excised S region 
mRNA forms a DNA-RNA hybrid with the genomic S region DNA, forming an R loop. 
It has been suggested that the donor and acceptor switch sites are held in close 
proximity by trans-spliced transcripts i. e. a transcript that includes the 5' end of S4 and 
the 3' of Se [Fujeida et al., 1996]. It is thought that the DNA is cleaved at the end of the 
R loop, where the DNA is single stranded [Tian and Alt, 2000]. Ongoing research into 
the exact mechanism of CSR has suggested that AID may mediate these DNA breaks 
[Petersen el al., 2001 ], [Petersen-Mahrt el al., 2002], which may be targeted to 
secondary structures in the single stranded DNA [Kinoshita and Honjo, 2001 ], [Chen el 
al., 2001]. (see section 1.10). The DNA breaks enable CSR between the two CH regions 
before the DNA is repaired by non-homologous end-joining [reviewed by Honjo el al. 
2002]. 
The seemingly clear sequence of events by which IL-4 mediates s germline 
transcription is confused by recent findings that a single B cell, when incubated in vitro 
with FL-4 and (xCD40, is in fact stimulated to produce germline transcripts of multiple 
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different isotypes [David Fear and Hannah Gould, unpublished observations]. What 
finally determines that the resultant switch, stimulated by EL-4 and ccCD40, is to IgE is 
therefore yet to be determined 
The process of CSR not only enables direct switching of IgM to IgE, for example, but 
also indirect switches e. g. from IgM to IgG and then to IgE, as a consequence of 
multiple CSR events. This has been identified by the analysis of switch circles, the loop 
of genomic DNA excised when the two heavy chain genes are brought together (Fig. 
1.7.1) [Zhang el al., 1994]. Switch circle DNA is therefore often used as a marker of 
CSR, although it is not thought to degrade quickly, but rather be diluted by cell division, 
A recent discovery that transcription of the switch circle DNA occurs for a limited 
amount of time, has led to the use of switch circle transcripts as a marker of recent CSR 
[Kinoshita et al., 2001 ]. 
In addition to stimulation by IL-4 and CD40L, CSR is also though to be dependent upon 
the number of cell divisions that the B cell has undergone. Experiments on murine B 
cells suggest that in the presence of IL-4 and ctCD40, F. germline transcription is 
stimulated after four cell divisions and CSR to IgE after five cell divisions. Germline 
transcription and CSR to other isotypes was observed to occur after fewer cell divisions 
[Hasbold el al., 1998], [McCall and Hodgkin, 1999]. 
1.8 Somatic hypermutation. 
Somatic hypermutation (SIM is the process by which the affinity of an antibody is 
increased, enabling the body to mount a more efficient immune response. As detailed 
in section 1.6, SHM only occurs in B cells that have been activated by the presence of 
both antigen and T cells and in normal circumstances takes place in the germinal centre 
dark zone, where B cells are present as centroblasts. 
Clonal expansion in the dark zone results in a population of closely related B cells that 
are distinguished by the different somatic mutations that they have accumulated. 
Competition between the B cells for a limited quantity of antigen, presented by 
follicular dendritic cells, occurs in the light zone of the germinal centre, where the B 
cells are present as centrocytes. Those B cells exhibiting mutations that increase their 
Chapter I Introduction 38 
affinity for antigen compete most successfully for antigen and may re-enter the germinal 
centre to undergo further rounds of SIHM, or differentiate to become memory or plasma 
B cells [reviewed by Berek and Ziegner, 19931 
This results in the accumulation of B cells that while related (as determined by an 
identical CDR3 sequence rearrangement), differ in the mutations they have acquired 
(and possible as a result of CSR, their isotype), but which can be positioned in a 
genealogical tree because of the step-wise accumulation of somatic mutations. In such a 
genealogical tree, mutations acquired early in the maturation of the B cell will be shared 
by the greatest number of sister clones, while each B cell will also exhibit mutations 
unique to its most recent round of SHM. 
Somatic mutation occurs at a rate of approximately 10-3 base pairs per generation 
[McKean el al., 1984], [Berek and Milstein, 1987). Antibody affinity generally 
increases in response to an increased number of mutations, however, the introduction of 
just one mutation has been demonstrated to be capable of increasing antibody affinity 
by a factor of 10 [Berek and Milstein, 19871. 
Somatic mutations usually take the form of single nucleotide substitutions (with 
deletions and insertions occurring rarely). These mutations are specifically introduced 
into VH and VL DNA in both productive and non-productively rearranged loci. Un- 
rearranged genes are not generally mutated [reviewed by Neuberger and Milstein, 
1995]. Somatic mutations are confined to approximately 2 kb surrounding the V region, 
such that mutations occur as far 5' as the promoter and as far 3' as the intron between 
the J gene and the constant gene [Lebecque and Gearhart, 1990]. The level of mutation 
follows a gradient, with the greatest number of mutations occurring in the V region 
itself, less in J and none in C. Bcl-6 is also subject to SEM, but at a lower level than the 
V region [Shen el al., 1998], [Pasqualucci el al., 1998]. 
The introduction of a mutation may have a silent effect on the amino acid that is 
encoded, or alternatively may result in an amino acid replacement. Only replacement 
mutations alter the affinity of an antibody. Mutations are referred to as non-intrinsic if 
they are a consequence of antigen selection. Even in the absence of antigen selection, 
SHM is not random. The intrinsic preferences of SHM were determined by the analysis 
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of passenger transgenes and sequences that flanked the V region and used to generate a 
summary of the preferences of SHM for particular bases (see appendix Q [Betz et al., 
1993b]. SHM has been suggested to be targeted to one DNA strand, the most obvious 
consequence being the biased occurrence of an A-T as opposed to a T-A mutation 
[Lebecque and Gearhart, 1990], [Betz el al., 1993b], [Insel and Varade, 1994], [Rogozin 
el al., 200 1 ]. 
Mutations that result in a transition (the replacement of one purine (A or G) with 
another, or one pyrimidine (C or T) with another) are more common than mutations that 
result in a transversion (the replacement of a purine with a pyrimidine, or vice versa) 
[Insel and Varade, 1994]. In addition, certain DNA sequence motifs have been 
demonstrated to be hotspots for SHM [reviewed by Rogozin and Pavlov, 2003]. These 
include RGYW, its reverse complement, WRCY and WA (where G or C are mutated 
and R= purine, Y= pyrimidine and W=A or T) [Rogozin and Kolchanov, 1992], 
[Rogozin et al., 2001]. In contrast, some residues are rarely targeted for mutation and 
are therefore regarded as cold spots. 
Even if a mutation does not adhere exactly to the RGYW motif, it is more likely to 
occur at a position that exhibits a similar motif [Rogozin and Pavlov, 2003]. In some 
instances a mutation may occur at a hotspot motif but not increase antibody affinity. 
However, if the overall mutational load of the antibody has a favourable effect on 
affinity, selection means that such mutations are perpetuated. These are referred to as 
intrinsic mutations and reflect the transition / transversion bias and the other intrinsic 
preferences of SHM. 
Within the V region, the complementarity determining regions (CDRs) are particularly 
heavily mutated [Insel and Varade, 1994]. It is thought that the CDRs evolved to 
exhibit a greater mutability because of their direct interaction with conventional 
antigens and therefore importance in antibody affinity. The VH CDRs are composed of 
sequences that are inherently more mutable [Chang and Casali, 19941. This is evident 
by the presence of a bias towards the AGY serine codon, as opposed to the TCN serine 
codon, with only AGY conforming to the RGY hotspot motif [Wagner et al., 1995]. 
However, not all mutations occur in the CDRs, indeed some mutations in the FVrRs 
have a positive effect on antigen affinity, either because the amino acid is at the edge of 
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the antigen binding site created by the CDRs, or because the FWR residue has an 
indirect affect upon the structure adopted by the CDRs [Tramontano el al., 1990], [Jolly 
et al., 1996]. 
The mechanism of SHM is not fully understood, although it is being elucidated as a 
consequence of the identification of AID. AID has been demonstrated to be required 
for SHM [Muramatsu el al., 1999], [Muramatsu ef al., 20001. Indeed, the induction of 
AID expression has been shown to artificially stimulate SHM in fibroblasts [Okazaki el 
al., 2002]. The latest thinking suggests that AID acts directly on V region DNA, 
deaminating cytosine to form uracil. The uracil is excised, generating a break in the 
DNA, whose repair introduces an error(s). 
The break that occurs in the DNA may be either single stranded, or double stranded if 
two cytosines on opposite DNA strands are deaminated (generating a staggered break) 
[Sale and Neuberger, 1998], [Papavasiliou and Schatz, 2000], [Bross et al., 2000]. 
These DNA breaks have been demonstrated to correspond to RGYW motifs [Bross et 
al., 2000]. 
To date, DNA polymerase ý, t, and -9 have been implicated in the error-prone repair 
[Zan et al., 2001], [Faili et al., 2002], [Rogozin et al., 2001], [Zeng el al., 20011, 
[Yavuz et al., 2002]. In particular, Pol Tj appeared to generate mutations that correlated 
with the WA hotspot motif and T/A bias [Rogozin et al., 2001], [Zeng et al., 2001], 
[Yavuz et al., 2002]. However the occurrence of mutations at RGYW / VVRCY 
appeared to be equally distributed on both DNA strands, suggesting that these effects 
were mediated separately [Rogozin el al., 2001 ], [Zeng el al., 20011, (see section 1.9). 
Even when the V region DNA is substituted, for example by P-globin, SHM still occurs 
[Yelamos et al., 1995]. The presence of a promotor (although not necessarily the V 
region promotor) and therefore transcription is necessary for somatic mutation [Betz et 
al., 1994], [Peters and Storb, 1996] although the full degree of mutation is dependent 
upon the presence of the V region enhancers [Betz el al., 19941. This may correlate 
with the necessity of transcription for cytidine deamination by AID and it has been 
proposed that the hotspots of SIHM may be a consequence of the secondary structure 
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that the single stranded DNA may adopt while transcription takes place (see section 
1.9). 
1.9 Activation-induced cytidine dearninase. 
Until recently, there was little information as to how either class switch recombination 
or somatic hypermutation were coordinated. Activation-induced cytidine deaminase 
(AID) was then demonstrated to be required for both processes [Muramatsu el al., 
1999], [Muramatsu el al., 2000]. Consistent with this observation, AID expression was 
identified in germinal centre B cells [Muramatsu et al., 1999] and lymphoid tissue 
[Muramatsu et al., 20001, [Muto el al., 20001. In addition, AID was also shown to be 
required for gene conversion [Arakawa el al., 20021, [Harris el al., 2002b], the process 
by which diversity is introduced into V genes in chickens, rabbits, cattle and pigs (as 
opposed to, or in addition to SHM) [reviewed by Janeway et al., 2000]. 
The importance of AID in the maturation of the immune response was reinforced by the 
observation that a subset of patients suffering from hyper-IgM syndrome (RIGM2), 
displayed mutations in AID that down-regulated or abrogated its expression [Revy et 
al., 2000], [Mnegishi el al., 2000]. As a consequence, these patients were subject to 
repeated infection, had enlarged germinal centres, severe depletion of antibody isotypes 
other than IgM and a lack of SHM. 
AID is a member of the APOBEC family of deaminases and has homology to 
APOBEC- I [Muramatsu et al., 1999]. Although members of the APOBEC family have 
been demonstrated to be able to dearninate DNA [Harris el al., 2002], [Petersen-Mahrt 
and Neuberger, 2003], in vivo APOBEC- I deaminates C-U in apoB RNA, introducing 
a premature stop codon. This RNA editing generates two functional proteins (apoBlOO 
and apoB48) with different functions [Innerarity el al., 1996). AID was also shown to 
exhibit cytidine deaminase activity [Muramatsu et al., 1999]. However, AID was not 
capable of dearninating RNA [Muramatsu el al., 19991, but was shown to act on DNA 
[Petersen-Mahrt el al., 2002], [Di Noia and Neuberger, 2002]. 
More specifically, AID has been shown to act on single stranded DNA and correlating 
with CSR and SFK AID activity is also dependent upon transcription [Ramiro et al., 
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2003], [Chaudhuri et al., 2003], [Sohail el al., 20031, [Bransteitter el al., 2003], 
[Dickerson et al., 2003], [Pham et al., 2003]. It has been suggested that mutations 
induced by AID are favoured at some positions (hotspots) as a consequence of the 
secondary structure that the single stranded DNA might adopt whilst undergoing 
transcription. It has been suggested that stem-loop structures, prone to deamination, 
may transiently occur in V region DNA whilst it is transcribed and also in the single 
stranded regions of S region DNA in the R loop during CSR [Kinoshita and Honjo, 
200 1 ], [Chen el al., 2001 ]. 
AID was demonstrated to deaminate DNA from C-U when expressed in E. coli. 
Mutations introduced as a consequence of AID expression were enhanced when uracil- 
DNA glycosylase (UNG) deficient E. coli we, re used [Petersen-Mahrt et al., 2002] and 
the trends in SHM distorted in both the DT40 (chicken) cell line in which UNG was 
inhibited and also in UNG deficient mice, [Di Noia and Neuberger, 2002], [Rada et al., 
2002]. 
A multi-phase mechanism was suggested to account for the characteristic traits 
observed in SEM, CSR and UNG deficiency [Petersen-Mahrt el al., 2002], (see Fig. 
1.9.1). Usually dU is removed from DNA by base excision repair, creating an abasic 
site, which when subsequently removed by an apyrimidinic-endonuci ease, causes a nick 
in the DNA. The DNA is then correctly repaired by a DNA polymerase. 
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Fici 1.9.1. The provosed mechanism bv which deamination of cvtosine bv AID mav lead to 
SHM. CSR and gene conversion fadaptecf from Petersen-Mahrt et aL. 20021. The 
dearnination of cytosine by AID leads to SHM and gene conversion in V region DNA, or CSIR in 
CH region DNA. Conventional base excision repairs the dearninated C correctly after the action 
of uracil-DNA glyGosylase (UNG), apyrimidic endonuclease (APE), a DNA polymerase (pol) and 
deoxyribophophodiesterase (dRPase). Somatic mutation is thought to occur in two phases 
[Rada et al., 19981, [Wiesendanger et al., 20001. In the first phase, if replication occurs across 
dU, transitions are generated (1 a) or alternatively if replication occurs across the abasic site 
(1 b), both transitions and transversions result. The DNA polymerase involved in phase 1b may 
introduce a nucleotide bias during repair. In the second phase, MSH2 and MSH6 are thought to. 
recognise dU and direct repair by a DNA pol, q for example. During repair, this DNA pol is 
thought to introduce mutations at A: T. The majority of CSIR event are thought to occur by APE 
generation of DNA breaks on opposite strands [Rada et al., 2002]. Gene conversion is similarly 
reliant on the generation of double stranded DNA breaks. 
If after AID deaminates C-U, DNA replication occurs while dU is still in place, 
replication of the dG strand results in the regeneration of a C: G pair. However, when 
the dU strand is replicated, the uracil would be replaced by thymine, resulting in 
mutation to T: A. This phase is termed phase 1A and would generate a C-T (and 
therefore, on the opposite strand, a G-A) transition [Petersen-Mahrt el al., 2002]. This 
transition bias is consistent with that observed in SHM and may correspond to the 
RGYW / WRCY hotspot motif The alternative is that DNA replication may occur after 
UNG activity, but before the abasic site is removed (phase IB). In this instance, dU 
may be replaced with any nucleotide, with two of the three mutating alternatives 
resulting in a transversion. 
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Somatic mutation was previously proposed to be introduced in two phases [Rada el al., 
1998], [Wiesendanger el al., 2000]. Phase 2 has therefore been suggested to result from 
the recognition of the U: G pair by MSH2 and MSH6 (which target repair). dU is then 
thought to be subject to repair by a DNA polymerase, such as pol 11. It has been 
hypothesised that this phase introduces A/T mutations and accounts for the W. A 
hotspot, as the DNA polymerase may introduce mutations at A: T pairs that are proximal 
to the original dearninated dC. 
Not only is this multiphase mechanism thought to generate somatic mutation in V 
region DNA, it is also thought to occur at the S regions (which are G: C rich) during 
CSR. Single base substitutions similar to SHM have been identified close to junctions 
of CSR [Chen el al., 2001] and are thought to result from unsuccessful attempts to 
switch. Successful CSR would only occur in situations where DNA breaks due to the 
dearnination of proximal cytosines occurred on opposite strands and the necessary 
repair factors were present [Petersen et al., 200 1 ]. 
This correlates with the observation that UNG-deficient mice have an inhibited ability 
to switch, as UNG would be needed for the DNA break to be introduced by the 
apyrimidic endonuclease [Rada el al., 2002], although this hypothesis may be 
complicated by reports that MSH2 and MSH6 are also important in CSR [Ehrenstein el 
al., 19991, [Schrader el al., 1999], [Schrader el al., 2002]. In a similar fashion, gene 
conversion is also thought to be mediated by AID when DNA double strand breaks are 
generated and the appropriate repair enzymes present [Petersen-Mahrt el al., 2002]. 
How SEIM and CSR are targeted to the appropriate DNA is not currently understood 
any further as a result of the identification of AID. While AID appears to be the only B 
cell specific molecule needed to induce CSR and SHM [Martin el al., 2002], [Okazaki 
el al., 2002], it is possible that a ubiquitously expressed molecule, when associated with 
AID, is able to generate specificity. For example, APOBEC-1 is only active when 
present with apobec-1 complementation factor, which has been proposed to be 
responsible for the efficient targeting of APOBEC's activity [Neuberger et al., 2003]. It 
is also possible the high level of immunoglobulin gene transcription has a role in 
targeting AID activity [Martin and Scharff, 2001]. The cofactor(s) needed to associate 
with AID to enable SHM may be different to that necessary for CSF, introducing a 
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further level of control and possibly explaining why SHM and CSR can occur 
separately [Oppezzo el al., 2003], [Ta ef al., 2003]. Without such targeting it is not 
surprising that inappropriate AID expression appears to be associated with malignancy 
[Okazaki et al., 2003], [Greeve et al., 2003]. 
This concludes the summary of information necessary to understand the basis of the 
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2.1 Aims of the project. 
In chapter 1, the association between IgE and allergic disease and also the main 
concepts in the generation of high affinity IgE were discussed. Allergen-specific IgE' 
plasma cells have been demonstrated to occur locally in the nasal mucosa of allergic 
rhinitis patients [KleinJan el at., 2000] and local production of IgE protein in the 
allergic nasal mucosa has been demonstrated ex vivo [Smurthwaite el al., 2001 ]. 
In addition, it has been demonstrated that CSR and SHM occur outside of the 
conventional sites of lymphoid tissue, particularly in disease states such as 
autoimmunity, characterised by chronic antigen stimulation (see section 1.6). As the 
allergic mucosa is chronically stimulated by allergen and responds by synthesis of local 
IgE, it has been hypothesised that a similarly localised molecular response, involving 
SHM, clonal expansion and CSR may also occur in the allergic mucosa. 
If the allergic response was demonstrated to be either entirely, or partially a 
consequence of locally instigated molecular events, a wider range of therapeutic targets 
would be available. Localised therapy would not only avoid systemic side-effects, for 
example, inhibition of CSR or SHM would only be viable at the local level, but may 
also prove successful with patients for whom conventional drug therapies are 
ineffective. Inhibition of high affinity IgE should be an ideal drug target, because of the 
redundancy of IgE for beneficial purposes in the developed world. 
Analysis of F, germline transcripts has suggested that local CSR may occur in the 
allergic lung mucosa [Ying el al., 2001], although while F- germline transcription 
preceeds successful CSR to IgE, B cells may not necessarily complete such a switch. 
However, further work on the allergic lung mucosa has demonstrated, by analysis of VH 
region mRNA, the presence of clonally related B cells of different isotypes, supporting 
the suggestion of local CSR and additionally, SHM and clonal expansion [Snow et al., 
1999]. The lung is known to be supported by BALT, which in the mouse, is able to 
respond to antigen challenge by the formation of germinal centres [Chvatchko et al., 
1996]. However, although evidence suggests local SHM and CSR in the human allergic 
lung mucosa, there have been no reports of local germinal centre formation. 
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While the upper and lower respiratory tracts are considered by some clinicians to be one 
organ [Mygind and Jacobi, 1997], secondary lymphoid tissue is not present in the 
human nasal mucosa, the closest site being Waldeyer's ring in the pharynx, 8- 10 cm 
distal from the inferior turbinate. However, local e germline transcription also occurs in 
response to allergen stimulation in the allergic nasal mucosa [Durham et al., 1997], 
[Cameron el al., 2000], although no supporting work, such as that carried out by Snow 
el al. in the lung, had been attempted. Additionally, no research has been conducted to 
determine whether local SUM and clonal expansion are also features of the allergic 
nasal mucosa. 
Such local activity in the nasal mucosa may be a consequence of germinal centre-like 
activity in non-lymphoid tissue. Immunohistochernical analysis has suggested that the 
allergic nasal mucosa is particularly rich in both immune cells, including B 
lymphocytes, T lymphocytes and dentritic cells [Fokkens el al., 1990] and 
consequentially with cytokines, such as tL-4. The local allergic mucosa may therefore 
be capable of acting as a specialised microenvironment, in which chronic allergen 
challenge results in the activation of local B cells, local CSR driven by IL-4 and also 
local SHM and clonal expansion. 
The aims of this project were therefore to analyse the allergic nasal mucosa, to 
determine whether there was evidence to support the hypothesis of local CSR and SHM. 
The main technique employed had previously been used in analysis of the allergic lung 
mucosa [Snow et al., 1999] and enabled the successful examination of local CSR, SHM 
and clonal expansion in the same sample. This goal was not achievable at the initiation 
of this project by any other experimental means. Initially therefore, VH region 
sequences were RT-PCR amplified from IgE' B cells from nasal biopsies taken from 
the inferior turbinate of allergic rhinitis patients. 
If a diverse population of IgE' B cells were shown to be present in the allergic nasal 
mucosa, then it was hypothesized that the presence of closely related IgE+ B cell clones 
in a small area would suggest that they had been subject to local SHM and clonal 
expansion. It would be much less likely that such cells would have each migrated from 
Waldeyer's ring, for example and yet still remained in close proximity to their sister 
clones. Furthermore, if related B cell clones expressing different isotypes were 
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isolated, applying the same principle, it would be likely that local CSR had occurred. 
Later in the project, immunohistochernistry and the analysis of AID mRNA expression 
were also introduced, in response to the development of both this project and research 




Materials and methods. 
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3.1 Materials. 
All chemicals were supplied by Sigma (Poole, UK) unless detailed otherwise. Tissue 
culture plastics were supplied by Invitrogen (Paisley, UK) unless otherwise stated. 
Ultrapure water was obtained from a MilliQ UF Plus machine supplied by Triple Red 
(Thame, UK) and was used at a purity of 18.2 mQ / cm. Reagents were prepared as 
follows: 
3.1.1 LB culture medium. 
5g of powdered LB (Invitrogen) was dissolved in 250 mi of MilliQ water and 
immediately autoclaved. The appropriate antibiotic was added immediately prior to 
use, ampicillin at a final concentration of 100 gg / mi and kanamycin at a final 
concentration of 50 ýtg / mi. 
3.1.2 LB culture plates. 
8g of powdered LB agar (Invitrogen) was dissolved in 250 ml of MilliQ water and 
immediately autoclaved. The LB agar was cooled to 50'C before the appropriate 
antibiotic was added (concentrations as above), mixed and the LB agar poured onto 
eight petri dishes. 
3.1.3 Xylene cyanol loading buffer. 
In order to prevent the VH-CF- PCR products from being obscured by the conventional 
bromophenol blue loading dye after being subjected to agarose gel electrophoresis and 
visualised under UV light, a loading buffer constituting 25 mg of xylene cyanol and 4g 
of sucrose dissolved in 9.5 ml of MilliQ H20 was used in all samples. 
3.1.4 TAE electrophoresis buffer. 
TAE electrophoresis buffer was used to make agarose gels and also used as 
electrophoresis running buffer (section 3.2.26). A 50X TAE stock was made and 
diluted as necessary, 242 g of Tris base was added to 57.1 ml glacial acetic acid and 100 
ml 0.5 M EDTA (pH 8.0). The volume was then made up to I litre with MilliQ H20 and 
the pH adjusted to 7.2,25pl of ethidium bromide was added per litre of IX TAE buffer. 
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3.1.5 TBS wash buffer. 
TBS was used as a wash buffer in immunohistochemistry experiments (sections 3.2.38 - 
One sachet of TBS powder (Dako, Ely, UK) was dissolved in I litre of MilliQ 
water to make a pH 7.6 solution and then filter sterilised. 
3.1.6 Denaturing buffer. 
Denaturing buffer for southern blot analysis was made by dissolving 315.5 g of NaCI 
and 28.8 g of NaOH in a final volume of 1800 ml of MilliQ water. This gave a final 
concentration of 3M NaCl and 0.4 M NaOH. 
3.1.7 Transfer buffer. 
Transfer buffer for southern blot analysis was made by dissolving 315.5 g of NaCl and 
0.6 g of NaOH in a final volume of 1800 ml of MilliQ water. This gave a final 
concentration of 3M NaC I and 0.01 M NaOH. 
3.1.8 SSC wash buffer. 
SSC buffer for southern blot analysis was made to a 20X stock by dissolving 156.6 8 
NaCl and 79.6 g sodium citrate in a final volume of 900 ml of MilliQ water. This stock 
solution was then further diluted with water as necessary. This gave a final 
concentration of 3M NaC I and 0.3 M sodium citrate. 
3.1.9 Yssels media. 
Yssels media was made according to that previously detailed [Yssel et al., 1984]: 50 ml 
fetal calf serum (Invitrogen), 2mM glutamine (Invitrogen), 100 ITJ / ml penicillin 
(Invitrogen), 100ýtg / ml streptomycin (Invitrogen), 2x 10-5 M ethanoalanine, 2.5gg / 
ml BSA, 1ýtg / ml palmitic acid, I pg / ml linoleic acid and I gg / ml oleic acid were each 
added to 500 ml of Iscoves media (Invitrogen). Immediately prior to use 354g / ml 
transferrin and 5gg / ml insulin were added. 
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3.2 Methods. 
3.2.1 Recruitment of human subjects for nasal biopsies. 
Human subjects were recruited according to the conditions approved by the Royal 
Brompton Hospital's local ethics committee. Male and female donors between the ages 
of eighteen and fifty-five were recruited from the Royal Brompton Hospital Allergy 
Clinic (London, UK) or by advertisement in the local press. None of the patients had 
received immunotherapy. Any steroid medication was discontinued at least two weeks 
before and anti-histamine at least two days before nasal biopsy. While the recruitment 
of smokers was avoided, they were not eliminated from the cohort of patients detailed 
below. There was no apparent difference in results obtained from the smokers 
compared to the non-smokers in this study. 
The allergic status of the donors was assessed by their medical history, skin-prick tests 
and radioallergosorbency test (RAST) to detect serum allergen specific IgE. Total 
serum IgE was also measured. The maximum limit of detection for serum allergen 
specific IgE was 101 IU / ml (normal < 0.35 IU / ml). Normal total serum IgE was 
taken to be within the range of 3- 150 IU / ml. Allergic rhinitis patients selected for 
the PCR amplification Of VH-C& sequences from the nasal mucosa exhibited a total 
serum IgE >200 IU / ml wherever possible, to ensure successful PCR amplification, as 
preliminary work suggested that while the serum IgE would not correlate exactly with 
local IgE, VH-C& PCR products were harder or impossible to amplify from patients 
exhibiting lower serum IgE values. Even when patients exhibiting a total serum IgE 
>200 IU / ml were recruited, VH-C6 PCR products could not always be amplified from 
every sample of the nasal mucosa, presumably as a result of variation between the 
random composition of different samples. 
3.2.2 Clinical data from allergic, normal and non-atopic subjects. 
The clinical details of subjects from whom data is presented in this study are listed 
below in Table 3.2.2.1, although when of particular importance they are again detailed 
in the main text. Patients from whom nasal biopsies were taken for 
immunohistochemical analysis are detailed in the text only. Normal total serum IgE is 
considered to be 3- 150 IU / mi and normal specific IgE <0.35 IU / mi. Patients were 
classified as in-season on the basis of the grass pollen season, encompassing June, July 
and August. 
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Patient Age Sex Status Total serum IgE Specific serum IgE Allergies c) 
at (ILI / ml) (IU / MI) 
b) 
biopsy 
HDM = 1.2 HDM, G, T, 
SL5 27 F I/p 164 G= 43.5 B, C, AF, A 
T=1.51 
M=3.44 
HDM = 1.28 HDM, G, 
CD6 19 M I/p 990 G= 72.9 M, T, B, C, 
T= 101 D 
JB7 37 M O/P 236 G=9.25 HDM, G, C, C= 11.1 D, CL 
HDM = 1.09 HDM, G, 
CM1 0 18 F O/P 382 G 101 M, T, B, C, 
C 3.36 D, H, CL 
HD14 21 F I/P 787 HDM = 2.68 HDM, G 
G= 101 
S016 37 M I/p 514 G= 101 G, T, B, D 
HD1 7 22 F 1 2745 G= 101 G C=0.39 
HDM = 1.23 HDM G C AP1 9 38 F I/P 414 G= 60.2 , , , D, H, CL C= 32.1 
HDM = 101 
DR20 31 M I/p 892 G= 97.9 ND 
C=1.41 
TL22 38 F N ND ND None 
JH23 25 M p 357 HDM = 1.1 G G= 42.3 
HDM = 11.4 
SJ24 36 F O/P 1264 G= 58.5 ND (severe 
C= 29.3 eczema) 
TL25 27 M I/P 304 G= 13.1 G, M, T, B, C=3.24 C, D 
ZC27 20 F 1 526 G= 95.6 G 
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GJ29 55 m Non- 
atopic 
1834 AF = 0.71 None 
CA30 26 F O/P 1025 HDM = 0.36 G= 101 G, D 
SLT1 38 F O/P ND ND HDM, G, B 
JF 31 m N ND ND None 
im 27 m N ND ND None 
vc 28 F N ND ND None 
ST 32 m N ND ND None 
Table 3. LZ1: Clinical data from allemic. non-atovic and normal subiects from whom 
data is orp-sentedin this study. a) In-season (1), out-of-season(O), perennial (P), nor7nal(N). 
b) Determined by RAST for, house dust mite (HDM), mixed grass (G), tree (1), cat (C). C) 
Determined by a skin-prick test >_2 mm diameter as; Dermatophagoides (house dust mite) 
(HDM), Phleum pratense (grass pollen) (G), mugwort (M), three trees M, silver birch (B), cat 
(C), dog (D), horse (H), Aspergillus furnigatus (AF), Cladospofium herbarum (CL), Alfemaria 
aftemata (A). ND = not determined. 
3.2.3 Procedure for the taking of a nasal biopsy from the inferior 
turbinate for RNA extraction. 
All nasal biopsies were performed at the Royal Brompton Hospital, London, UK, with 
the patients' written informed consent and under the approval of the Royal Brompton 
Ethics Committee. Biopsies were taken with Gerritsma forceps according to a previous 
detailed protocol [Durham el al., 1992]. Briefly, a 2.5 mm 3 biopsy was randomly taken 
from the under surface of the inferior turbinate, behind the anterior insertion into the 
lateral wall of the nose and 8-10 cm distal to the nearest lymphoid tissue, Walcleyer's 
ring in the pharynx. The random nature of the biopsies prevented the sampling of any 
defined cell populations from within the inferior turbinate. 
Biopsies were immediately placed in 1.5 ml chilled Hank's balanced saline solution 
(Invitrogen) and mixed to remove any surface blood. Each biopsy was then carefully 
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transferred with a pipette tip into a cryotube, snap frozen in liquid N2 and stored at 
-70'C until use. 
3.2.4 Tissue samples obtained from infedor turbinectomies. 
Inferior turbinates were obtained as a by-product of routine surgery for turbinate 
sectioning, carried out by Ms. E. Chevretton at Guy's Hospital, London, UK. Tissue 
was obtained with the approval of the Guy's Research Ethics Committee and with the 
patient's written, informed consent. 
3.2.5 Procedure for the taking of a nasal biopsy from the infedor 
turbinate for immunohistochemical analysis. 
A drop of OCT embedding medium (Merck, Hoddesdon, UK) was placed on a small 
rectangle of thin cardboard (0.8 cm x 1.5 cm). Biopsies were taken as detailed in 
section 3.2.3, then placed into the OCT, such that the epithelium was perpendicular to 
the card. The embedded biopsy on the cardboard was then lowered horizontally into a 
beaker of isopentane (pre-chilled in liquid N2). The frozen biopsy was stored at -700C 
until used for immunohistochemical analysis (chapter 6). 
3.2.6 In vivo allefgen challenge of the nasal mucosa. 
In order to challenge the allergic nasal mucosa in vivo with grass pollen allergen 
(chapter 8). Two actuations of grass pollen (520 BU /spray), (ALIC, Hungerford, LJK) 
were sprayed into the selected nostril. After 15 min another two actuations were 
administered. All patients reported symptoms of rhinitis at the end of the procedure. 
All grass pollen challenges took place outside of the pollen season. After five, six or 
seven days, nasal biopsies were taken according to the usual procedure. 
3.2.7 In vitro culture of nasal biopsies. 
For the analysis of biopsies cultured in vitro (chapter 8), biopsies were taken as detailed 
in section 3.2.3, but were not frozen. Rather, the biopsies were transported in Hank's 
balanced saline solution at 40C as quickly as possible (always within 2 hrs). Each 
biopsy was cultured at 37T in a round bottomed 96 well plate (Nunc, New York, USA) 
with pre-warmed Yssels medium, EL4 (200 IU / ml) (R&D Systems, Minneapolis, USA) 
and anti-CD40 (I pg / ml) (Pharmingen, San Diego, USA) for six days. The nasal 
biopsy was then removed, placed in a cryotube, snap frozen in liquid N2 and stored at - 
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70'C until use. The cell pellet from the culture supernatant was also frozen at -70'C. 
All manipulation took place in a class 11 laminar flow hood under sterile conditions. 
3.2.8 Isolation of human pedpheral blood mononuclear cells from whole 
blood. 
25 ml blood was immediately mixed with acid citrate dextrose (I ml in a final volume of 
10 ml). Whole blood was diluted by mixing with 25 ml phosphate buffered saline 
(PBS), (Invitrogen) before peripheral blood mononuclear cells (PBMC) were extracted 
with Ficoll-Paque (Pharmacia, Ontario, Canada) according to the manufacturers 
instructions in a class 11 laminar flow hood under sterile conditions. Briefly, 50 ml of 
diluted blood was carefully layered onto Ficoll with a3: 4 ratio of Ficoll : blood, such 
that 20ml of blood was added to each of two tubes containing 15 ml Ficoll and 10 ml 
blood was added to one tube containing 7.5 ml of Ficoll. The tubes were then 
centrifuged at 2000 rpm for 20 min at room temperature in a benchtop centrifuge with 
the brake off. A pasteur pipette was then used to remove the white mononuclear cell 
layer in between the serum and the Ficoll. The PBMC were diluted 1: 3 with sterile PBS 
and centrifuged again at 1500 rpm for 10 min at 4'C in a benchtop centrifuge with the 
brake on. The cell pellets were then combined and resuspended in 10 ml PBS. 
Approximately 4x 107 cells were usually isolated from 25 ml whole blood. 
3.2.9 Quantitation of cells. 
Cells were mixed in equal volumes with 0.4% trypan blue (a viability dye that stains 
dead cells blue). Viable cell numbers were determined using a Neubauer Improved 
hemocytometer, the average number of cells within the innermost 25 large squares of 
the two grids, multiplied by 10 000, multiplied by the dilution factor, to generate the 
number of viable cells per ml, 
3.2.10 In vitro cufture of human PBUC. 
PBMC from 75 ml whole blood were isolated as detailed in section 3.2.7 for a time- 
course experiment (chapter 8). 1.5 x 10 6 PBMC, resuspended in Yssels media were 
seeded into each of the inner eight wells of a 24 well flat bottomed plate (Nunc). The 
outer wells were filled with PBS. To each well was also added IL4 (200 IU / ml) and 
anti-CD40 (IýLg / ml). 9X 106 p13MC were frozen at -700C as a day 0 control, but the 
PBMC cultured for the time-course of the experiment (either seven or fourteen days). 
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At each appropriate time point, the contents of four wells were pipetted to resuspend 
adhered cells, the supernatants pooled and then pulsed at high speed in a microfuge. 
The supernatant was discarded and the wells washed with 100 ýtl of PBS, which was 
then added to the cell pellet and pulsed again. The supernatant was again discarded and 
the cell pellet stored at -700C. 
3.2.11 In vitro cufture of the AFIO cell line. 
The IgE expressing AFIO B cell line (U266) was cultured at 37C in sterile conditions 
from frozen stocks obtained from Professor Andrew Saxon, UCLA School of Medicine, 
USA. Between 5x 105 and 5x 106 cells / ml were maintained in RPMI 1640 media 
(Invitrogen) with 10% fetal calf serum (Invitrogen), 2 mM glutamine (Invitrogen) and 
10 U penicillin / streptomycin (Invitrogen). 
3.2.12 In vitro cufture of the RAMOS cell line. 
The AID expressing RAMOS IgM B cell line was cultured in sterile conditions from 
frozen stocks obtained from the ATCC (Manassas, USA). Between 2x 105 and 2x 106 
cells / ml were maintained in RPMI 1640 media with 10% fetal calf serum, 2 mM 
glutamine and 10 U penicillin/ streptomycin. 
3.2.13 Total RNA extraction from nasal biopsies. 
Total RNA was extracted from nasal biopsies with RNAwiz buffer (Ambion, 
Huntington, UK) using a modified version of the manufacturers protocol: the biopsy 
was transferred with a pipette tip into an eppendorf tube and 250 pl of RNAWIZ added. 
The biopsy was disrupted with 300 vigorous pulses with a manual pellet pestle 
homogeniser (Anachem, Luton, UK). The homogenate was incubated at room 
temperature for 5 min before the addition of 50 pl of chloroform. The homogenate was 
shaken vigorously for 20 seconds and then incubated at room temperature for 10 min. 
The homogenate was centrifuged at 13 000 rpm in a benchtop centrifuge at 4'C for 15 
min and then upper aqueous phase removed and placed in a new eppendorf tube. 125 Al 
of RNase free H20 was added to the aqueous phase, mixed and then 250 PI of 
isopropanol added and again mixed well. This was allowed to incubate at room 
temperature for 10 min before being centrifuged at 13 000 rpm at 4'C for 15 min. The 
supernatant was removed and the pellet washed with 250 ýd of cold 75% ethanol and 
then centrifuged at 13 000 rpm at 40C for 5 min. The supernatant was again discarded 
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and the pellet air-dried for 10 min before being resuspended in 20 ýil RNase free H20. 
All tubes were RNase free and RNase free filtered pipette tips were used at all times 
when preparing and handling RNA. RNA samples were stored at -70'C 
3.2.14 Total RNA extraction from PBUC. 
I ml of RNAWIZ buffer was used to resuspend the PBMC cell pellet isolated from 25 ml 
of whole blood (approximately 4x 107 cells). This homogenate was divided into four 
aliquots each of 250 ýtl and then the protocol followed as detailed in section 3.2.12 to 
isolate total RNA. 
3.2.15 Total RNA extraction from ceft lines. 
The cells were shaken gently, then 2x 106 cells harvested and centrifuged in a Sorvall 
RT 6000 D centrifuge at 1500 for 7 min at room temperature. The supernatant was 
removed and the pellets frozen at -700C for at least 30 min to aid homogenisation. The 
cell pellet was resuspended in 500 ýLl RNAWIZ buffer and then the protocol detailed in 
3.2.12 followed in order to isolate total RNA, except double volumes of all reagents 
were used. 
3.2.16 QuantitationofRNAandDNA. 
Quantitation of total RNA and DNA was carried out by spectophotometry at 260nm on 
a Cary UV spectrophotometer. Only OD readings between 0.1 and I were viewed as 
reliable. For quantitation of RNA, 2 gl was added to 98 pl of H20 and the OD reading 
multiplied by dilution (50), multiplied by the concentration of RNA that absorbed I OD 
unit at 260 nm (40 pg / pl) to determine actual concentration of RNA in the sample (gg 
/ ýtl). For DNA (generated by minipreparation of plasmids, for example) 10 41 was 
added to 90 gl of H20 and the OD reading multiplied by the dilution factor of 10 and 
then multiplied by the concentration of DNA that absorbed I OD unit at 260 nm (50 gg 
/ ýtl) to determine the actual concentration of DNA in the sample (ýtg / pl). 
3.2.17 Synthesis of cDNA. 
Initially in the study, an oligo dT primer was used to make cDNA. This protocol was 
mainly applied to the samples analysed in chapters 4 and 5 (with the exception of the 
subject GJ29): 5 ýtg of total RNA was denatured at 70'C for 2 min and then placed on 
ice, before adding 5X first strand buffer (Invitrogen), DTT to a final concentration of 
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5mM (Invitrogen), dNTPs to a final concentration of 0.4 mM each (Invitrogen), 0.2 ýlg 
oligo dT primer, 16 U RNase OUT (Invitrogen), 400 U M-MLV reverse transcriptase 
(Invitrogen) and the appropriate quantity of RNase free H20 to a 40 ýLl reaction. The 
reaction was then incubated at 42'C for I hr. 
A modification to this protocol was suggested by a colleague and was used to make 
cDNA from GJ29 and later samples. This generated a greater quantity of cDNA that 
appeared to be of better quality: 5 gg of total RNA was denatured at 700C for 2 min and 
then placed on ice, before adding 5X first strand buffer, DTT to a final concentration of 
5mM, dNTPs to a final concentration of 0.4 mM each, 0.2 ýig oligo dT primer, 5 gg 
d(N)jo random primers (Molecular Biology Unit, KCL, London, UK), 16 U RNase 
OUT, 400 U M-MLV reverse transcriptase and the appropriate quantity of RNase free 
H20 to a 40 gl reaction. This was then incubated at 37'C for 10 min, 42'C for 40 min 
and then 500C for 10 min. 160 gl of sterile H20 was then added to the cDNA before 
incubating at I OOOC for 2 min. 
3.2.18 PCRampifficationof VtrCecDNA transcripts. 
All PCR primers were manufactured by the Molecular Biology Unit, King's College 
London. 
The VH-C& PCR was designed such that transcripts encoding both secreted and non- 
secreted forms of IgE were amplified. Germline transcripts and unrearranged genes 
were not amplified by this PCR. Initially, in order to PCR amplify VH-CF. transcripts 
(approx. 450 bp) Taq DNA polymerase was used as follows; 5 pl of cDNA was added 
to a 50 pl PCR reaction that included family-specific primers homologous with the VH 
region leader sequence (VHIL-VH6L, VH7 being amplified by VHIL) at 0.2 PM and a 
C&I specific primer (Cel) at 0.2 gM. IOX buffer, dNTP's each at 0.5 mM, 1.5 MM 
MgCI2 and 2.5 U of Platinum Taq DNA polymerase (Invitrogen) were also included. 
The reaction was initially denatured at 95'C for 5 min, then subjected to 30 cycles of 
denaturation at 94'C for I min, annealing at 56'C for I min, and extension at 72'C for I 
min before a final extension at 72'C for 5 min. All PCRs were carried out in a Perkin 
Elmer GeneAmp 2400 PCR machine. 
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5 ýtl of the first PCR reaction was transferred into a second, nested, PCR that differed 
only in that it included family-specific primers homologous with FWRI of the Vtj 
region (VHIF-Vtl6F, V117 being amplified by VHIF) and an inner CF-I primer (CS2). 
This PCR had an initial denaturation at 95'C for 5 min, then 30 cycles of denaturation at 
94'C for I min, annealing at 650C for I min, extension at 72'C for I min and a final 
extension at 72'C for 5 min. 
After the analysis of data from patient SL5 (chapter 4), all subsequent VH-CH 
amplification utilised the proof-reading Pfu DNA polymerase as follows; 5 ýfl of cDNA 
was added to a 50 41 PCR reaction that included family-specific primers homologous 
with the VH region leader sequence (VHIL-VH6L, VH7 being amplified by VHIL) at 0.5 
gM and a CF-I specific primer (CF. 1) at 0.5 pM. IOX buffer, dNTP's each at 0.25 mM 
and 1.26 U of Pfu DNA polymerase (Promega, Southampton, UK) were also included. 
The reaction was initially denatured at 95'C for 2 min, then subjected to 30 cycles of 
denaturation at 94'C for I min, annealing at 56'C for 2 min, and extension at 72'C for 2 
min before a final extension at 72'C for 10 min. 
5 ýtl of the first PCR reaction was transferred into a second, nested, PCR that differed 
only in that it included family-specific primers homologous with FWRI of the VH 
region (VIIIF-VH6F, VH7 being amplified by VHIF) and an inner Cel primer (Ce2). 
This PCR had an initial denaturation at 95'C for 2 min, then 30 cycles of denaturation at 
94'C for I min, annealing at 65'C for 2 min, extension at 72'C for 2 min and a final 
extension at 72'C for 10 min. 
When a particular V1, gene class was analysed just the appropriate VH region primers 
were used. 














These primers were based on VH region primers published previously [Campbell el al., 
19921, [Hawkins el al., 1994]. 
C61: 5'-TGTCCCGTTGAGGGAGCCTGT-3', 
Cs2: 5'-GGGTCGACAGTCACGGAGGTGGCATT-3', 
These primers were based on Ce primers published previously [Van der Stoep el al., 
1993]. 
3.2-19 PCR ampiffication of VtrCil, KrCa or VtrCy cDNA transcripts (PCR 
I and 2). 
In order to amplify VH-CP, VH-CCC or VH-CY transcripts (approx. 450 bp) a protocol 
based on that used by previous researchers was used [Efremov et al., 1993], [Snow et 
aL, 1998] (see chapter 5, particularly Fig. 5.2.1). This enabled the selective 
amplification of cDNA from any clones that were related to an IgE B cell clone, but 
which expressed a different antibody isotype. The conditions employed in the first PCR 
and the second, nested PCR were the same as detailed for VH-CF- in 3.2.18 with the 
following exceptions: Only the appropriate VH region primers were used (e. g. if related 
clones from a VH5 family were being investigated, the VH5 primers were used). These 
were used in conjunction with each of the Sets Of CH primers (Cp I, Cot I or Cy I in PCR 
1, Cg2, Ca2 or Cy2 in PCR 2) as separate reactions. If the VH5 gene class was being 
amplified the primer VH5Fm was used in PCR 2 instead of VH51F. The annealing 
temperature used in PCR 2 was 54'C for 2 min. 
The primers used were as follows: 
VH5Fm: 5'-TGCAGCTGCTCYCAGTCTG-3' 
Cýtl: 5'-GCTCGTATCCGACGGGGAAT-3' 






The Qt2 and Ca2 primers were based on that published [Sahota et al., 1996], [Snow et 
al., 1997]. 
The PCR products from PCR 2 were subjected to agarose gel electrophoresis on a 1% 
agarose gel, the PCR products excised and the DNA extracted from the gel. 
3.2.20 PCR ampiffication of signature region cDNA transcripts joined to 
Cli, Ca or Cr (PCR 3). 
5pl of the gel extracted PCR 2 product (section 3.2.18) was carried forward into a third, 
semi-nested PCR for each isotype. This reaction utilized Cp2, Ccc2 or Cy2 in 
conjunction with a primer homologous to theVH-D region specific to the signature 
region of the B cell clonal family that was being investigated. The other reagents used 
in the PCR remained the same as that detailed in section 3.2.18. 
In order to amplify the signature region specific to the family of interest in conjunction 
with the CH region, PCR 3 was employed. PCR 3 used the same reagents as detailed in 
section 3.2.18, but the appropriate inner CH primer was used in conjunction with a 
primer homologous to the VH-D region of the particular B cell clonal family. Therefore 
in order to identify clones from other isotypes that may have been related to the family 
Of VH3 IgE B cell clones from SO 16 (chapter 5), PCR I and 2 amplified VH3-CP, VH3- 
C(x and VH3-Cy transcripts in separate reactions. In PCR 3a sample of the PCR 2 VH3- 
Cot products was further amplified using the family specific VH-D region primer B 16V3 
in conjunction with the inner IgA primer (Ccc2). PCR 3 used an initial denaturation at 
95'C for 2 min, then 20 cycles of denaturation at 940C for I min, annealing at 53'C for 
2 min, extension at 72'C for 2 min and then a final extension at 720C for 15 min. 
B16V3: 5'-GTGAAAGCCCGTTATAGTGC-3' 
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In order to identify clones from other isotypes that may have been related to the family 
Of VH5 IgE B cell clones isolated from S016 (chapter 5), PCR I and 2 amplified VH5- 
Cp, V115-Ca and Vt, 5-Cy transcripts in separate reactions. In PCR 3 samples of the 
PCR 2 V1,5-Coc and VH5-C-( products were amplified further using the family specific 
VH-D region primer (B I 6V5) in conjunction with the inner IgA (C(x2) and the inner IgG 
(Cy2) primer in separate reactions, to generate 95 bp and 94 bp PCR products 
respectively. This PCR 3 used the same cycling conditions detailed above for B 16V3. 
B16V5: 5'-AGACATAAGAGTGGCTCG-3' 
In order to identify clones from other isotypes that may have been related to the family 
Of V115 IgE B cell clones isolated from AP 19 (chapter 5), PCR I and 2 amplified V, 15 - 
Cp, VO-Cot and V115 -Cy transcripts in separate reactions. In PCR 3a sample of the 
PCR 2 V115-Cp and V, 15-Ccc products were amplified further using the family specific 
VH-D region primer (B19V5) in conjunction with the inner IgM (C42), IgA (Cct2) and 
the inner IgG (Cy2) primer in separate reactions. This PCR 3 also used the same 
cycling conditions detailed above for B16V3. 
B19V5: 5'-TATTACTGTGCGGCGGC -3' 
In order to identify clones from other isotypes that may have been related to the family 
Of VH3 IgE B cell clones isolated from CMIO (chapter 5), PCR1 and 2 amplified V113- 
Cý4 VH3-Ca and VH3-Cy transcripts in separate reactions. In PCR 3a sample of the 
PCR 2 VI-13-Cot and VH3-Cy products were amplified further using the family specific 
VH-D region primer (B I OV3) in conjunction with the inner IgA (Cet2) and the inner IgG 
(Cy2) primer in separate reactions. This PCR 3 used an initial denaturation at 95"C for 
2 min, then 20 cycles of denaturation at 940C for I min, annealing at 52'C for 2 min, 
extension at 72'C for 2 min and then a final extension at 72'C for 15 min. 
BIOV3: 5'-TATTACTGTGC/TGAGCCACGAA-3' 
In order to identify any IgE clones in SJ24B that were related to the family of IgE' VH4 
B cell clones isolated from the other half of the biopsy SJ24A (chapter 6), in PCR I and 
Chapter 3 Matefials and methods 65 
2 VH4-C& transcripts were specifically amplified. In PCR 3a sample of the PCR 2 VH4- 
CF. products was amplified further using the family specific VH-D region primer 
(SJ24B3) in conjunction with the inner IgE (CF. 2) primer. This PCR 3 used an initial 
denaturation at 950C for 2 min, then 20 cycles of denaturation at 940C for I min, 
annealing at 65'C for 2 min, extension at 72'C for 2 min and then a final extension at 
72'C for 15 min and generated PCR products of 175 bp. 
SJ24B3: 5'-CCAGAGATTTGGGGCGTTATTACTATGGTTCAGGGACG -3' 
The successful PCR products from the PCR 3 experiments were subjected to agarose 
gel electrophoresis on a 1% or 2% gel, the DNA extracted from the gel, cloned and 
sequenced. 
3.2.21 PCR ampiffication of VtrD-JH IgA cDNA transcripts (PCR 4). 
In order to analyse the VH region sequence from any clones identified in PCR 2 from 
which the correct signature region sequence had been amplified in PCR 3 (in this study 
only the V115 IgA clones amplified from the nasal mucosa of S016), 5 41 of the gel 
extracted PCR 2 products was carried forward into a semi-nested PCR 4. This used 
identical reagents to those detailed in section 3.2.18, except that the inner VH5 primer 
(VH5Fm) was used in conjunction with a primer homologous to the D-J junction unique 
to the S016 VH5 family of clones (SO16A4). An initial denaturation at 95'C for 2 min 
was followed by 20 cycles of denaturation at 94'C for I min, annealing at 54'C for 2 
min, extension at 72'C for 2 min, before a final extension at 720C for 15 min. Resultant 
PCR products (327 bp) were subjected to agarose gel electrophoresis on a 1% gel, the 
DNA extracted from the gel, cloned and sequenced. 
S016A4: 5'-TGGCCCCAGTAGTCAGC-3' 
3.2.22 PCR ampiffication of CDRI-D-JH IgA cDNA transcdpts (PCR 5). 
A further experiment to re-amplify the complete sequence of one of the IgA clonal 
family members (VH5-IgA CI) from the CDRI in the VH region to Cet was carried out 
by PCR 5 (previously PCR 3 and PCR 4 generated either part of the full sequence). 
PCR 5 was again semi-nested, using 5 ýd of the gel extracted PCR 2 products. The 
reagents were the same as detailed in 3.2.18, except that a primer homologous to the 
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mutated CDRI region of the clone (Bl6V5Cl) was used in conjunction with the inner 
IgA (C(x2) primer. The PCR was initially denatured at 95'C for 2 min and then was 
subjected to 20 cycles of denaturation at 94'C for I min, annealing at 53'C for 2 min, 
extension at 72'C for 2 min, before a final extension at 72'C for 15 min. Resultant PCR 
products (308 bp) were subjected to agarose gel electrophoresis on a 1% gel, the DNA 
extracted, cloned and sequenced. 
B16V5CI: 5'-TATAAGTTTGCCACCTATGCC-3' 
3.2.23 PCR ampiffication of GAPDH. 
The housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
amplified to confirm either that the cDNA was of sufficient quality for PCR analysis, or 
that approximately comparable amounts of cDNA were used in the PCR amplification 
of different samples. GAPDH amplification by Taq DNA polymerase was as follows; 
2.5 ýJ of cDNA was added to a 25 ýd PCR reaction that included the primers GAPDHF2 
and GAPDHR2 at I pM, I OX buffer, 1.5MM M902, dNTP's each at 0.2 mM and 1.25 
U of Platinum Taq DNA polymerase. The reaction was initially denatured at 95'C for 5 
min, then subjected to denaturation at 94'C for I min, annealing at 591C for I min, 
extension at 72'C for I min before a final extension at 72'C for 5 min. 
GAPDH amplification by Pfu DNA polymerase was as follows; 2.5 PI of cDNA was 
added to a 25 pl PCR reaction that included the primers GAPDBF2 and GAPDHR2 at I 
^ IOX buffer, dNTP's each at 0.25 mM and 0.63 U of P! fu DNA polymerase. The 
reaction was initially denatured at 95'C for 2 min, then subjected to denaturation at 
94'C for I min, annealing at 59'C for 2 min, and extension at 72'C for 2 min before a 
final extension at 72'C for 10 min. 
Normally 30 cycles of PCR were undertaken, but when samples were being normalised 
to GAPDH expression levels, PCR products were removed at 15,20,25 and 30 cycles 
for comparison. 393 bp PCR products resulted. The GAPDH primers were designed by 
David Fear in the Gould group. 
GAPDHIF2: 5'-ATTTGGTCGTATTGGGCGCCTGGTC-3' 
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GAPDHR2: 5'-TCATACTTCTCATTGTTCACACCCATG-3' 
3.2.24 PCR ampiffication of AID. 
In this study, amplification of AID cDNA transcripts was carried out using both a single 
and a nested PCR protocol (chapter 8). To amplify AID in one PCR the following was 
carried out; 5 ýtl of cDNA was added to a 25 ýLl PCR reaction that included the primers 
AID3 and AID4 at 0.2 ýtM, IOX buffer, I MM MgC12, dNTP's each at 0.2 mM and 1.25 
U of Platinum Taq DNA polymerase. The reaction was initially denatured at 95'C for 5 
min, then 40 cycles of denaturation at 94'C for I min, annealing at 56'C for I min, 
extension at 72'C for 2 min before a final extension at 72'C for 5 min to generate a 647 
bp PCR product. 
When amplification of AID by a nested PCR was carried out, the initial PCR was 
exactly as detailed above, although the reaction was only subjected to 30 cycles. 5 gl of 
the initial PCR was carried over and included in the second, nested 25 ýtl PCR with the 
same reagents as detailed above except that the inner primers AIDI and AID2 at 0.2 PM 
were used. The reaction was initially denatured at 95'C for 5 min, then 30 cycles of 
denaturation at 94'C for I min, annealing at 60'C for I min, extension at 72'C for 2 
min before a final extension at 72'C for 5 min, to generate a 335 bp PCR product. 





These primers were based on AID primers published previously [Muto et al., 2000], 
[Revy et al., 2000]. 
3.2.25 Southem blot analysis of AID mRNA expression. 
The presence of AID PCR products was confirmed by Southern blot analysis (chapter 
8). 10 41 of the nested AID PCR was subjected to electrophoresis on a 1.5% agarose 
gel. The agarose gel was then incubated with 200 ml of denaturing buffer shaking, at 
room temperature for 45 min. Nylon membrane (Sigma) was briefly immersed in 
Chapter 3 Materials and methods 68 
transfer buffer and then positioned under the inverted gel (also rinsed briefly with 
Transfer Buffer) and placed under vacuum. Once the vacuum had sealed, transfer 
buffer was added to cover the gel and the DNA left to transfer to the membrane for 45 
min 
The nylon membrane was rinsed briefly in MilliQ water, then dried and stored at room 
temperature until needed. In order to probe for AID RT-PCR products, 25 ng of an AID 
specific probe (spanning the 3' of exon 3 and the 5' of exon 4) was labelled by random 
priming, briefly the probe was denatured at 100'C for 2 min and then added to a DNA 
labelling bead (Amersham, Chalfont St. Giles, LJK), resuspended in 35 gl of H20.5gl 
of cAM32 was added to the mix to end-label the probe. This reaction was incubated 
for I hr at 37 T before being transferred onto a pre-spun G25 column (Roche, Basel, 
Switzerland) and the labelled probe harvested by centrifugation of the column at 20OOg 
for 4 min in a benchtop centrifuge, according to the manufacturers instructions. 
The membrane was placed inside a roller bottle, containing 20 ml of pre-hybridisation 
buffer (Ambion) and incubated, rotating, at 42'C for 45 min before 81AI of the labelled 
probe was added and the membrane incubated at 420C, rotating, overnight. The probe 
was then removed and 200 ml of 5X SSC buffer added to the roller bottle to wash the 
membrane for 20 min at 420C, rotating. The membrane was then subjected to a further 
two washes with IX SSC buffer, one wash with 0.2X SSC buffer and finally one wash 
with 0.1 X SSC buffer. The membrane was then covered with Saran Wrap and exposed 
to Kodak MR-I Biomax fast film (Sigma) overnight, at room temperature, using 
amplifying screens. The film was then developed using a Kodak automatic developer, 
AID probe, 5'- CCGGGGTGCAAATAGCCATCATGACCTTCAAAGATTATTT 
TTACTGCTGGAATACTTTTG -3' 
3.2.26 Agarose gel electrophoresis. 
DNA was subjected to agarose gel electrophoresis as follows; agarose (0.5,1 and 2g 
for a 0.5,1 or 2% gel respectively) was dissolved in 100 ml of TAE buffer for 3 min at 
70'C in the microwave. The molten agarose, was left at room temperature to cool for 10 
- 15 min before adding I gl of ethidium bromide and mixing. The molten agarose was 
then poured into a gel tray and the appropriate sized comb added. The agarose was left 
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for 30 min at room temperature to solidify. The comb was removed and the agarose gel 
was placed, still in the gel tray in an electrophoresis tank and immersed in TAE that also 
contained ethidium bromide. An appropriate DNA ladder was loaded onto the gel. I ýtl 
of xylene cyanol loading buffer was added for every 10 ýtl of DNA that was then loaded 
into each well. A constant voltage of H5V was then applied. When the DNA bands 
were separated, after approximately 35 min for most PCR products, the gel was exposed 
to ultra violet light. Pictures of the DNA bands evident were taken with a Kodak 
Poloroid camera or the Syngene Gene Genius Bioimaging System (Cambridge, UK). 
Get pictures presented in this study are almost always presented as the inverse (black 
bands on a pale background) because of the better resolution this provided when images 
were processed with the Syngene Gene Genius Bioimaging System. 
3.2.27 DNA ladders. 
Two different DNA ladders were used in this study. The Hpa 11 ladder (Molecular 
Biology Unit, KCL) comprised DNA fragments evident between 157 bp and 710 bp 
generated by the digestion of the plasmid pBS Sk by Hl)ti 11 (Fig, 3.2.25.1). 7 ýLl of 








Fhq. 3.2.25.1; A-garose gel electrophoresis of Hpa H ladder 7 ýd Hpa 11 ladder (MBU, King's 
College London) was subjected to electrophoresis on a 1% agarose gel and visualised under 
UV. The number of base pairs (bp) comprising each DNA fragment from 157 - 710 bp are 
labelled. 
A 100 bp ladder (Promega) was also used. This ladder comprised a range of different 
DNA fragments between 100 bp and 1500 bp (Fig. 3.2.25.2). 5 ýtl of ladder was loaded 
into a single well of each agarose gel. 
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1500 bp----> 
900 bp < 1000 bp 
700 bp---> <--- 800 bp 
<- -- 600 bp 500 bp- > 
400 bp 
300 bp > 
<-- 200 bp 
100 bp > 
Rg. 3.2.25.2; Agarose get electrophoresis of 100 bp ladder. 5 ýd 100 bp ladder (Promega) 
was subjected to electrophoresis on a1% agarose gel and visualised under UV. The number of 
base pairs (bp) comprising each DNA fragment from 100 -1500 bp are labelled. 
3.2.28 Gel extraction of DNA. 
In order to purify PCR products that had been subjected to agarose gel electrophoresis, 
the DNA band was carefully excised from the agarose gel with a razor blade and the 
weight of the gel slice calculated. DNA was extracted from the gel slice using the 
QlAquick Get Extraction kit (Qiagen, Crawley, UK) with a microcentrifuge according 
to the manufacturers instructions. DNA was eluted in 50 ýJ of the elution buffer EB, 
unless the original DNA band had appeared faint on the agarose gel, in which case DNA 
was eluted in 30 ýtl of the elution buffer. 
3.2.29 Quantitation of gel extracted DNA for ligation. 
15 ýil gel extracted DNA was subjected to electrophoresis on a 1% agarose gel. The 
intensity of the extracted DNA was determined using the GeneTools software package 
in the Syngene Gene Genius Bioimaging System and compared to the intensity of a 
known quantity of DNA from one of the DNA ladders. This enabled the approximate 
concentration of each DNA sample to be determined. 
3.2.30 Cloning of PCR products generated by Taq DNA polyrnerase. 
Where possible, 20 ng of gel extracted DNA was included in each ligation reaction. 
The 'TOPO TA cloning kit for sequencing' (Invitrogen) was used for both the ligation 
and transformation. The manufacturers instructions for the transformation of 
chemically competent A. coli (One Shot TOP 10 cells) was followed. Wherever 
relevant, the ligation and transformation was incubated for the longest amount of time 
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recommended by the manufacturer in order to ensure that the procedure was as efficient 
as possible. 100 ýtl of transformation mix was spread on each of three LB agar plates 
containing ampicillin and incubated at 37'C overnight to allow the positive selection of 
recombinants (as a result of disruption of the lethal ccdB gene). 
3.2.31 Cloning of PCR products generated by Pfu DNA polymerase. 
Where possible, 20 ng of gel extracted DNA was included in each ligation reaction. 
Where DNA from the PBMC and the nasal biopsy of the same patient was being ligated 
in parallel experiments, the quantity of DNA included in each was identical. The 'Zero 
Blunt TOPO PCR cloning kit' (Invitrogen) was used for both the ligation and 
transformation. The manufacturers instructions for the transformation of chemically 
competent E coli (One Shot TOP 10 cells) was followed. Wherever relevant, the 
ligation and transformation was incubated for the longest amount of time recommended 
by the manufacturer in order to ensure that the procedure was as efficient as possible. 
100 gl of transformation mix was spread on each of three LB agar plates containing 
kanamycin and incubated at 37T overnight to allow the positive selection of 
recombinants (as a result of disruption of the lethal ccdB gene). 
3.2.32 Overnight 3ml cultures of transformed E. coli. 
3 ml overnight cultures were used to grow sufficient of a transformed bacterial colony 
to enable plasmid minipreparation. 3 ml of LB (with ampicillin if the DNA was 
generated by Taq, or kanamycin if generated by Pfu) was placed in a 50 ml universal 
tube. Each tube was innoculated with a single discreet transformed bacterial colony and 
incubated overnight, shaking (225 rpm) at 37T. 
3.2.33 Mini-preparation of plasmid DNA. 
Plasmid DNA was isolated from a 3ml overnight culture. The culture was transferred to 
an Eppendorf tube and the E. coli pelleted by centrifugation in a microcentrifiage at 
10,000 rpm for 5 min. Isolation of plasmid DNA from the bacteria was then carried out 
using the 'Wizard Plus SV Miniprep DNA Purification System' (Promega) by 
microcentrifiagation, according to the manufacturers instructions. Briefly, the cell pellet 
was resuspended in 250 gl of Cell Resuspension Solution (Promega) and then 250 gl of 
Cell Lysis Solution (Promega) added. The tube was inverted four times and then 10 gl 
of Alkaline Protease Solution (Promega. ) added, again inverted four times and incubated 
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for 5 min at room temperature. 350 gl of Neutralisation Solution was added, inverted 
again four times and then centrifuged at 13,000 rpm for 13 min at room temperature in a 
benchtop microfuge. The lysate was then added to a Spin Column with Collection Tube 
(Promega) and centrifuged at 13,000 rpm in a benchtop centrifuge for I min at room 
temperature. The flowthrough was discarded and 750 gl of Wash Solution (Promega) 
added, centriffiged again as above and repeated with 250 pl of Wash Solution, the 
flowthrough discarded and then centrifuged at 13,000 rpm in a benchtop centrifuge for 2 
min at room temperature. The column was transferred to a 1.5 ml Eppendorf tube and 
100g] of H20. This was centrifuged at 13,000 rpm in a benchtop centrifuge for I min at 
room temperature to elute the resuspended plasmid DNA which was stored at -200C or 
below. 
3.2.34 EcoRl digestion of plasmid DNA. 
In order to confirm that each plasmid isolated by mini-preparation contained the 
expected DNA insert, I gl of plasmid DNA was subjected to EcoRl digestion in a 10 41 
reaction that also included I pl IOX buffer, and 10 U of EcoRl (Promega). The 
restriction digest was incubated at 370C for 2 hrs before being subjected to agarose gel 
electrophoresis. Any plasmid from which the expected size DNA fragment was not 
excised were discarded. 
3.2.35 Sequencing of plasmid DNA. 
Plasmid DNA containing the sequence of interest as an insert was sequenced using the 
M13 forward or M13 reverse primer and an ABI 3100 Automated DNA sequencer 
(Perkin Elmer, Beconsfield, UK) by the Advanced Biotechnology Centre (Imperial 
College, London, UK). Sequences of importance e. g. those isolated for VH region 
analysis were always repeated. 
MI 3 forward (-20): 5'-GTAAAACGACGGCCAG-3' 
M13 reverse: 5'-CAGGAAACAGCTATGAC-3' 
3.2.36 DNA sequence analysis. 
Alignment of multiple sequences was carried out with the use of the 'GeneTool Lite' 
program (DoubleTwist. com). The identity of non-VHregion sequences was determined 
by use of the BLAST database (http: //www. ncbi. nlm. nih. gov/BLAST). 
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The identity of VII region sequences was determined by use of the VBase database 
(www. mrc-cpe. cam. ac. uk), enabling assignment Of VH, D and JH genes and their 
somatic mutations according to their closest homology to a germline sequence. When 
the identity of aD gene was assigned with a score of less than 50, the D gene was 
classified as not reliably identified (+5 being awarded for a nucleotide match, -4 for a 
mismatch). Where the assignment of the VH and D gene, or the D and JH gene 
overlapped, precedence was given to the VH sequence and JH sequence respectively, 
such that an apparently short D gene sequence was presented in some sequences. All 
the sequences were identified as having an in-frame rearrangement, implying translation 
of the mRNA into protein. 
The signature region, defining the clonal identity of aB cell, included the VH-D-JH 
recombination junction (CDR3 / FNVR4), at which non-templated (N) nucleotides were 
often also inserted. Genealogical trees of related B cell clones were constructed based 
on the premise that VH region mutations shared by related B cell clones were acquired 
by SHM early in the evolution of the clonal family, while mutations unique to each B 
cell clone were acquired later. Mutations were detailed such that 31(2) refeffed to a 
mutation at codon 31, position 2. The polymorphic codons 31a, 31b, 52a, 52b, 52c, 
82a, 82b and 82c were detailed as such. Some previous researchers had included these 
within the normal numbering. In this study, the polymorphic codons are distinguished 
as 31a, for example, rather than 32. This means that the mutation at Ala72 refeffed to 
by [Snow et al., 1997] corresponds to and is detailed as Ala7l. in this study. 
The details of all VH region sequences were added to a database to enable any 
contaminants (i. e. identical VH-D-JH sequences isolated from different patients) to be 
identified and eliminated from the study. Any sequences that demonstrated evidence of 
being a possible PCR artefact (i. e. the 5' of one sequence and the 3' of another) were 
also eliminated from the study. 
3.2.37 Frozen nasal biopsy sections. 
All immunohistochemistry (chapter 6) utilised 6gm sections cut at -200C by cryostat 
from nasal biopsy samples mounted in OCT. Section were placed on polysine 
microscope slides (BDH Laboratory Supplies, Poole, UK), stored at -70 T and used as 
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quickly as possible. Frozen tissue sections were used in order to preserve the integrity 
of the RNA for the intended RT-PCR of microdissected cells and no counter-staining 
was undertaken. All sections were visualised with a Zeiss Axioscop microscope (New 
York, USA). Images were processed using an Axiocarn colour CCD camera and 
Axiovision software. Fluorescent images stained with FITC were visualised using a 
band pass filter with an excitation of 450 - 490 nm, a dichroic mirror at 510 nm and a 
band pass filter with an emission spectrum of 515-565 nm. Fluorescent images stained 
with Cy3 were visualised with a narrow pass filter with an excitation spectrum of 546 ± 
12 nm, a dichroic mirror at 560 nm and a band pass filter with an emission spectrum of 
575 - 640 nm. Chromogen stained sections were stored at room temperature for future 
reference. Fluorescent stained sections were stored in the dark at 4'C for no longer than 
I week. 
3.2.38 Double staining of CD138 and JgE in nasal biopsy sections, 
visualised by chromogenic substrates. 
The frozen nasal biopsy sections used in this protocol were fixed in 4% 
paraformaldehyde after being cut on the cryostat, before being snap-frozen in liquid N2 
and stored at -700C. The sections were thawed at room temperature for I min before 
being washed twice, for 2 min in TBS. The sections were then incubated for 10 min 
with peroxidase blocking reagent (Dako, S2001) before again being washed for 2 min in 
TBS. The sections were additionally incubated in 0.2% H202 for 5 min and then 
washed twice for 2 min in TBS before being incubated in blocking solution for 15 min 
(ISCOVE's media with additionally 10% fetal calf serum, 10% normal goat serum 
(Vector Laboratories, Burlingame, USA) and 10% normal horse serum (Vector 
Laboratories), 10 U penicillin / strepamycin and 2 mM glutamine. (The antibodies were 
also diluted in this blocking medium). An avidin / biotin block (Vector Laboratories) 
was then applied, each for 10 min with a2 min TBS wash in between. 
The sections were incubated with goat anti-human IgE-biotin antibody (12.5 ýtg / ml), 
(Vector Laboratories, BA-3040) or (as an isotype control) biotinylated goat-IgG (Vector 
Laboratories, BI-1001) for 35 mins. The sections were washed three times for 2 min in 
TBS and then incubated with streptavidin-IIRP (2 gg / ml), (Dako, P0397) for 35 min 
before washing three times for 5 min in TBS. The sections were then incubated with 
mouse anti-human CD138 antibody (0.1 mg / ml), (Serotec, MCA681H, Oxford, UK) or 
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as an isotype control, mouse MOPC21 antibody (5pg / ml), (Sigma, M7894), both for 
35 min. After washing three times in TBS each for 2 min, the sections were then 
incubated with goat anti-mouse immunoglobulins-alkaline phosphatase antibody (20 pg 
/ ml), (Dako, D0486) for 35 min. After washing three times in TBS for 5 min the 
sections were then incubated with Fuschin chromogenic substrate (Dako) and 
Levamisole (Dako) for 7 min, washed twice in 0.2 M sodium acetate (pH 4.6) for 5 min, 
then incubated with DAB chromogenic substrate (Dako) for 10 min. 
The sections were finally washed in MilliQ H20 for 5 min, before being mounted with a 
coverslip and Glycergel (Dako). 
3.2.39 Double staining of CD138 and JgE in nasal biopsy sections, 
visuallsed by fluorescence. 
The frozen nasal biopsy sections used in this protocol were fixed in 4% 
paraformaldehyde after being cut on the cryostat, before being snap-frozen in liquid N2 
and stored at -70'C. The sections were thawed at room temperature for I min before 
being washed twice, for 2 min in TBS. The sections were then incubated for 10 min 
with peroxidase blocking reagent before again being washed for 2 min in TBS. The 
sections were additionally incubated in 0.2% H202for 5 min and then washed twice for 
2 min in TBS before being incubated in blocking solution for 15 min (ISCOVE's media 
with additionally 101/6 fetal calf seruniý 101/o normal goat serum and 10% normal horse 
serum, 10 U penicillin / strepamycin and 2 mM glutamine. (The antibodies were also 
diluted in this blocking medium). An avidin / biotin block was then applied, each for 10 
min with a2 min TBS wash in between. 
The sections were incubated with mouse anti-human CD 13 8 antibody (0.1 mg / ml) or 
as an isotype control, mouse MOPC21 antibody (5pg / mi), for 35 minutes. The 
sections were washed three times for 2 min in TBS and then incubated with goat anti- 
mouse immunoglobulins-FITC (13.3 pg / ml), (Dako, F0479) for 35 mins, before 
washing three times for 5 min in TBS. The sections were then incubated with goat anti- 
human IgE-biotin antibody (12.5 gg / ml) or (as an isotype control) biotinylated goat- 
IgG (Vector Laboratories, Bl- 100 1), for 35 min. After washing three times in TBS each 
for 2 min, the sections were then incubated with streptavidin-Cy3 (20 gg / ml), 
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(Amersham) for 35 min and then finally washed three times in TBS for 5 min before 
being mounted with a coverslip and fluorescence mountant (Dako). 
3.2.40 Staining of CD19 in nasal biopsy sections, visualised by 
chromogenic substrate. 
This protocol was based on that previously published [KleinJan et al., 2000]. The 
frozen nasal biopsy sections were thawed at room temperature for I min before being 
fixed in acetone at room temperature for 10 min. The sections were then washed twice, 
for 2 min in TBS before being incubated in blocking solution for 15 min (ISCOVE's 
media with additionally 10% fetal calf serum, 10% normal goat serum and 10% normal 
horse serum, 10 U penicillin / strepamycin and 2 mM glutamine. (The antibodies were 
also diluted in this blocking medium). An avidin / biotin block was then applied, each 
for 10 min with a2 min TBS wash in between. 
The sections were incubated with mouse anti-human CD19 antibody (25 gg / ml), 
(Immunotech-Coulter, IM1283, Miami, USA) or as an isotype control, mouse MOPC21 
antibody (5 ýtg / ml) for 60 min. The sections were washed three times for 2 min in 
TBS and then incubated with biotinylated goat anti-mouse IgG (10 Ag / ml), (Vector 
Laboratories, BA-9200) for 30 min. After washing three times in TBS each for 2 min, 
the sections were then incubated with alkaline phosphatase-conjugated streptavidin (5 
gg / ml), (Vector Laboratories, SA-5100) for 30 min. After three 5 min washes in TBS, 
the sections were incubated for 10 min with Fuschin chromogenic substrate and 
Levamisole for 10 min. 
The sections were finally washed in MilliQ H20 for 5 min, before being mounted with a 
coverslip and Glycergel. 
3.2.41 Staining of CD19 in nasal biopsy sections, visualised by 
fluorescence. 
The protocol described in 3.2.38 was followed until the third antibody incubation where 
incubation of the sections was commenced in the dark with Cy3-conjugated streptavidin 
(20 pg / ml), (Amersham, PA 43001) for 30 min. After three 5 min washes in TBS, the 
sections were then mounted with a coverslip and fluorescence mountant. 
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Chapter 4 
Local somatic hypermutation and clonal expansion in the 
nasal mucosa, of allergic rhinitis patients. 
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4.1 Introduction. 
In order to determine whether somatic hypermutation and the subsequent expansion of 
IgE' B cell clones with increased affinity occurs locally within the allergic nasal 
mucosa, total RNA was isolated from nasal biopsy and PBMC samples from allergic 
rhinitis patients. cDNA from B cell Vii-Ce transcripts was amplified by PCR. VH 
region somatic mutations were identified by comparison of theVH-CF. sequences with 
the germline repertoire. The relatedness of the B cells was determined on the basis that 
sequences originating from clonally related B cells, sharing a common progenitor, 
exhibit identical 'signature region' sequences across the VH-D and D-JH junctions 
resulting from the unique VH-D-JH gene rearrangement in the progenitor. Related 
clones exhibited both shared and unique somatic mutations inVH. 
4.2 DNA polymerase usage for the PCR amplification Of VH-CE. 
The initial experiment to analyse VH-CF- sequences from a nasal biopsy followed a 
previously published protocol [Snow el at, 1997], utilising Taq DNA polymerase in a 
nested PCR reaction to amplify VII-Ce (see 3.2.18 for details). The PCR products were 
subjected to agarose gel electrophoresis, extracted from the agarose gel, cloned and 
sequenced, according to the methods described in sections 3.2.26 - 36. This experiment 
generated misleading data and its results indicated the importance of using the proof- 
reading Pfu DNA polymerase in future work. 
Eighteen sequences were analysed from a nasal biopsy taken from patient SL5 (see 
Table 4.2.1 for patient details). Of the eighteen sequences analysed, eight were 
different and could be divided into members of two families of clonally related IgE' B 
cells (Fig. 4.2.1), each family originating from a progenitor cell expressing a distinct 
VH-D-JH rearrangement that had been subject to somatic hypermutation. Identical 
sequences were assumed to have resulted from multiple PCR products amplified from 
the same cell and were represented only once in the data analysis. 
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Patient Age Sex Status Total serum IgE Specific serum IgE Allergies c' 
at (lu MI) vu / ml) 1) 
biopsy a) (Norm 3- 150) (Norm < 0.35) 
SL5 27 F I/P 164 HDM = 1.2 HDM, G, T, 
G= 43.5 B, C, AF, A 
T=1.51 
M=3.44 
Table tZl: Clinkal data from Dadent SLA a) In-season (1), perennial (P). b) Determined 
by RAST for house dust mite (HDM), mixed grass (G), tree (T), cat (C), mixed mould (M). c) 
Determined by a skin-prick test >-2mm as Dermatophagoides (house dust mite) (HDIVI), Phieum 
pratense (grass pollen) (G), mugwort (M), three trees (T), silver birch (B), cat (C), dog (D), horse 
(H), Aspergillus fumigatus (AF), Cladosporium herbarum (CL), Mernaria afternata (A). 
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Fiq. 4.2.1. Families of related lQE* B cell clones isolated from the nasal mucosa of Datient 
SL5 and the Y,, CD7JH sequences. A) VH3 family expressing genes mapped to the locus VH3- 
09, D5-24 and JI-13a. B) V[14 family expressing VH4-30-1/4-31, an unidentified D gene and 
JH4b. In both A) and B) the closest germline homology determined by VBase is depicted in a 
black box. Related clones are depicted as ovals. Hypothetical clones, not isolated 
experimentally but which must be interTnediates are denoted X. Mutations in the VH region are 
detailed such that 40(3) represents a mutation at codon 40, position 3. Additional mutations in 
the D and JH regions are also detailed. In C) and D) the sequences of the VH3 and V[44 clones 
are detailed respectively. The N region constitutes non-templated nucleotide insertions. GL 
represents the closest germline homology as determined by VBase. Primer binding regions are 
underlined and no mutations occurring in these regions are included. Homology to the germline 
is represented with a dot, whereas mutations from the germline are depicted either in upper 
case (if causing an amino acid replacement) or lower case (if having a silent effect upon the 
amino acid). Where the link between clones is dependent on one, two or three mutations, these 
are highlighted in red. The CDR regions are detailed. 
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One of the families of B cells consisted of sequences isolated from four B cell clones 
(Fig. 4.2.1 A). The closest germline gene arrangement was determined (using the 
VBase database) to be a VH3 gene mapped to locus VH3-09, the D gene D5-24 and the 
J gene JF13a. Clone C4 exhibited twelve mutations that were different from the 
germline VH3-09 gene. The other members of the family were represented by three 
sequences that were almost identical to C4, sharing in particular the same VH-D and D- 
JH signature region and the same somatic mutations, but each of which differed by up to 
three additional mutations, some of which occurred in the D and JH regions (an 
acknowledged occurrence [Lebecque and Gearhart, 1990]). This provided evidence of a 
family of related B cell clones in which C4 exhibited closest homology to the germline 
and C2, C3 and C8 appeared to have matured and expanded from C4 with the 
acquisition of further somatic mutations. 
The second family isolated from the nasal mucosa of SL5 exhibited a greater diversity 
in the mutations accumulated by its component clones, although every member 
expressed the VH4 gene mapped to VH4-30.1/4-3 1, the same D gene sequence (the 
extent of mutation meant the germline gene could not be reliably identified) and JH4b 
(, Vig. 4.2.1 B). While the extent of differences between the clones that formed the two 
main branches of the VH4 family was such that there was a possibility that the family 
could, in fact, be divided into two small families (C9 and C 11, C 13 and C 18), careful 
analysis suggested that they were more likely to be one family of related clones which 
had diverged significantly as each clone exhibited the same D and JH genes recombined 
in the same fashion. The hypothetical intermediate detailed in Fig. 4.2.1 B represents 
the clone that must have accumulated the Six VH region mutations shared between the 
two branches of the family, but which was not isolated experimentally. C13 exhibited 
greatest sequence homology with the hypothetical intermediate, sharing the six VH 
mutations, but exhibiting an additional five VH and two JH mutations. C 18 had 
accumulated a further three VH mutations. From the other branch of the clonal family, 
C9 contained twelve additional VH region mutations and four additional JH region 
mutations compared to the hypothetical intermediate. CII exhibited a single additional 
mutation to that of C9. 
When a PBMC sample from SL5 was examined, evidence of related IgE+ B cell clones 
was also observed. Twenty VH-CE; PBMC sequences were analysed, of which thirteen 
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were different. All of the clones could be classified into one of three distinct B cell 
clonal families (Fig. 4.2.2 A, B and C). The V1, I family (VH 1-69, an unidentified D 
gene and JH4b) consisted of two clones, C16 exhibited sixteen mutations from the 
germline and C 13, which had accumulated one further mutation (Fig. 4.2.2 A). The 
second family of B cells expressed VH3-09,135-24 and JH3b and consisted of eight 
related clones, C7 exhibited eight V1, mutations from the germline. Seven further 
clones appeared to be related to C7, each exhibiting one or two additional mutations 
(Fig. 4.2.2 B). A further family (VH3-48, DI-26, JH4b) comprised three clones, C6 
differed by twenty-six Vil mutations from the germline, while C2 exhibited one 
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(Figure leclend on thilowincl page). 
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D 
----- CDRI ------ 
VHI-69 20 20 30 40 
OL CAGC; TGCh=TGGTOMOTCTOGOOCTGAGGTOARGARGOCTGocrrccTcomaLLoaTc? ccrocALGOcTTcToahmCACCTTr-LacAacr&? GC? ATCAOCTOCIGTGCGACAGGOOCCTW. A 
CIG ........................................................................................ A.. ' .... A.. T .......................... C13 ........................................................................................ A.. ''.... A.. T 
----------------------- CDR2 ------------------------ 
50 60 70 00 
OL CC TGM C; CIATOGGAGOG&TCATCCCTATCTTTOGrACACWJLOJLCTACOCACASAAGTTCýCKMAGAUTCACCLhTTACCOCOGACGAATCCACGAUCACACPCCTACATOCOkOCTOKO 
.I.............................. C ................................. ................................................ C.. -A .... C13 ............................. .................................. ................................. G ..................... ýA .... 
90 w D4-17 JH4b M CAOCCT(UýTýýACACCKXCUTOTATTACTGTWGAGAO" ---- T(ULCTACOMOOCTA ACTACTTTGACTACTGKPOWOkOO(MACCCTGGfC&CCGTCTCCTCAG 
CIG .. CA .... C ............................... G. q. ; C. 3G A. T ...... G .... G t.. LGCG ........................... GTt .......... 
C13 .. 'A .... I ................................ G. g. A. T ....... 3 .... G t.. I", ........................... IýTt .......... 
E 
----------------------- CDR2 ------------------------ 
50 60 10 80 
OL AACIDWCTOGWGrCKMCTCAOMATTAUrTGCMATAOTOMAOCATACKaC? ATWMWTCTGTaAIUM=GATTCACCATCTCrAGkMCAACGCCAAGAACTCCCTOTATCTOCAAATGAAC 
C7 ........................ G... I .............. A-- ................ t ......................................................... T. 7 
cl ........................ "... ............... A. G... C ............... t ......................................................... T. T 
C3 ......................... ;... c .............. A....., ................ t ......................................................... T. T 
C4 ........................ G-1 .............. A ...................... I ....................................... C ................. T. T 
cs ....................... cýG... C .............. A..... C ............... t ......................................................... T. T 
C9 ........................ G... C .............. A..... C ............... I ......................................................... T. T 
C20 ......................... ; ... C .............. A....., ............... I ......................................................... T. T 
C20 ......................... i ... c ......... .... A ..... C ............... t ......................................................... T. T 
N D5-24 JH3b 
------- MMULGATOGICTAChAT TiNkTOCrTTTGATATCTOOIXICCA&G OGACAATOUTCACCOTCTCTTý 
aý-ýTTA ............... C. ..... G ......... C ........... ...... A ................. 
ýýITTA ............... 1. .... -.. C ...... .......... ...... A ................. 
ýý=TA ............... C. .......... I ........... . .... A ................. 
. ýCTTA ............... C. ..... G ......... G .......... ...... A ................. 
aGCCTTA ............... C. ..... 6 ......... ........... ...... A ................. 
&C, -CTTA ............... C. ..... G ......... G. A ........ ...... A ................. 
*-TTA ............... c. ..... G ......... G ... A ...... ...... A ................. 
AGCCTTA ............... C. ......... G .......... ...... A ................. 
F 
CDRI 
VH3-46 10 20 30 40 
G(20CTOOTOGROTCT200ýTOMACAOCCTOGGOOMCCCTOAGACTCTCCTCPfOCAOCCrCTýTTCACCTTýWýATA13CATGAACTGGWCMCCAao==ý 
C6 ......................................... c ........................ IATTAA. 
C2 ........ ******'* ...... * .................. G ......... T ............. C ................. ATTAA. 
C12 ......................................... G ....................... I .................. A ............... r... A ...... A. 
---------------------- ýR2 ---------------------- 
50 go 10 so 
M AAQOQ&CTGGP"fCXMTTCATACATTýýTAOTACTACCATATACTA4: CWJLGWýCTCYrQWkGOOCCOATTCACMTCTCCAAL%GACAATOCCAAGAACTCILCT(MATCTOCAA&TOARCAOC 
C6 ............... C ....... T ..... C ... C. C. C ...... ...................... T ....................... C .... C ................ 
C2 ............... C ....... T ..... C ... C. C. c ...... CAC ....... ; .......................... T ....................... C .... C ................ 
C12 ............... c ....... T ..... c ... C. C. C ...... IAC ...... G .......................... T ....................... C .... C ................ 
90 DI-26 N jH4b 
OL CTýC=QWýCIOCTGTGTATTACTQTGCýý A131000AGM Ac - ACrAC? T? 12ACTACT13000CýIX=43trrCkCC(? rC'tCCT 
cs .. '. A.. T... A ......... 
C2 C. A.. T ... A ......... .......... 
ý:: ý: .... CG.. T. G ', ýýT ....................... T .................. 1. 
....... .... CO. . T. 13 G CT ........................ r .................. C. 
C22 
ý. 
C. A.. T ... A .................... C ......... ......... 'G.. T. G G. CT ....................... T .................. C. 
Fla. 4. L2: Families of /me related B cell clones isolated from the PBMC of Datlent SL5 
and the VcDL-Jm seguences. A) VH1 family expressing genes mapped to the locus VH1 -69, an 
unidentified D gene and JH4b. B) VH3 family expressing VI-13-09, D5-24 and JI-13b. C) VH3 
family expressing VI-13-48, Dl-26 and JH4b. In A), B) and C) the closest germline homology as 
determined by VBase is depicted in a black box. Related clones are depicted as ovals. The N 
region constitutes non-templated nucleotide insertions. Mutations in the VH region are detailed 
such that 75(l) represents a mutation at codon 75, position 1. Additional mutations in the D and 
JH regions are also detailed. In D), E) and F) the sequences of the VH1, VH3-09 and VH3-48 
families are detailed respectively. GL represents the closest germline homology as determined 
by VBase. Primer binding regions are underlined and no mutations occurring in these regions 
are included. Homology to the germline is represented with a dot, whereas mutations from the 
germline are depicted either in upper case (if causing an amino acid replacement) or lower case 
(if having a silent effect upon the amino acid). When the link between clones is dependent on 
one or two mutations, these are highlighted in red. The CDR regions are detailed. 
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The sequence data from SL5 appeared to suggest that related IgE'- B cells existed within 
the nasal mucosa and also in the peripheral blood. The presence of closely related B 
cells in the tissue might suggest that local SFIM and clonal expansion had taken place 
(resulting in distinct families of closely related clones). It was however slightly 
surprising that all of the clones could be grouped into aB cell clonal family. More 
importantly, the apparent extent of related B cell clones in the peripheral blood cast 
doubt over the entire experiment and prevented such conclusions of local SHM and 
clonal expansion in the nasal mucosa being justified. If the data was reliable, then an 
extremely restricted repertoire of IgE' B cells must have existed in the blood. Concern, 
particularly over the apparent clonality of cells isolated from PBMC prompted a more 
detailed analysis of the data. 
SHM typically introduces nucleotide substitutions in which transitions (especially C-->T 
and G-->A) are favoured over transversions [Betz el al., 1993b], [Insel and Varade, 
1994]. It was evident however, that in both the nasal biopsy and PBMC samples from 
SL5, the mutations that determined the relatedness of the clones were (with the 
exception of the multiple mutations differing between the C9 and 03 branch of the 
VH4-X 1/4-31 family in the nasal mucosa) biased completely towards those between C 
and T or A and G. 
Taq DNA polymerase, used habitually in this and previous such PCR amplification of 
VH-D-JH transcripts (e. g. [Snow el at, 1997], [Snow el al., 1999], [Van der Stoep et al, 
1993]) introduces errors during nucleotide incorporation because of its inability to 
proofread. The error rate for Taq is generally accepted to vary between 1.1 x 104 and 
8.9 x 10-5 mutation frequency per base pair per duplication (mut bp-1 dup-) depending 
on the experimental systems in which it is used [Tindall et al., 1988], [Barnes, 1992], 
[Cariello et at, 1991]. Taq also has a tendency to cause errors that are nucleotide 
transitions rather than transversions, especially T-+C and A-->G [Rotherfluh et al., 
1993], [Zylstra et at, 1998]. It therefore seemed likely that the mutations observed in 
samples from SL5 and on the basis of which the families of related B cell clones had 
been constructed, may have resulted in part or completely as a result of errors 
incorporated by Taq. 
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Assuming that all of the mutations observed in the B cell clones from SL5 that were 
responsible for the formation of families of related clones (with the exception of those 
differing between C9 and C13 in the nasal biopsy) resulted from errors introduced 
experimentally by Taq, the error rate in this experiment was calculated to be I in every 
630 bp of DNA amplified. This equated to anefforrateof 2.7 x 10-5 mut bp-' dup-1 in 
this experimental system, consistent with that detailed previously (see appendix A for 
all calculations) without taking account of the small contribution to error made by the 
reverse transcriptase. 
If all these mutations were incorporated by Taq, the structure of the families would be 
significantly altered, resulting in the possibility that all of the families observed in the 
PBMC and all except for the distantly related C9 and C13 in the nasal biopsy sample 
would be eliminated. This alters the data set significantly, limiting the families in the 
nasal biopsy to just the one VH4-30.1/4-31 family, with a hypothetical intermediate 
linking two distantly related B cells. It was evident therefore, that Taq DNA 
polymerase introduced experimental errors at a rate that prevented meaningful 
interpretation of the data. Whilst the conditions employed in the PCR are known to be 
able to improve the fidelity of a PCR [Cline el aL, 1996], this was not deemed to be 
sufficient and the use of another DNA polymerase, I! fu, was investigated. 
Pfu DNA polymerase has a lower error rate (approximately 1.3 x 10 -6 mut bp-' dup-') 
than Taq as a consequence of a proofreading ability conferred by the 3'--> 5' 
exonuclease activity that it exhibits [Cline el aL, 1996]. In order to analyse the exact 
effect of Taq compared to Pfu in a more accurate manner, analysis of the number of 
mutations incorporated into the Cel region amplified 3' of each Vii region, a region 
known to be unaffected by SHM [Lebecque and Gearhart, 1990] was analysed. 
On the basis of mutations introduced experimentally into the constant Cel region, the 
error rate for Taq DNA polymerase in the amplification of the nasal biopsy and PBMC 
samples from SL5 was calculated to be approximately 3.4 x 10-5 mut bp-1 dup-I (I 
mutation for every 487 bp incorporated), confirming that it was likely that all of the 
mutations observed in the VH regions amplified from SLS were introduced 
experimentally. In contrast, when CF-I sequences amplified by Pfu were analysed, 
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under conditions optimal for fidelity [Cline el aL, 19961, an error rate of 3.5 x 10 -6 mut 
bp-1 dup-1 (I mutation every 4720 bp) was determined. 
While Pfu exhibited a much greater accuracy than Taq in the experimental system, an 
error rate of 3.5 x 10-6 mut bp-' dup-' is not as low as that observed by other researchers 
(1.3 x 10-6 mut bp-' dup-' [Cline et aL, 1996] and 0.9 - 1.0 x 10-6 mut bp-1 dup-' [Slater 
et al., 1998]). Differences in the observed error rate compared to those stated in the 
literature may have resulted from the inevitable inaccuracies incurred in attempting to 
quantitate a nested PCR. 
It was decided on the basis of the error rates exhibited by the DNA polymerases that Pfu 
would be used in all future experiments in order to enable the confident interpretation of 
data, although it was noted that I mutation approximately every 4720 bp (17 VH-D-J 
sequences) was likely to result from experimental error. 
4.3 Analysis Of VH-CF- sequences amplified by Pfu from the nasal 
mucosa and PBMC of a cohort of seven allergic rhinitis patients. 
In order to continue investigating whether local SHM and clonal expansion occurred 
locally in the nose, nasal biopsy and for comparison, PBMC samples, were studied from 
a cohort of seven allergic rhinitis patients, three male and four female, aged between 
eighteen and thirty-eight. While all seven patients were allergic to Phleum pratense 
(grass pollen), six were allergic to multiple aeroallergens and only one (HD17) was 
grass pollen mono-allergic (as determined by skin-prick test and RAST). All the 
patients selected for this study exhibited a total serum IgE > 200 IU / ml (in order to 
increase the probability of successful PCR amplification Of VH-Ce). The samples were 
taken randomly throughout the year, such that some samples were taken within and 
some outside the grass pollen season (Table 4.3.1). Nasal biopsy and PBMC samples 
were not taken from normal subjects for control purposes, because normal IgE even in 
the serum, is prohibitively low. 
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Patient Age Sex Status Total serum IgE Specific serum IgE Allergies c' 
at (IU ml) (IU / MI) 
b) 
biopsy (Norm 3- 150) (Norm < 0.35) 
HDM = 1.28 HDM, G, 
CD6 19 M I/P 990 G= 72.9 M, T, B, C, 
T= 101 D 
JB7 37 M O/P 236 G=9.25 HDM, G, C, C= 11.1 D, CL 
HDM = 1.09 HDM, G, 
CM1 0 18 F O/P 382 G= 101 M, T, B, C, 
C=3.36 D, H, CL 
HD14 21 F I/P 787 HDM = 2.68 HDM G G= 101 , 
S016 37 M UP 514 G= 101 G, T, B, D 
HD17 22 F 1 2745 G= 101 G C=0.39 
HDM = 1.23 HDM G C AN 9 38 F I/P 414 G= 60.2 , , , H, CL D C= 32.1 , 
Table 43.1: Clinical data from alteruic rhinitis Patfents CD6. JB7. CMIO. HD14, SOIG. 
HD17 and AP19. a) In-season (1), out-of-season (0), perennial (P). b) Determined by RAST 
for the allergens; house dust mite (HDM), mixed grass (G), tree(T), cat (C). c) Determined by a 
skin-prick test of ý-2 mm diameter as; Dermatophagoides (house dust mite) (HDM), Phleum 
pratense (grass pollen) (G), mugwort (M), three trees (T), silver birch (B), cat (C), dog (D), horse 
(H), Aspergillus fumigatus (AF), Cladosporium herbarum (CL), Altemaria aftemata (A). 
VH-CF- sequences were amplified from each nasal biopsy and PBMC sample with Pfu 
DNA polymerase in order to minimise, the introduction of experimental errors (as 
discussed in section 4.2 and according to the methods detailed in section 3.2.18). The 
PCR products from each sample were subjected to agarose gel electrophoresis (Fig. 
4.3.1), extracted from the agarose gel, cloned and fifteen sequences analysed from 
almost every sample (see Tables 4.3.2 and 4.3.3 for details), according to the methods 
described in sections 3.2.26 - 36. The analysis of fifteen sequences was chosen as an 
appropriate sample size on the basis that when a further ten sequences, generated from a 
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sample PCR were analysed, only one further unique sequence was identified (data not 
shown). 
Rg. 4.3.1, A-garose 
-qel 
electrophoresis of Vý&C PCR products amplified from the nasal 
mucosa, and PBMC of allergic rhinitis patient CD6. A typical example Of VH-Ci, PCIR 
products (indicated at approximately 450 bp) subjected to agarose gel electrophoresis on a 1% 
agarose gel and visualised under UV. Lane 1 -1 Hpa /I DNA ladder (L), (488bp indicated). Lane 
2-, VH-CI- PCIR products amplified from the nasal mucosa of patient CD6 (NM). Lane 3: VH-Cf- 
PCIR products amplified from PBMC of patient CD6 (PB). Lane 4, VH-Ci, PCIR positive control 
(AR 0 cells). Lane 5; VH-Q: PCIR negative control (no DNA). 
V11 genes from each of the Vill to V117 classes, with the exception of V112, one of the 
most infrequently expressed Vil classes [Brezinschek el al., 2000], were amplified from 
different samples. Independent experiments demonstrated that V112 and CF- primers 
were successfully able to amplify V112 from a PBMC sample, although it is possible that 
the pnmers worked with decreased efficiency compared to those for the other Vil gene 
classes. 
All sequences demonstrated rearranged VII-DAII genes expressing diversity across the 
junctions, including in many cases the insertion of non-templated nucleotides (N) at the 
V, I-D or D-JI 1 junction. With the exception of two distinct clones (C I and C 13 isolated 
from the PBMC of CMIO), all of the VII-CF, sequences contained mutations in the VII 
region. The average degree of VII gene mutation in sequences isolated from the nasal 
biopsy samples was 6.6% (range 1.8 - 22.7%) compared to 5.5% in the PBMC (range 0 
- 11.7%) (see Tables 4.3.2 and 4.3.3). The slightly increased average (and range) of 
somatic hypermutation in sequences from the nasal biopsies possibly reflecting 
increased affinity maturation by SHM in response to (perhaps local) allergen exposure. 
L NM PB +ive Ave 
12345 
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The general pattern of mutations observed in the sequences isolated from both the nasal 
biopsy and PBMC samples was consistent with that previously observed to be 
characteristic of somatic hypermutation (analysed in detail in chapter 7). As previously, 
identical sequences were repeatedly isolated from each of the samples (Tables 4.3.2 and 
4.3.3), but were assumed to have resulted from one clone. 
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Patient Unique sequences Predicted germline 'Yo Mutation Number of identical 
isolated from nasal VH gene usage from sequences 
biopsy samples germline isolated 
C2 3-23 6.2 2 
C12 3-30/3-30.5 5.2 1 
CD6 C1 3-30.3 4.0 6 
C5 3-33 4.0 4 
C13 6-01 5.7 2 
C14 1-46 22.7 1 
C9 3-23 5.5 1 
JB7 C17 3-74 4.8 8 
C22 4-04 7.3 5 
C7* 3-30/3-30.5 2.9 1 
CM10 C13 3-30/3-30.5 4.4 1 
C1 3-66 10.9 1 
C2 3-66 10.7 12 
C16 1-02 5.9 1 
C9 3-15 9.9 1 
C4 3-30 11.0 1 
HD14 C2 3-30 7.0 8 
C11 4-59 6.4 1 
C19 5-a 4.5 1 
C7 5-51 7.4 1 
C12 5-51 4.8 1 
C12 3-20 3.3 2 
C18 3-23 1.8 1 
C2** 3-30 4.1 1 
C3** 3-30 5.2 2 
CIO 3-33 5.6 2 
S016 C1 3-65 ND 1 
C13 4-39 3.7 1 
C5* 5-51 2.9 1 
5-51 8.1 1 
5-51 7.3 1 
5-51 7.3 2 
C13 1-69 4.8 1 
C1 3-30 9.6 1 
C16 4-ND 12.1 1 
HD17 C9 4-30.1/4-31 8.4 1 C37 4-30.1/4-31 8.8 1 
C15* 4-30.2 7.7 5 
C31 4-30.2 8.5 3 
C32 4-59 5.6 1 
C7 7-04.1 3.7 1 
C16 1-18 2.2 1 
C6 4-04 5.2 1 
C3 4-30.1/4-31 2.5 2 
AP19 C2 5-51 7.1 8 
C4 5-51 6.4 1 
C8 5-51 ND 1 
C14 5-51 7.5 1 
Table 4.3.2: V clene usage and % Yj, muftfion of YjcCe sequences isolated from nasal 
biopsies from allervik rhinibs Dadents CD6. JB7, CM10. HD14. S016. HD17 and AP19. VH 
gene usage is detailed such that a gene mapped to the locus 5-51 is a VH5 gene. VH genes that 
could not be determined are denoted ND. Sequences highlighted in red represent related clones 
isolated from that patient (or in yellow where more than one family of related clones was isolated 
from the same sample). Where an identical sequence was isolated from the patient's 
corresponding PBMC sample it is marked with an asterisk. Where a sequence representing a 
distantly related clone was isolated from the patient's corresponding PBMC sample it is marked by 
two asterisks (see Table 4.3.3). 
Table 4.3.3: Y :H mutaWon of y cone usage and %VV isoMed firom the jcCeseauences nl-hpew 
of allemic rhinids DaVents CD6. JB7. CM10. HD14. S016. HD17 andAPI& VH gene usage is 
detailed such that a gene mapped to the locus 5-51 is a VH5 gene. VH genes that could not be 
determined are denoted ND. Sequences highlighted in red represent related clones isolated frorn 
that patient (or in yellow where more than one family of related clones was isolated from the 
same sample). Where an identical sequence was isolated from the patient's corresponding nasal 
biopsy it is marked with an asterisk. Where a sequence representing a distantly related clone 
was isolated from the patient's corresponding nasal biopsy it is marked by two asterisks (see 
Table 4.3.2). 
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Patient Unique sequences Predicted germline % Mutation Number of identical 
isolated from PBMC VH gene usage from sequences 
samples germline isolated 
C2b 1-18 5.5 1 
C28 3-30.3 4.0 2 
CD6 C33 3-33 2.6 1 
C1 4-30.2 3.7 10 
CO 6-01 5.7 1 
C2 1-18 4.4 2 
C17 3-30/3-30.5 7.0 2 
C3 3-30/3-30.5 4.0 3 
JB7 C18 3-73 8.3 2 
C4 3-73 8.7 2 
C16 5-a 3.0 2 
C13 3-23 0 1 
CM10 C3* 3-30/3-30.5 2.9 13 
C1 3-30.3 0 1 
C2 1-18 7.0 1 
C17 1-18 6.6 1 
C4 3-30 4.8 3 
C16 3-30 3.7 2 
HD14 C3 4-04 6.6 2 
C1 4-04 5.5 1 
C8 4-30.1/4-31 6.2 2 
C13 4-39 1.8 2 
C7 5-a 10.0 1 
C5 1-08 7.0 1 
C2 3-23 4.7 2 
C10 3-30 3.3 1 
C3 3-30 1.9 2 
C4 3-33 5.2 1 
S016 C7 3-33 6.7 1 C1 4-39 ND 1 
C8 5-51 8.1 1 
C11 3-09 6-7 1 
C9** 3-30 5.6 1 
C14 3-33 4.8 1 
C15* 5-51 2.6 1 
C9 1-09 6.7 1 
C28 3-30 6.7 1 
C12 3-30 4.1 1 
C1 3-30 6.7 1 
C18 3-30 5.9 1 
C23 3-66 4.4 1 HD17 C15 4-04 7.4 1 
C7 4-30.1/4-31 2.6 2 
C1I* 4-30.2 7.7 1 
C14 4-30.2 8.1 1 
7-04.1 11.4 1 
7-04.1 11.7 1 
C24 7-04.1 7.3 2 
C20 3-30 2.9 1 
C19 3-13 8.6 1 
C7 3-33 4.0 1 
C8 4-30.1/4-31 3.6 1 
AP19 C16 4-30.1/4-31 2.5 1 
C15 4-30.1/4-31 2.9 1 
C1 4-61 10.3 3 
C10 5-51 7.0 2 
C2 6-01 9.6 4 
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When sequences isolated from each sample were analysed, the presence of families of 
related B cell clones (with identical signature regions, but diverse VH mutations) was 
apparent in four of the six nasal biopsy samples (CMIO, S016, HD17 and AP19) and 
three of the six PBMC samples (JB7, HD17 and AP19), (Fig. 4.3.2 and 4.3.3). No 
families of related B cells were isolated from either the nasal biopsy or PBMC samples 
of CD6 and HD 14. 
In addition, sequence analysis suggested that in each of three patients (CM10, HD17 
and S016) aB cell clone(s) with the same signature region to that isolated from the 
nasal mucosa was present in the patient's PBMC (see Tables 4.3.2 and 4.3.3). In both 
CM 10 and HD 17 the clones in the nasal mucosa and PBMC were shown to be identical. 
However in patient S016, while one identical clone to that in the nasal mucosa was 
isolated from the PBMC sample, an additional clone was isolated from the PBMC that 
was distantly related to the VH3 family of B cell clones isolated from the nasal mucosa 
(Fig. 4.3.4). This PBMC clone (PC9) exhibited multiple distinct mutations throughout 
the VH region in addition to mutations shared with the related family of B cell clones in 
the nasal mucosa. 
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F&A. 3.2; Families of related hqE+ B cell clones isolated from the nasal mucosa of alleruic 
rhinitis patients A) CMIO, B) S016, Q HD17 and D) AP19. A) CM1 0; VH3 family expressing 
genes mapped to the locus VH3-66, an unidentified D gene and JH3a. B) S016, two families-, a 
VH3 family expressing VH3-30, D6-113 and JH5b and a VH5 family expressing VH5-51, an 
unidentified D gene and JH4b. C) HD17; VA family expressing VH4-30, an unidentified D gene 
and JH4b. D) AP19; VH5 family expressing VH5-51, an unidentified D gene and JH3b. In A) to 
D) the closest germline homology as determined by VBase is depicted in a black box. Related 
clones are depicted as ovals. Hypothetical clones, not isolated experimentally but which must 
be intermediates are denoted X. Mutations are detailed such that 93(2) represents a mutation 
at codon 93, position 2. Additional mutations in the D region are also detailed. 
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Fia. 4.3.3: Families of related laE' B cell clones isolated from the PBMC of alleruic rhinitis 
patients A) JB7, B) HD17 and Q AP19. A) JB7, VH3 family expressing genes mapped to the 
locus VI-13-73, D3-9 and JI-15b. B) HD17-1 two families; a VA family expressing VH4-30.2, an 
unidentified D gene and JH3b and a VH7 family expressing VH7-04.1, an unidentified D gene 
and JH6b (and in which the nucleotide substitutions at 30(l) and 89(3) differ between C6 and 
C25). C) AP19; VA family expressing VH4-30.1/4-31, D5-112 and JH4b. In A), B) and C) the 
closest germline homology as determined by VBase is depicted in a black box. Related clones 
are depicted as ovals. Hypothetical clones, not isolated experimentally but which must be 
intermediates are denoted X. Mutations are detailed such that 37(3) represents a mutation at 
codon 37, position 3. Additional mutations in the D and JH regions are also detailed. 
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Fhcj. 4.3.4. Family of related hqE+ B cell clones isolated from the nasal mucosa and PBMC 
of aflergic rhinitis patient S016. VH3 family expressing genes mapped to the locus VH3-30, 
D6-13 and JH5b. It was assumed that the identical mutation at 84(l) arose spontaneously in 
both NC2 and PC9. The nucleotide substituted at 84(l) differed in NC3. The nucleotide 
substitutions also differ between the repeated mutations in different clones at 55(2) and 78(3). 
The closest germline homology as determined by VBase is depicted in a black box. Related 
clones are depicted as ovals. Hypothetical clones, not isolated experimentally but which must 
be intermediates are denoted X or Y. In this figure clones isolated from the nasal mucosa are 
preceded by an N (corresponding to those in Fig. 4.3.2 B) and those isolated from PBMC by a 
P. Mutations are detailed such that 16(2) represents a mutation at codon 16, position 2. 
Additional mutations in the D and JH regions are also detailed. 
As discussed in section 4.2, even with the use of P . 
fu DNA Polymerase, the 
experimental error rate determined for this system was shown to be approximately I in 
4720 bp. As the number of bases analysed in each VII region is approximately 270 bp 
(excluding the primer region and depending on the gene and any polymorphisms), this 
equates to approximately I mutation being artificially generated in the Vil region of 
approximately every 17.5 sequences generated. From this cohort of seven patients a 
total of 207 sequences were analysed from the nasal biopsy and PBMC. Assuming the 
error rate did not vary between the samples, this implies that eleven or twelve mutations 
would be predicted to result from experimental error amongst the 207 sequences 
studied, affecting eleven or twelve sequences (assuming an even distribution of such 
mutations). However, such errors would only be identifiable, if an identical sequence 
that had not been subject to experimental error, was also isolated from the sample for 
comparison, this in turn being heavily dependent upon the cycle number of the PCR in 
which the error was introduced. 
In order to ensure that data resulting from experimental errors did not influence the 
validity of the results presented in this thesis, it was decided that any sequences that 
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implied the existence of families of related B cell clones on the basis of only one 
nucleotide difference between the clones would be discarded for the purposes of data 
analysis. This resulted in the elimination of five families of B cells (in the nasal mucosa; 
CMIO VH3 and HD17 VH4 and in the PBMC; JB7 VH3, RD17 VH4 and AP19 VH4). As 
each eliminated family comprised just two related clones, this implied five instances in 
which experimental mutations were introduced into the VH region and in which an 
unmutated sequence was also isolated for comparison. The remaining reliable families 
of B cell clones, in which the basis of the families was not solely dependent upon a 
single nucleotide difference are summarised below. 
Sequences indicating the presence of three reliable families of related IgE' B cell clones 
were isolated from the nasal mucosa of two of the seven allergic rhinitis patients studied 
(two families from S016 (Fig. 4.3.2 B) and one family from AP19 (Fig. 4.3.2D)) and 
are summarised in Fig. 4.3.5. Two related B cells in one family from nasal biopsy 
S016 expressed the genes VH3-30, D6-13 and JH5b and shared nine VHmutations with 
a hypothetical intermediate whilst differing from each other by sevenVH and two D 
region mutations. The second family isolated from nasal biopsy S016 consisted of 
three related B cell clones each expressing VH5-51, D4-17 and JH4b. These clones 
were linked by a hypothetical intermediate with which all the clones shared seventeen 
mutations. Both CI I and C14 had one additional mutation to the hypothetical 
intermediate and the third clone, C8 differed from C 14 by a further two mutations. The 
family of related B cells isolated from AP19 comprised three related clones, all of 
which shared sixteenVHmutations with a hypothetical intermediate. C4 differed from 
the hypothetical intermediate by one further mutation, while C2 differed by three further 
mutations. C14 exhibited an additional mutation compared to C2. 
In each of these reliable families isolated from nasal biopsies SO 16 and AP 19, while the 
relationship of aB cell with its sister clones may be altered if a single individual 
mutation were demonstrated to be an experimental artefact, the clone would in each 
case take another position within the family, for example, in the VH5-51 family from 
isolated from the nasal mucosa of SO 16, if the single mutation at 82b(3), linking CII to 
the rest of the family were discredited, CII would move to take the place of the 
hypothetical intermediate. Such families were not therefore eliminated from the data 
set. 
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The presence of only one reliable family of related B cell clones (VH7-04.1 in Fig. 
4.33 B) was isolated from the PBMC (HD]7). This family consisted of two related B 
cell clones; C6 and C25 shared twenty-two VH mutations with a hypothetical 
intermediate, but differed by nineteen VH mutations. In addition, whilst a distinct 
signature region was shared by the two clones, four D region mutations (two of which 
included mutation of the same nucleotide) and one JH mutation differed between the 
clones. In view of the slight variation at the D-JH junction, the likelihood of C6 and 
C25 being related was strengthened by the number Of VH region mutations shared 
between these clones. No other reliable related B cell clones were isolated from the 
PBMC of any of the other patients in the cohort. 
There was one reliable example of a clone isolated from the PBMC and yet related to a 
family of related B cells from the nasal biopsy (SO16, Fig. 4.3.4). The PBMC clone 
(PC9) shared junctional homology and five VH mutations with the family of B cells 
isolated from the nasal mucosa and that expressed the genes VH3-30, D6-13 and JH5b. 
PC9 differed by ten VH mutations, one D and two JH mutations from the hypothetical 
intermediate that linked it with other members of the clonal family. The JH region 
mutations were distant to the D-J junction, located in the body of the JH segment. 
Chapter 4 Local somatic hvpermutation and clonal expansion 98 
A 





78(3), 84 (1 )D 






300), 3301 33(3), 38(3) 30(l 41(3) 44(3) 48(l 
56(3) 64(l 73(l) 74(3) 69t 1 76(3), 7 8(l) S3(3ý 71(; ý) 33k, " 89(3), 940 30 84(3) 89(3) 1D 14, 
410) 
CD 
PBMC NASAL MUCOSA 
Fia. 4.3.5: Families of related laE+ B cell clones cienerated from reliable data from either 
the nasal mucosa or PBMC of aftenclic rhinitis patients A) S016. B) HD17 and Q AP19. A) 
S016, two families; a VH3 family of two clones from the nasal mucosa and one related clone 
from the PBMC expressing VI-13-30, D6-13 and JH5b. The VH5 family of related clones in S016 
were all isolated from the nasal mucosa and expressed VH5-51, an unidentified D gene and 
JH4b. B) HD17; VH7 family of clones isolated from the PBMC expressing VH7-04.1, an 
unidentified D gene and JH6b. C) AP19; VH5 family of cAones all isolated forTn the nasal 
mucosa and expressing VH5-51, an unidentified D gene and JH3b. The closest germline 
homology as determined by VBase is depicted in a black box. Related clones are depicted as 
ovals. Clones isolated from the nasal mucosa are denoted INIC and those from the PBMC, PC. 
The hypothetical clones, not isolated experimentally but which must be intermediates are 
denoted X or Y. Mutations are detailed such that 16(2) represents a mutation at codon 16, 
position 2. Additional mutations in the D and JH regions are also detailed. 
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............................................. c ................................................... 
9 ............ .............. 
........... , ................................. 
c ................................................... 19 .............. , 
r .......................... ........................ .................................................................. , 
ib -------------------- CDR2 ------- &6 ---------------- 70 80 
GL AILGGG=GGAGTGGGrGGCAGTTATATCATATr. ATGCAAGrAILTAAATACTACCCArACTCCGTGRAGGGCCGATTCACCATCTCCAGAGKCAILTTCCA&GAACKCGCTGTATCTGCAAATGAAC 
C3 .............................. G ......... 7. (-ý ...... T ......................... G ............................ -. 11 ............. 
C2 .............................. G ............................................ G ........................ ........... T ............. 
Pcq .............................. G ......... r .................................. G .......... r ......................... IT............. 
90 N D6-13 iHsb 
aL AGCCTGJLGAaCT cGocTaTcTikTTAzTGTccGAaA --- GaaT&TAGcAac&acTGGT J6CTGGTTýCGACCCCTGGGr. CCAGOGAACCCTrgTCA=GTCTCCTCAG 
C3 ......... ................. .. 
T ........ T.. A. GCC C. t ..... tGc ........ . .... ........................................... 
C2 .......... , ................ .. 
T ........ T. A. GCC C ....... tGc ........ ................................................ 
9C9 ......... A ................ .......... 
T.... G--c C. ý..... tGC ........ .............................. T ........... 
B ----- CDRI ------ 
-5 5 l 0 l 20 30 40 M . rl .. GCJLCrA GAG4rT C-%AAAJLGC CrCTCAAGATCTCCTGT CAZCTTTACCAa=JkCrGrATCGGC7G4rWGCOCCAGILTOMCGG 
Cil ....... ...................................... c .. ... ........... ... ....... ....... A .... G ... C ..... cc .......................... 
C14 ....... ...................................... C .. 
:ý 
... ... a ...... .... ....... ..... t. A.... G.,. C ..... IC .......................... 
ce ....... ...................................... C .. ........ a ...... .... .A..... ..... .......................... 
---------------------- CDR2 ------------------------- 
50 60 70 so 
GL AAAArGC CrGGAGrGGATGGGGILTCATCTATCCrGGrGK=GXTJLCCAGJLTJLCOLGCCCGrCCrMCAAGGCCAG(7rCACCATCTCArCeGACAAGrCCKTCAGCJLCCGCCTACCrGCAGTG" 
c 11 ... 9 ... .................... ...... A. . ..... A.. .. C ................. .c..... ..... A ........ T .............. A .................... 
c1 4 ... 11 ... 
: : ý: 
.............. ..... A. . ..... A.. - ... . .. C ................. .c..... ..... A ........ T .............. A .................... 
c 8 ... . ...... A .......... ............... ............. .C..... ..... A ........ T .............. A .................... 
90 N D4-17 JH4b 
GL GCAGCCTGAAGGCCTOGGACA=GCCATC? rArrACr(; TGCraGACA ------ TGACTACGC; rGACTAC TGGGGCCAGGGAACCCTGGTCACCGrCMCTr. AG 
Cil .... I .... G .................. T ................. tAAGAG .. G.. CG. C ....... .................................. 
C14 ......... G .................. T ................. tAAGAG .. G.. CG. C ....... .................................. 
ce ......... G .................. T ................. tAAGAG .. G.. CG. C ....... .................................. 
C 
V7-04 10 20 30 
----- CD11 ------ 
40 
GL CAGOTOL OCAATCrGGqrCTGh6-ITGAAGAAGCCTGGGGCCTCAGrGAAGGTTTCCTGCAAGGCTTCTGGATACACCTTCACTAGCTATOCrATGA&TTGGGrGLGACAGGCCCCTGC 
.......................................... C.. A .... a ........ ............... I'A. G. t ........ C ..................... - c 
................................................... 
C.. A ............. ............... ý-, A. G. t... C. - .C........... I ........... 
----------------------- CDR2 ------------------------ 
so 60 70 so 
GL CJL#, rGG=GAGTGGATIGGGATGGATCAJW-ACCAJW. ACTGGGJLACCCAACGTAXGCCCAGGGCTTCACAraýrrGrCrrCrCC7'rrGACJL=CTGTCAGCACGOCKTATCrGCAGATCAG 




.... AC ... C ... t ............... T ....... a ..... g .............. C --- A.. g. 
C ..................... 
9" D- m6b 
GL AG=AAAr. GCTGAGGACACTOCCGrGTAT17XTGr(; CGIlrAak OrrATCGffAIRCC GTATGrACOTCTG=GCCAAGOGMCACGGTCJkCC(; TCrCCTCAG 
C6 .. t ...... C. r .............. I .............. g.. ... CA-CC .... G .................................. ........... C25 .. t ...... C ............................. C. g.. ý., -CA-CC.. T. G ............................................. 
D ----- OD111 ------ 
-51 10 20 30 40 
GL 
ý: 5.. 
GCRGTCrrýGhGCAGAGGTCAAAAAGCCCGGGr. P. GTCTCTGAAGATCrCCrGTJUk(nMI=G(NLTACArCrrrACCAGCrACrr42LTCGrCrGG=CGCCAG&7'GCCCGC 
C4 '*"'''*'**'* .......................... T .......................... C. ........ A.. A ..... t ...... G. ........ ...... 
C2 '* . ............. * ..................... T .......................... C. 
ýý'- ......... 
A.. A ..... t ...... G, .................. G ...... 





---------------------- CDit2 ------------------------- 
so 60 70 80 
- ---------------- 
................... tT............ .............. t ............................................. 
GA C ............ 
. ................. 
tT...... 9 ..... I .............. t ............................... T ............. CA 7 ............ 
................... tT...... 9 ..... .............. t ............................... T ............. GA c ............ 
90 N D- JH3b 
GL Ar-%-rC-%AGWCTCGrACA=GCCATGTJKrTACTGrGCG GGrATAGTGGGAGCT TGICGCrrrrGhTAT GrcTcrTCAG 
C4 .......................... A ............ GCGGC .. C.. T. G ..... T. .. G ............................................... 
C2 ....... G .................. A ............ GCGGC .. C.. T. G ..... T. .. G ............................................... 
C14 ....... G .................. A ............ GCGGC .. C.. T. G ..... T. .. G ............................................... 
Fid. 4.3.6: Alianment of VwD4m seauences from related IOEI-4' Bu cell clones aenerated b 
reliable data from A) the nasal mucosa and P mucose of Solo. 
Q the PBUC of HD17 and Q) the nasal mucosa of AP19. A) S016; VH3 family of related 
clones (including PC9 from PBMC) expressing the genes V113-30, D6-13 and JH5b. B) S016; 
VH5 family expressing V115-51,134-17 and JH4b. C) HD17; VH7 family expressing V117-04.1, an 
unidentified D gene and JF16b. D) AP19; VH5 family expressing VI-15-51, an unidentified D gene 
and JH3b. GL represents the closest germline gene homology as determined by VBase. 
Primer binding regions are underlined and no mutations in these regions included. Homology to 
GL is represented by a dot, mutations from GL are in upper case (if a replacement amino acid 
mutation) or lower case (if a silent amino acid mutation). Mutations that determine families are 
depicted in red. CDR regions are detailed. 
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It is of interest that the three reliable families of related IgE+ B cell clones isolated from 
the nasal mucosa samples S016 and AP19 were both from biopsies taken within the 
grass pollen season, although related IgE+ B cell clones were not isolated from the other 
nasal biopsy samples also taken in-season (CD6, HD14 and HD17), preventing any 
complete correlation with the presence of related clones in the nasal mucosa and the 
time at which the nasal biopsies were taken. Unfortunately, no out-of-season biopsies 
were taken from grass pollen mono-allergic patients for comparison. There was also no 
apparent correlation between the number of different clones isolated from a sample and 
the likelihood of detecting a family of related clones from that sample, as while a 
comparatively wide range of different clones were isolated from S016 and AP19, 
similar numbers of different clones were isolated from biopsy samples in which no 
related clones were detected e. g. HD14. S016 and AP19 were allergic to multiple 
allergens, sharing only an allergy to grass and dog. Exposure of the patients to non- 
grass allergens could not be assessed. Both patients were within the middle of the range 
of total serum IgE values exhibited by the cohort of patients. It was notable that of the 
three families of clones isolated from the nasal mucosa, two of the families comprised 
clones expressing VH5-51 (discussed in greater detail in chapter 7). 
In each of the three B cell clonal families isolated from the nasal mucosa the 
relationship between the clones was very close, with one hypothetical intermediate 
needed to link each set of related clones. The presence of these clones indicates that it 
is likely that local SHM and clonal expansion occurred in the nasal mucosa, in order 
that clones with such a close degree of relatedness were generated in such a small area 
(approx. 2.5 MM) . The alternative to this, the individual migration of each of the 
related clones from the lymphoid tissue (which could not have been inadvertently 
sampled, the nearest being Waldeyer's Ring in the pharynx, approximately 8- 10 cm 
distal to the inferior turbinate) to the same small area of the inferior turbinate sampled 
by biopsy, is unlikely. 
In contrast to the three families of closely related IgE' B cells isolated from the nasal 
mucosa, only one family of related IgE' B cell clones (patient HD17) was isolated from 
the corresponding seven PBMC samples examined. This PBMC family also 
incorporated a hypothetical intermediate, but comprised two clones that were more 
distantly related than any of the clones in the nasal mucosa. While no families were 
isolated from the nasal biopsy of patient HD 17, HD 17 exhibited by far the highest total 
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serum IgE value in the cohort. In addition, HD17 was determined tobe monoallergicto 
grass by skin-prick testing (although RAST results suggested that while the hugely 
predominant quantity of specific IgE was directed against grass, a minor quantity of 
anti-cat IgE was also present). It is possible that there was an increased chance of 
detecting related PBMC clones from patient HD17 because of the nature of the IgE 
repertoire they expressed, directed in significant manner towards restricted antigens 
(although the number of clones exhibiting different VH regions did not appear restricted 
compared to other patients). 
The detection of identical clones from the nasal biopsy and PBMC sample of CMIO, 
S016 and HD17 implies that, unless cross-contamination between nasal biopsy and 
PBMC occurred in each set of samples, identical sister B cell clones may move between 
the nasal mucosa and PBMC. It is impossible to determine whether the clones isolated 
in the PBMC resulted from the 'overspill' of locally generated B cell clones in the nasal 
mucosa, or whether they were examples of B cells subjected to SHM and clonal 
expansion in the lymphoid tissue, which then migrated independently into the blood and 
via the blood, into the nasal mucosa. There would seem to be no evidence to exclude 
the possibility that some individual IgE+ B cells in the nasal mucosa result from the 
conventional routes of maturation and migration, while other families of clonally related 
IgE+ B cells are generated locally in the mucosa. Alternatively, while it would seem 
unlikely, it is possible that a clone detected in the nasal biopsy was identical to a clone 
from the PBMC because it resulted from a PBMC present within the nasal biopsy itself. 
In SO 16, the only sample in which clones distantly related in both the nasal mucosa and 
PBMC were detected, the PBMC clone (PC9) was related to the VH3 family of B cell 
clones from the nasal mucosa. The branching of PC9 from the family occurred early in 
the evolution of the clonal family, as it was much more distantly related than its sister 
clones isolated from the nasal mucosa. It is again possible that clones migrated 
independently into both the nasal mucosa and peripheral blood from the lymphoid 
tissue, and that the related B cell clones isolated from the nasal mucosa were then 
generated locally. It is also possible that PC9 was generated in the nasal mucosa and 
migrated into the blood circulation. 
It was impossible to determine what type of B cell the sequences generated by PCR 
originated from, e. g. memory cell or plasma cell. It might be assumed that as plasma 
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cells would produce by far the greatest number Of 
VH-C& mRNA transcripts, 
amplification of sequences may have been biased towards these cells when they were 
present 
4.4 Analysis of local IgE production in the nasal mucosa of a non- 
atopic subject with elevated systemic IgE. 
In order to increase the efficacy of the PCR reaction, all of the patients selected for this 
study exhibited total serum IgE values of >200 fU / ml, the highest being 2745 IU / ml 
exhibited by HD17 (normal range 3- 150 IU / ml). It was therefore important to 
determine if the presence of related IgE' B cells in the nasal mucosa occurred as a 
consequence of high total serum IgE rather than as a consequence of allergic rhinitis 
(e. g. by the random migration of the B cells such that they would be present in any 
tissue). While this explanation seemed unlikely as analysis of the repertoire of B cells 
in the PBMC of allergic rhinitics did not suggest a close similarity to the B cell 
repertoire in the nasal mucosa, it was necessary to exclude the possibility, pwfieuWly 
as the lymphoid pool had not been sampled. 
Several different experiments would have enabled investigation of the hypothesis that 
families of related IgE' B cells in the nasal mucosa resulted from random migration 
from a systemic pool of IgE' B cells, all of these based on analysis Of VH-CF, sequences 
and the presence or absence of families of related IgE+ B cells in the nasal mucosa of 
subjects exhibiting high total serum IgE, but no respiratory symptoms and in particular 
no allergic rhinitis. Unfortunately access to a food or bee venom allergic patient with a 
high total serum IgE but who did not suffer from any respiratory symptoms was not 
possible. Nor was it possible to gain access to a patient suffering from a gastrointestinal 
parasitic infection. 
A suitable subject, GJ29, was however recruited and a nasal biopsy and PBMC sample 
obtained. GJ29 reported no history of any allergic reactions or respiratory conditions. 
In addition, whilst GJ29's childhood was spent in Asia, there was no evidence to 
suggest recent parasitic infection, although he exhibited a total serum IgE of 1834 IU / 
ml as determined by RAST (a value in excess of that exhibited by all but one of the 
allergic rhinitis patients studied). In addition, the skin-prick test showed a negative 
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reaction to all the tested aeroallergens, although a slightly raised RAST (0.71 IU / ml, 
compared to the norm of <0,35) to Avpergillusfiumigafus was noted (Table 4.4.1). 
Patient Age Sex Status Total serum IgE Specific serum IgE Allergies 51 
at (IU ml) (IU / MI) 2) 
biopsy (Norm 3- 150) (Norm < 0.35) 
GJ29 55 M Non- 1834 AF = 0.71 None 
atopic 
Table 4.4.1: Clinical data from non-atopic subject GJ29. a) Determined by RAST for the 
allergens; house dust mite (HDM), mixed grass (G), cat (C), Aspergillus fumigatus (AF). b) 
Determined by skin-prick test for-I Dermatophagoides (house dust mite) (HDM), Phleum 
pratense (grass pollen) (G), mugwort (M), three trees (T), silver birch (B), cat (C), dog (D), horse 
(H), Aspergillus fumigatus (AF), Cladosporium herbarum (CL), Altemaria altemata (A). 
The nasal biopsy and PBMC samples were processed exactly as those in section 4.3 
(although the cDNA reaction was modified according to a newly available protocol such 
that even greater efficacy of PCR amplification was enabled (see section 3.2.17 for 
details). PCR experiments repeatedly yielded Vii-C6 products from the PBMC (Fig. 
4.4.1). These PCR products appeared to consist of clones exhibiting VII regions from 
different classes (data not shown). In contrast, no V11-CE PCR products were amplified 
from the nasal mucosa in any of the repeated experiments (Fig. 4.4.1). 
Rcl. 4.4.1, Ac jarose qet electrophoresis of V -Cc PCR Products amplified from the nasal ,, r 
mucosa and PBMC of non-atopic subject GJ29. VH-CI- PCR products were subjected to 
agarose gel electrophoresis on a 1% agarose gel and visualised under UV. Lane 11ý 100 bp 
ladder (L), (500bp indicated). Lane 2; VH-CI- PCR products amplified from the nasal mucosa 
(NM) of subject GJ29. Lane 3; VH-Q'- PCR products amplified from PBMC (PB) of subject 
GJ29. Lane 4-, VH-CF PCR negative control (no RNA in cDNA reaction). 
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PCR analysis of GAPDH expression in the nasal biopsy and PBMC samples both 
yielded positive signals, demonstrating that poor sample quality was unlikely to be the 
cause of the negative VH-CF PCR from the nasal biopsy sample (Fig. 4.4.2). 





Fia. 4.4.2: Aaarose ael electrophoresis of GAPDH PCR products amplified from the nasal 
mucosa and PBMC of non-atovic subject GJ29. GAPDH PCR products (393 bp) were 
subjected to agarose gel electrophoresis on a 1% agarose gel and visualised under UV. Lane 
1- 100 bp ladder (L), (500bp indicated). Lane I GAPDH PCR products amplified from the 
nýsal mucosa (NM) of subject GJ29. Lane I GAPbH PCR products amplified from PBMC (PB) 
of subject GJ29. Lane 4; GAPDH PCR negaiive control (no RNA included in clDNA reaction). 
In addition, further PCR experiments yielded products corresponding to Vji-Cýt, Vjj-CCt 
and V11-Cy transcripts in both the nasal biopsy and PBMC sample (Fig. 4.4.3), 
suggesting that the inability to PCR amplifyVH-CF- transcripts from the nasal biopsy 
sample was likely to have resulted from an absence, or very low level, of CF, transcripts 
in the sample. 
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Fia. 4.4.3. Amarose ciel electroDhoresis of VwCjj. VwCa and VwCy PCR Droducts 
amplified from the nasal mucosa and PBMC of non-atopic subject GJ29. VH-Cýt (450 bp), 
VH-C(I (450 bp) and VH-CY (450 bp) PCR products were subjected to agarose gel 
eleGtrophoresis on a1% agarose gel and visualised under UV. Lane 1; 100 bp ladder (L), (500 
bp indicated). Lane 2; VH-CýL PCR products amplified from the nasal mucosa (NM) of subject 
GJ29. Lane 3; VH-C4 PCR products amplified from PBMC (PB) of subject GJ29. Lane 4; VH- 
Cýt negative control (no clDNA). Lane 5; VH-Cýt negative control (no PCR product carried into 
the second PCR). Lane 6; VH-COC PCR products amplified from the nasal mucosa of subject 
GJ29. Lane 7; VH-C(4 PCR products amplified from PBMC of subject GJ29. Lane 8; VH-C(x 
negative control (no cDNA). Lane 9; VH-C(x negative control (no PCR product carried into the 
second, PCR). Lane 10; VH-CY PCR products amplified from the nasal mucosa of subject 
GJ29. Lane 11; VH-C7 PCR products amplified from PBMC of subject GJ29. Lane 12', VH-Cy 
negative control (no cDNA). Lane 13; VH-Cy negative control (no PCR product carried into the 
second PCR). Lane 14-1 100 bp ladder. 
The possibility that the biopsy contained no amplifiable VII-CF transcripts because of 
sampling (as seen in a small proportion of allergic rhinitis patients with high systemic 
total IgE) must be acknowledged, although it was not possible to take further nasal 
biopsies from GJ29 or to recruit similar patients to consolidate these findings. The 
analysis of GJ29 would seem to suggest that a high total serum IgE value does not result 
in the random migration of IgE' B cells into the nasal mucosa in a non-atopic subject. 
This data supports the evidence presented in section 4.3 suggesting that the families of 
clonally related IgE' B cells resulted from local SHM and clonal expansion in the nasal 
mucosa of the allergic rhinitis patients in this study. 
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4.5 Discussion. 
Whilst previous investigators have demonstrated that B cells producing IgE protein are 
present in the nasal mucosa of allergic rhinitis patients [Smurthwaite el al, 2001], 
[KleinJan el al., 200 1 ], the sites at which the decision is made at the molecular level for 
mucosal B cells to switch to the production of IgE and at which affinity maturation of 
IgE' B cells occurs has not been elucidated. To establish whether the location of SHM 
and clonal expansion was local to the nasal mucosa of allergic rhinitis patients, VH-CH 
sequences were amplified from the mRNA of IgE' B cells from nasal biopsy samples 
and compared to those from the peripheral blood of the same allergic rhinitis patients. 
In this chapter, evidence has been presented that suggests that local SHM and clonal 
expansion occurs in the nasal mucosa of allergic rhinitis patients and additionally the 
role that DNA polymerases may play in the misinterpretation of results. 
Initial analysis of sequences generated by PCR amplification with Taq DNA 
polymerase from the nasal biopsy and PBMC samples of patient SI-5 indicated that the 
experimental error rate in the system was too high to enable a confident distinction to be 
made between somatic mutations and experimentally induced errors (despite such data 
being previously published [Van der Stoep et al., 19931, [Snow et al., 1995], [Snow et 
al., 1999]). Pfu DNA polymerase was shown to incorporate far fewer errors than Taq, 
although the error rate was still such that approximately one in seventeen VH region 
sequences were likely to contain an experimental error. Therefore when apparently 
related B cell clones were Pfu amplified in the experiments detailed in this thesis, only 
relationships confirmed by multiple mutations were acknowledged as genuine. 
VH-CE sequences isolated from nasal biopsy samples from the cohort of seven allergic 
rhinitis patients demonstrated reliable evidence of clonally related IgE+ B cells from the 
nasal biopsies of two of the patients. VH region sequence alignment enabled the 
construction of genealogical trees for three separate families of related IgE+ B cell 
clones (two from S016 and one from AP19, each composed of either two or three 
isolated IgE+ B cell clones from the nasal mucosa). The clones from each family 
displayed clear relatedness, evident from the shared VH-D-JH signature region distinct to 
the clonally related members of each individual family and indicative of the unique VH- 
D-JH recombination that occurred in the progenitor B cell of each family. In addition, 
each family of B cell clones exhibited both shared and diverse somatic mutations, 
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indicative both of their shared ancestry and also individual affinity maturation and 
clonal expansion. 
The IgE+ B cell clones isolated from the nasal mucosa were so closely related and so 
concentrated that it is probable that they resulted from local SUM and clonal expansion. 
The less likely alternative would be that each related clone migrated individually from 
the lymphoid tissue to the same region of the inferior turbinate. This would only seem 
to be a viable option if the repertoire of IgE+ B cells in the nasal mucosa was extremely 
limited, such that if aB cell were to randomly migrate into the mucosa it would be close 
to a related clone, whereas VH region sequence analysis in this study showed that a 
diverse range IgE+ B cell clones existed in the nasal mucosa. 
In contrast to the three families of closely related IgE+ B cells isolated from the nasal 
biopsy samples, only one instance of related IgE+ B cell clones was detected from 
peripheral blood. Two distantly related IgE+ B cells were isolated from the PBMC of 
patient HD 17, the only mono-allergic patient and the patient exhibiting the highest total 
serum IgE. The more distant relationship between the two related PBMC clones was in 
contrast to the closely related IgE+ B cell clones isolated from the nasal mucosa. It is 
possible that such small sampling of the total PBMC pool may not have fully 
represented the extent of related IgE' B cells, which would be distributed throughout the 
entire volume of peripheral blood. 
Instances of identical clones being isolated from both the nasal biopsy and PBMC 
occurred in three patients (CM10, S016 and HD17). In each instance the clones were 
unique and not members of aB cell family that had been isolated, suggesting that they 
may have resulted from independent migration of identical sister clones into the nasal 
mucosa and peripheral blood from the lymphoid tissue, or that the clone isolated from 
the PBMC originated from the nasal mucosa. Alternatively the duplicated sequences 
may have resulted in each case, from cross-contamination between the nasal biopsy and 
PBMC samples (at any stage of the experiment), or from the presence of PBMC within 
the nasal biopsy itself 
In only one instance (SO16) was a clone isolated from the PBMC that was distantly 
related to a clone isolated from the same patient's nasal biopsy sample. In this instance 
the clone isolated ftom the PBMC was related to a family of IgE' B cell clones isolated 
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from the nasal mucosa. It appeared that the PBMC clone may have diverged at an 
earlier stage than the generation of the family of clones. It is again possible that this 
peripheral blood B cell clone was generated in the nasal mucosa, but it is also possible 
that the clone migrated into the peripheral blood from the lymphoid tissue, and that the 
family of IgE' B cells was generated in the nasal mucosa but founded by a sister B cell 
clone that had also migrated from the lymphoid tissue. 
Whilst VH-C6 sequences were amplified from all of the nasal biopsy and peripheral 
blood samples in the cohort of seven patients, families of related B cells were only 
found in the nasal mucosa of S016 and AP19 and not, as might be expected, from 
highly allergic patients such as HD17. It is possible that some genuinely related clones 
were eliminated because of concerns over experimental errors and also that instances of 
multiple, identical sister clones were overlooked as the difference between multiple 
identical clones and multiple identical transcripts generated by one clone could not be 
distinguished in this system and so were assumed to originate from one clone. It would 
seem likely that if local SHM and clonal expansion occur in the nasal mucosa, that the 
related cells may be organised in clusters (see chapter 6). It may therefore be the 
random sampling by a single nasal biopsy from the whole of the inferior turbinate that 
resulted in the detection of related IgE' B cell clones from only two of the seven 
patients. These clusters of related B cells may be dispersed randomly throughout the 
inferior turbinate. Multiple biopsies from each patient (a procedure not ethically 
possible) may be necessary in order to consistently detect B cell clonal families. 
While it is unlikely that a family of clonally related IgE+ B cells would migrate 
individually from the lymphoid tissue to the same approximate 2.5 MM3 area of the 
nasal mucosa, particularly as the VH-CF- sequences isolated from the nasal mucosa 
indicated the presence of a diverse rather than extremely limited repertoire of B cells, it 
was important to eliminate the possibility that a high serum IgE value resulted in the 
saturation of the nasal mucosa with IgE+ B cells: PCR analysis Of VH-C& Sequences 
from the nasal mucosa of a non-atopic subject who exhibited highly elevated serum IgE 
but no respiratory symptoms was conducted. No VH-CF- PCR products could be 
amplified from this nasal biopsy sample, even after repeated attempts, although VH-CF 
PCR products were easily amplified ftom the peripheral blood. 
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This research indicates that a high total serum IgE in the absence of allergic rhinitis 
does not result in the presence of families of related IgE+ B cell clones in the nasal 
mucosa, but rather that their presence is inherently linked to the state of allergic rhinitis. 
Furthermore, in allergic rhinitis patients the existence of families of closely related B 
cell clones is indicative of successive cycles of local somatic hypermutation and clonal 
expansion in the nasal mucosa. 
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Chapter 5 
Local class switch recombination in the nasal mucosa of an 
allergic rhinitis patient 
Chapter 5 Local class switch recombination ill 
5.1 Introduction 
The data presented in Chapter 4 suggested that local somatic hypermutation and clonal 
expansion had occurred in the nasal biopsy samples from at least two of the seven 
allergic rhinitis patients that had been studied. Previous research has suggested by the 
analysis of I& and C& RNA transcripts, that local class switch recombination (CSR) also 
occurs in the nasal mucosa of allergic rhinitis patients [Durham el aL, 19971 and the 
lung mucosa of allergic asthmatics [Ying et al., 2001]. Further work in the lung 
implicated the respiratory mucosa as a site of local events when the analysis Of VH 
transcripts from clonally related B cells was used to obtain evidence for the occurrence 
of CSR in the lung mucosa of allergic asthmatics [Snow el al., 1999]. 
As the results presented in chapter 4 suggested that the signals necessary for SHM were 
present in the allergic nasal mucosa, further work was carried out to determine if any 
evidence of local CSR could be established in that cohort of patients. This investigation 
into local CSR was undertaken by the analysis Of VH region sequences based on the 
methods previously applied to the lung mucosa [Snow et al., 1999]. Research was 
concentrated on the analysis of sequences from the nasal biopsy samples from which 
families of related IgE+ B cell clones had been detected previously. As little evidence 
of families of related IgE+ clones in the PBMC was established in chapter 4, with only 
one instance of two distantly related clones being identified, this area of research was 
not extended to the peripheral blood. 
5.2 Investigation of IgM+, IgA+ or IgG+ B cell clones related to the VH3 
and VHS family of IgE+ B cell clones previously isolated from the nasal 
biopsy of allergic rhinitis patient S016. 
The PCR protocol utilised to investigate local CSR in the nasal mucosa of allergic 
rhinitis patients was based on the protocol detailed by previous researchers [Efremov el 
al., 1993], [Snow et al., 1998] and [Snow et al., 1999], with the addition of a further 
PCR to validate the results, as described in Fig. 5.2.1. The protocol incorporated an 
initial nested PCR (I and 2) that specifically amplified all transcripts in which the VH 
class of interest (i. e. VHI-VH7) was present, in conjunction with either Cg (Igm), CcE 
(IgA) or Cy (IgG), each as a separate reaction. A subsequent, highly specific semi- 
nested PCR (reaction 3) was then employed to further amplify from PCR 2 any cDNA 
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expressing the clonal signature region unique to the particular B cell clonal family of 
interest. If the semi-nested PCR 3 successfully demonstrated the presence of either CýL, 
Cct or Cy transcripts in conjunction with the signature region specific for the IgE family 
of clones, further semi-nested PCRs, each using a sample from PCR 2 were used to 
determine the exact VH region sequence (PCR 4) and also, in this study, to confirm the 
validity of the full length of sequence, from the highly mutated CDRI of aB cell clone 
through to the CH region (PCR 5). 
The rational behind this experimental approach was that the presence of B cell clones 
related to a family of IgE+ B cells, but that expressed IgK IgA or IgG in the same nasal 
biopsy sample implied that local CSR had occurred, resulting in the occurrence of such 
geographically close, related B cell clones of different isotypes. 
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Nested V. 5 primers 
PCRI and 2 generate a pool of 
VH5-C, 
ILeaderl VIDIJICI 
Nested CýL, Ccc or Cy 
primers 
PCR3 identifies the correct 
signature region sequence joined 
ILeaderl vIDIJIC 
to different C, regions. 14 
CýL, Ca or C7 
inner primer 
OR 
PCR4 amplifies the V. region from 
Inner V. 5 primer 
clones with the correct signature Leader vDIJC 




PCR5 amplifies the V. region 3'of -- --0- CDR1, the signature region and FLeadeTr vI DT JIC the C, region of a particular clone 
ofinterest. 14 
Cý4 CcE or Cy 
inner primer 
Fid. & 2.1: Dimarammatic representation of the PCR protocol for the ampim 
Q4 VFrCa and YVJ&rseauences from specific B cell clones. To amplify VH-CH sequences 
from B cells of a particular clonal origin, an initial nested PCR was undertaken in which (in the 
case of aB cell expressing a VH5 gene) VH5-CýL, VH5-C(x, and VH5-Cy sequences were each 
amplified separately by nested PCIR 1 and 2. A semi-nested PCIR 3 was then used to amplify 
the specific signature region of the required clone from a sample taken from PCIR 2, utilising the 
inner CR, Coc, or Cy primers in conjunction with the appropriate primer (unique to each clonal 
family) that bridged the VH-D junction of the signature region. If the appropriate signature region 
was isolated from PCR 3a further sample of PCIR 2 was used in the semi-nested PCIR 4 to 
amplify from the inner VH5 primer to the specific D-JH junction of the signature region. To 
ensure that the fragments of sequence amplified in PCR 3 and 4 formed one complete 
transcript, a sample of the appropriate PCIR 2 was used in a semi-nested PCIR 5, to amplify from 
the uniquely mutated CDR1 of the particular B cell clone to the inner Cýt, Cot, or Cy primer. The 
PCIR products generated by PCIR 2 were gel purified before use in subsequent reactions. PCIR 
products from PCIR 3,4 and 5 were cloned and sequenced. PCIR I and 2 each utilised 30 
cycles of amplification and PCIR 3,4 and 5,20 cycles of amplification. Based on a protocol 
detailed by [Efremov et al., 1993], [Snow et at, 19981, [Snow et aL, 19991. 
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This protocol was applied to the analysis of cDNA from the allergic rhinitis patient 
S016 from whom two families of related IgE-' B cell clones had been identified in the 
nasal mucosa (section 4.3). Of the two families of related IgE' B cell clones isolated 
from nasal biopsy SO16, one family comprised B cells expressing the VH3 gene VH3- 
30 and the other comprised B cells expressing the VH5 gene VH5-51 (Fig. 4.3.2 B and 
4.3.5 B). It was therefore necessary to design two separate PCR strategies, 
incorporating two different family specific primers to amplify VH-CýL, Cot and Cy from 
B cells from either the VH3 or VH5 B cell clonal family (see 3.2.19 - 22 for details). 
When theVH3 PCR products generated from PCR I and 2 were subjected to agarose gel 
electrophoresis and visualised under UV, products of the correct size were apparent 
from only theVH3-Ccc reaction. However, even when the annealing temperature was 
varied, no products could be detected in PCR3, the signature region specific PCR (data 
not shown), implying that while IgA' B cell clones expressing VH3 were present in the 
nasal mucosa of SO 16, none of the clones were related to theVI-13 family of IgE+ B cells 
isolated previously. NoVH3-Cýi or VH3-Cy transcripts could be successfully amplified 
from the nasal biopsy of SO 16. 
In contrast to the VH3 PCRs, when PCR products amplified from B cells expressing 
VH5 were subjected to agarose gel electrophoresis and visualised under UV, products 
correlating to both VH5-C(x and VH5-Cy (although not Cg) transcripts were evident after 
PCR I and 2. In addition, when the VH5-Ccc and Cy PCR products were further 
amplified in PCR 3 to specifically isolate the signature region associated with the VH5 
family, PCR products were generated from both the VH5-Cot and Cy reactions (Fig. 
5.2.2 A). 
When the V115-Coc and Cy PCR 3 products were cloned and sequenced, the VH5-Cy 
sequences did not contain the correct signature region. In contrast, the signature region 
sequence generated from the VH5-Coc PCR (Fig. 5.2.2 B) was identical to that of the 
related family of IgE+ B clones isolated previously from the nasal mucosa of S016. 
Instead of expressing Ce however, the signature region was joined to Ccc2. This 
indicated the presence of at least one B cell clone that originated from the same 
progenitor cell as the component members of the VH5 family of IgE-' B cell clones, but 
which had undergone CSR to IgA2. 
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VH N D4-17 JH4b CH 
19E CL A(A'A FAA 1' A, -1', -A, A, Aý; Al; '', "WIP 
IgA2 CL A,; N'A 'T AA ý IA G T(-, o "I" ; 6ý'i%; ACTA" A,; ý; G ""TCA "I', G CA WCCCGACCAGCCCC AAGG TCTWC(: QC TGAG 
IgA2 GL ý'ATCCCCGACCAGCCCCAAGGTCTTCCCGCTGAG 
Rq. 5.2.2. Agarose 
-qei electrophoresis of 
V145-Ca and VmS-C2, signature rec fion PCR 
products and the sequence of the IcIA2 shclnature rec lion, bath mplifled from the nasal 
mucosa of patient S016. A) VH5-CoL (95 bp) and VH5-Cy (94 bp) signature region PCR 
products (PCR 3) were subjected to agarose gel electrophoresis on a 2% agarose gel and 
visualised under UV. Lane 1; VH5-C(x signature region PCIR products amplified from the nasal 
mucosa (NM) of patient S016. Lane 2; VH5-C(x negative control (no clDNA). Lane 3; 100 bp 
ladder (L), (500 bp indicated). Lane 4; VH5-Cy signature region PCR products amplified from 
the nasal mucosa of patient S016. Lane 5; VH5-Cy negative control (no clDNA). B) Alignment 
of the IgA2 signature region sequence isolated from PCR 3, aligned with the signature region 
sequence exhibited by the related IgE* B cell clones and also aligned with the IgA2 germline 
sequence, demonstrating the homology of the IgA2 clone with the IgE* clones across the 
signature region but homology with IgA2 in the constant region. CL represents a clonal 
sequence. GL represents a germline sequence. Homology between nucleotides is represented 
by a vertical line. Primer regions are underlined. 
In order to establish the relationship of the IgA2 clone(s) with the V115 IgE' B cell clonal 
family, PCR 4 was carried out to amplify the V11 region and enable analysis of the 
somatic mutations. The resultant PCR products were subjected to agarose gel 
electrophoresis (5.2.3 A), cloned and fifteen sequences analysed. Five of the fifleen 
clones clearly shared the correct VII-D junction. In addition, analysis of the V11 region 
sequences from the IgA clones demonstrated that while some mutations were common 
to the IgA clones and some were the same as those in the related IgE' B cell clones, all 
exhibited additional unique mutations throughout the length of the V11 region (hig. 5.2.3 
B), 
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-------------------- CDFL2 --------------------------- 
so 60 70 so 
GL CCGGGAAAGGCCTGGA=GGPLTGGGGATCATCTATCCTGGTGACTCTrATACCACJLTAJCAWCCGrCCTTCCAAGGCCAGGTCACCATC7rr-%WCGJkCAAGTCCATC. AGCACCGCCTACCTG 
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... - ............................................... 
t. C .................. C ... ....... 





G. .. C.. T .... A .......... A ...... C .... t ..... LC ........ ................ Tg ...... ...... 
CA ............. 
gA C5 .................................................. 
C,... c ...................... ........................ ....... 
A .......... t.. 




G .............. ........................ ..................... 
IgA C17 ......................... ........ ... AA ..................................... .T...................... ........ ý! ... F........ 
90 N D4-11 JH4b 
GL CAGrGGAGCAGCCTGAAGGCCTCGGAJCACCGCCATGrArrACTGTGCGAGAr-A ------ TGACTACGGTGACrAC TGGGGCCAG 
. ýAA61AG .. G.. CG. c ....... ......... 7g 'K CC 1 
41 
........ ................. 
A CG. C ....... ......... 
gE C8 ..... 11 .............. AGAG .. G CG. ý ....... ......... 
JqA Cl ............. .................. A ..... t ........... tAAGAG .. G.. CG. C ....... ......... 
IqA c ................................... T ................. tAAGAG .. G.. CG. C ....... ......... 
ýIgA CS - . ". - ......... c ................... A ..... t ........... tAAGAG .. G.. CG. C ....... ......... 
IgA C14 ................. ... .... G ...... c ................. t 
AAGAG .. G.. CG. C ....... ......... 
IgA C17 T .... .......... I IIIAI; ....... ......... 
Fie. 5.2.3. Aqarose ael electrophoresis of VjrD-Jw PCR products from hqA+ B ceff clones 
and the sequence alkinment of those hqA sequences with the related hgE' B cell clones 
previously amplified from the nasal mucosa of iWient S016. A) VH-D-JH PCR products 
from IgA' B cells (327 bp) (PCR 4) were subjected to agarose gel electrophoresis on a 2% 
agarose gel and visualised under UV. Lane 1; 100 bp ladder (L), (500 bp indicated). Lane 2; 
VH-D-JH PCR products amplified IgA+ B cells from the nasal mucosa (NM) of patient S016. 
Lane 3; VH-D-JH negative control (no cDNA). B) Alignment Of VH-D-JH sequences (expressing 
the genes VH5-51, D4-17 and JH4b) amplified from related IgA* and IgE+ B cell clones isolated 
from the nasal mucosa of patient S016. GL represents the closest germline gene homology as 
determined by VBase. N denotes non-templated nucleotide insertions. The primer regions 
used for amplification of the IgA clones are underlined and no mutations in the primer regions 
are included. Homology to GL is represented by a dot, mutations from GL are in uppercase (if a 
replacement amino acid mutation) or lowercase (if a silent amino acid mutation). CDR regions 
are detailed. 
While the IgA' and IgE' B cell clones were clearly related, it was difficult to construct a 
meaningful genealogical tree since the range of mutations was so diverse. Furthermore, 
there were instances where identical mutations occurred in what must have been 
different branches of the clonal family, making it difficult to reliably establish the exact 
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position of some of the IgA clones within the family. Consequently, although both the 
IgA and IgE sequences were aligned (Fig. 5.2.3 B), they were not used to construct 
what may have been an erroneously structured genealogical tree. 
When the alignment of the VH region sequences from the related IgA and IgE clones 
was studied, evidence of antigen selection was observed throughout the family of B cell 
clones; an average of 5.6% of the FWR was mutated in contrast to 12.7% of the CDR. 
Moreover, when the replacement / silent (R/S) amino acid mutation ratio of all the 
mutations accumulated within the family was compared in the CDRs as opposed to the 
FWRs, the CDR R/S ratio was 4.2, whereas in the FWR the R/S ratio was 2.6. This 
high R/S ratio in the CDRs is indicative of conventional antigen selection across the 
region [Shlomchik el aL, 1987]. 
Although a copy of the correct signature region, identical to that expressed by the IgE' 
VH5 family of related B cells, had been amplified from an IgA2+ B cell in PCR 3, the 
possibility could not be excluded that the VH region sequences detailed in 5.2.3 B, that 
had been assumed to be from IgA+ B cells, may have instead resulted from IgE 
sequences non-specifically amplified by the IgA primer set (as PCR 4 did not extend to 
amplify the CH region). It was also possible that while the signature region had been 
amplified from an IgA2 cell, some or all of the VH sequences may have originated from 
an IgAi B cell(s). The amplification of the full VH-D-JH-COL sequence was not possible 
in PCR 4 because of the inability to amplify from the inner VH5 primer through to the 
Cct region, whilst still maintaining the specificity for sequences from the particular B 
cell clonal family. Attempts to amplify from the inner VH5 primer to the JH-CH junction 
were unsuccessful because of the largely conserved nature of the 3' region of the JH 
genes (data not shown). 
Previous researchers had assumed that the VH region sequences amplified in PCR 4 
would have originated from the same isotype as the signature region [Efi-emov el al., 
1993], [Snow et al, 19981, [Snow et al., 19991. To be doubly sure, a novel PCR5 was 
designed in this study for control purposes. The (supposedly IgA+) B cell clone CI was 
chosen at random and a primer designed that was specific to its (considerably mutated) 
CDRI. In PCR 5 the VH5-D-JH-C(X sequence of clone C 13' to CDRI was amplified. 
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PCR 5 successfully amplified a sequence identical in the VH-D-JH sequence previously 
amplified from the clone Cl, although in addition the VH region was joined to COC2 
(Fig. 5.2.4). (An additional base mutation in the D region was evident, although this 
may have accumulated experimentally as the signature region and all somatic mutations 
were otherwise identical), This CDRI-D-JH-COL sequence confirmed the validity of the 
previous results, suggesting that at least one of the IgA' sequences was derived from an 
IgA2 B cell. Time constraints prevented analysis of the other four IgA clones by PCR5. 
VHS-51 10 20 30 
CMP. 1----- 
GL GAi=GCAGCTGGrGCAGTCTGGaGCJLGAGGTGAAAARGOCCGGGGAGTCTCTGRAGATCTCCT07JkG= 
IgA cl .............................. c .............. c .................................. t, 
AG... G ... C ... tGCC..... t 
IgA CTL .. t. AG ... 
G. .. C'. .. t G(-(7.. . .. t 
-------------------- CDR2 --------------------------- 
40 50 60 70 
GL TGGGrGCGCCACMGCCCGGGAAAGOCCTCGAGTGGATGGGGATCATCTATCCTGGTGACTCTGATACCAGATACAGCCCgTCCrrCCAAGGCCAGGTCACC*ATCT 
19A Cl .................... ....................................... t. 
C .................. 
C .......... A ..... 
IgA CTL .................... a ............................................... t. c .................. 
c .......... A ..... 
80 90 GL CAGCMACAAOT GMAr. C; CCTCGGAC7, MGLOC-ATGTXrTACTGTCKXMANkCA 
I, rA Cl ... T .............. 
A .......... t .... C ............. G .................. A ..... t ........... 
IgA CTL ... T .............. A .......... t .... C ............. C ................... A ..... t ........... 
N D4-17 JH4b CQ2 
GL ------ TGAjLTArGGrGACrAjC TGGGGCCAGGGAArCCTGGTCACCGrCTCCTC3LG CATCCMGACCAOCCOr-AAMTrr=CQ2CrgM 
IgA Cl tAAGAG .. G.. CG. C ....... ......... 
IgA CTL tAAGAG .. G.. C7G. C.. ... C . .................................. .................................. 
Fid. 5.2.4. Seauence aflunment of the VrD-J,, seauence amoiffied from cione Cl In PCR4 
with the CDRI=D-J led in PCR5. conrirmin-a that C1 was indeed an I A9 clone. H amptir -a Both sequences were isolated from the nowl mucasa of jurdent S016. PCR 5 specifically 
amplified from the mutated CDR1 of the sequence from the B cell clone C1, through to the IgA2 
constant region (IgA CTQ, confirming that the sequence isolated from clone C1 in PCR 4 QgA 
Cl) was indeed from an IgA2+ B cell. Both sequences expressed the genes VH5-51,134-17 and 
JH4b and were isolated from the nasal mucosa of patient S016. GL represents the closest 
germline gene homology as determined by VBase. N region constitutes non-templated 
nucleotide insertions. Primer regions for the amplification of the control sequence are 
underlined and no mutations in these regions were included. Homology to GL is represented by 
a dot, mutations from GL are in upper case (if a replacement amino acid mutation) or lower 
case (if a silent amino acid mutation). CDR regions are detailed. 
5.3 Investigation of IgM*, IgA* or IgG* B cell clones related to the VHS 
family of IgE* B cell clones previously isolated from the nasal biopsy of 
allergic rhinitis patient AP19. 
As sequences from IgA' B cell clones had been isolated from the nasal biopsy of SO 16, 
that were clearly related both to each other and also to the VH5 IgE' family of B cell 
clones from the same nasal biopsy, it seemed likely that related clones of an isotype 
other than IgE might be detected in nasal biopsy AP19. A family of related VH5 IgEB 
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cell clones had been previously isolated from AP19 (Fig. 4.3.2 D and 4.3.5 Q. PCR I 
and 2 therefore targeted amplification of cDNA from VH5-Cp, Cct and Cy transcripts in 
the same manner as for S016. When the PCR 2 products were subjected to agarose 
gel electrophoresis and visualised under UV, DNA bands indicative Of VH5-Cýt, Ccc and 
Cy clones were observed. 
PCR 3 was employed as previously using a primer specific for the particular VII-D 
junction of the VH5 family from AP19 in order to amplify the correct signature region, 
joined to CH- In contrast to S016, no appropriate signature region sequences were 
isolated, for while PCR products, particularly from Cy, were evident upon agarose gel 
electrophoresis, when cloned and sequenced it was clear that all of the products had 
been non-specifically amplified. No further progress could be made, suggesting that 
while VH5 clones expressing IgM, IgA and IgG were present in the nasal biopsy AP19, 
none appeared to be related to the VH5 family of clonally related IgE' B cells. Time 
constraints did however mean that experiments were focused on the investigation of 
S016 and these experiments were not repeated multiple times. It may therefore have 
been that the clones could not be easily detected, rather than that they were absent from 
the sample. 
5.4 Investigation of IgM"*, IgA" or IgG+ B cell clones related to the VH3 
family of IgE+ B cell clones previously isolated from the nasal biopsy of 
allergic rhinitis patient CM10. 
As the experimental work described in section 4.3 progressed, it became evident that 
certain B cell clonal families should be regarded as unreliable as a consequence of the 
experimental error rate. Initially however, an attempt was made to investigate whether 
B cell clones expressing isotypes other than IgE, related to the family of related IgE' B 
cell clones from nasal biopsy CMIO could be amplified. The apparent family of related 
clones isolated from the nasal mucosa of CMIO was small, comprising two VH3 B cell 
clones that differed by just one mutation (Fig. 4.3.2 A). The primers used in PCR I and 
2 were targeted to amplify cDNA from VO-Cp, VH3-Ca and VH3-Cy transcripts. 
These initial PCRs successfully amplified VO-Coc and VH3-Cy cDNA (data not 
shown). However, sequence analysis demonstrated that the signature region products 
amplified in the subsequent PCR 3 were generated non-specifically, regardless of the 
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annealing temperature used in PCR 3. No evidence could therefore be provided to 
suggest that local CSR had occurred in the nasal biopsy sample from allergic rhinitis 
patient CM 10. 
5.5 Discussion 
A greater body of research has been directed towards the study of local class switch 
recombination than towards the study of local somatic hypermutation because of its 
appeal as a potential therapeutic target for the prevention of the local allergic response. 
Examples of previous research include in situ hybridisation studies of nasal biopsy 
samples which demonstrated that while the number of B cells in the nasal mucosa did 
not increase after stimulation with grass pollen allergen, the proportion that expressed le 
and Ce did, indicative of the stimulation of epsilon germline transcription; the first step 
in CSR to IgE [Durham el aL, 1997]. However, this approach did not conclusively 
demonstrate that the molecular process of CSR had occurred locally and it did not 
indicate which isotypes CSR was occurring between, or enable analysis Of VH region 
sequences from the relevant B cell clones. 
An alternative approach, in which VH region sequences were analysed from an 
asthmatic patient, was used to demonstrate local CSR, in the allergic lung mucosa 
[Snow el al. 19991; VH region sequences from clonally related IgM+, IgG+ and IgE+ B 
cells were identified, suggesting that it was likely that local CSR had occurred (rather 
than the alternative; that the related clones had been subjected to CSR in the lymphoid 
tissue and then migrated to exactly the same site of biopsy). While this approach did 
not conclusively demonstrate local CSR it again suggested its likelihood. 
Conclusive evidence of local CSR has very recently been demonstrated by the presence 
of switch circle transcripts in the nasal mucosa of allergic rhinitis patients (a project 
undertaken in the Gould group) [Takhar el al., manuscript in preparation] and supported 
by evidence that DNA switch circles (generated by both Cp to Cc and additionally Cy to 
Cc switches) are stimulated in the nasal mucosa as a consequence of ex vivo allergen 
challenge [Cameron el al., 2003]. It was however of interest to apply the technique of 
VH region sequenc-- analysis for the first time to nasal biopsy samples and to investigate 
local CSR in samples fi7orn allergic rhinitis patients that had previously been analysed 
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(section 4.3) to determine if the results correlated with those observed in the allergic 
lung mucosa [Ying el aL, 20011, [Snow et al., 1999] and in the allergic nasal mucosa 
[Durham et al., 1997], [Cameron et al., 2003], [Takhar el al., manuscript in 
preparation]. 
The data presented in section 5.2 suggested that there was no evidence of local CSR in 
the nasal biopsy samples from the allergic rhinitis patients CMIO or AP19. With 
hindsight this was perhaps not surprising in CMIO, as the analysis of the PCR error rate 
later suggested that the family of related IgE'- B cell clones was unlikely to be genuine. 
Perhaps more surprising was the lack of evidence to support local CSR in the nasal 
biopsy from AP19 as previous analysis of the IgE+ clones had suggested on the basis of 
reliable data the presence of a family of at least three related IgE+ B cell clones in the 
nasal biopsy (thus suggesting the microenvironment might be suitable for local CSR). 
It is possible that no related clones from alternative isotypes were detected because the 
family of IgE' B cells was founded in the nasal mucosa by aB cell that had already 
switched to IgE outside of the nasal mucosa (as discussed in section 4.5 there would 
seem to be no reason why such events in the lymphoid tissue would not occur in 
addition to those in the nasal mucosa). Alternatively, if CSR had occurred locally in 
AP19, related clones of different isotypes may have been outside of the biopsied area. 
it must also be acknowledged that the PCR strategy may simply have failed to 
successfully isolate clones that were present, particularly as while non-specific products 
were isolated from PCR 3, no specific positive control could be applied to the reaction. 
In contrast to the results from CMIO and AP19, while no evidence of non-IgE' B cells 
related to the VH3 family of B cell clones from the nasal biopsy of S016 was 
established, there was clear evidence suggestive of local CSR associated with the VH5 
family of IgE' B cell clones from S016; a signature region sequence demonstrating the 
presence of an IgA2 clone related to the family of VH5 IgE+ B cell clones was isolated. 
Furthermore, when the VH region sequences from the IgA clones were analysed it was 
evident that at least a further four related IgA clones existed in the nasal biopsy sample. 
Concern over the specificity of the PCR reactions was alleviated by evidence that the 
sequence of a clone that had been assumed to originate from an IgA+ B cell was indeed 
joined to a Ccc2 constant region. 
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The IgA clones expressed some mutations that were identical to those observed in the 
IgE' clones and some that differed. The different mutations were evident throughout 
the sequence and not, for example, only at the 5' or 3' end which might have otherwise 
suggested the isolation of experimental artefacts. It was also of interest that while the 
construction of a genealogical tree displaying the exact relationships between the clones 
could not be reliably constructed, there did appear to be evidence of antigen selection, 
both in that the percentage mutation and the R/S ratio was higher in the CDR than the 
FWR (indicative of greater antigen selection of replacement mutations across the CDR). 
The somatic mutations observed in the IgA clones further supported the data presented 
in chapter 4 in suggesting that local SHM and clonal. expansion had occurred locally in 
this allergic rhinitis nasal biopsy sample. Furthermore, it appeared that local CSR had 
occurred locally, rather than the unlikely event of clones in the lymphoid tissue, 
switching and then each migrating individually to exactly the same site of biopsy in the 
nasal mucosa. Although the analysis of the clonal repertoire of the whole inferior 
turbinate of S016 (if this could have been surgically removed) may have strengthened 
this suggestion (as it is possible to argue that a huge proportion of the B cell population 
may have been related and therefore that random migration might result in close 
proximity to a sister clone), previous sequence analysis (section 4.3) did not suggest that 
the diversity of B cell clones in the nasal mucosa of SO 16 was that restricted. 
While it may not perhaps have been surprising to see evidence of a switch from IgM, or 
particularly IgG to IgE, related IgE and IgA B cell clones were of particular interest, 
IgA being regarded as the most important antibody isotype in the healthy respiratory 
tract [Lamm, 1997]. It is however possible that local CSR may not have been between 
IgE and IgA, but rather that separate incidences of local CSR from related IgM or IgG B 
cell clones to both IgE and also IgA may have occurred (although no VH-Cýt sequences 
were detected). 
The predominant stimulant for CSR to either IgAi or IgA2 has been demonstrated to be 
TGFO [Islam et al., 199 11, although IIL-4 and CD40 ligand have also been demonstrated 
to stimulate the same switch in a lymphoma B cell line [Cerutti et al, 1998]. Some 
researchers have suggested however that for CSR to occur to different isotypes, a 
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certain number of cell divisions must have occurred e. g. five for CSR to IgE in the 
mouse [Hasbold el a[, 19981. If the local CSR had taken place between IgE and IgA, it 
is possible that in a family of clones such as this, clearly highly specific and maturing in 
affinity in response to an antigen, stimulation to clonally expand may have resulted in a 
high number of cell divisions favouring a CSR event from IgE to IgA2. 
The repertoire of clones evident in the nasal biopsy samples of CM 10, SO 16 and AP 19 
are also worthy of comment. The broadly specific PCR I and 2 provided evidence of 
IgE, IgA and IgG clones in the nasal mucosa. However while the IgM PCR had been 
successfully used to amplify IgM transcripts in previous experiments, only in nasal 
biopsy AP19 was evidence of IgM (VH5) PCR products detected. It is therefore 
possible that while IgM was clearly evident in the non-atopic GJ29 nasal biopsy 
(section 4.4), in the allergic nasal mucosa there may be less IgM' B cells, although a 
more detailed study would need to be carried out for this observation to be reliable. 
The results presented in this chapter suggest that all of the major antibody isotypes 
appear to be expressed in the allergic nasal mucosa, although it is possible either that 
(VH3 and VH5) IgM' cells are present to a lesser extent or that this PCR is less efficient. 
In addition, related B cell clones expressing antibody isotypes other than IgE do not 
appear to be an automatic consequence of the presence of a family of related IgE' B cell 
clones in the allergic nasal mucosa. However, clear evidence has been presented to 
suggest that in one of the three reliable families of related IgE' B cell clones described 
in section 4.3, at least five related IgA' B cell clones exhibiting a variety of shared and 
conserved somatic mutations across the VH regions were also present. While this data 
strengthens the evidence for local SHM and clonal expansion proposed in chapter 4, 
importantly it additionally suggests that local CSR occurs in the nasal mucosa of 
allergic rhinitis patients. 
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Chapter 6 
The distribution of IgE+ B cells in the nasal mucosa of 
ailergic rhinitis patients. 
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6.1 Introduction. 
It was evident from the results obtained in chapters 4 and 5 that it was important to learn 
more about the distribution of IgE+ B cells in the nasal mucosa of allergic rhinitis 
patients, both in terms of the types and also the geographical distribution of the B cells. 
If, for example, related B cells were present in distinct clusters, this might suggest that 
sampling was indeed responsible for the detection of families of related B cell clones 
from only some patients. To this end, two different experimental approaches were 
utilised: 
Firstly, immunohistochemical (IHQ staining of frozen sections from nasal biopsies was 
undertaken. It was intended that this would provide data on the geographical 
distribution of the IgE' B cells within the nasal mucosa and also the type of B cells 
present i. e. CD19+ B cell, or terminally differentiated CD138' plasma cell. Initially, 
IFIC experiments were designed to enable the quick identification of IgE' B cells for 
subsequent single cell microdissection and RT-PCR analysis Of VH-CF. sequences 
isolated from those single B cells. This would have additionally enabled sequence data 
to be generated from either a single or a particular group of IgE' B cells. Unfortunately, 
due to technical problems (see below), microdissection of the B cells was not attempted, 
although the preliminary IHC results alone generated interesting results. 
The second experimental approach consisted of the sequence analysis of RT-PCR 
amplified VH-C& transcripts from adjacent pieces of the nasal mucosa, either two halves 
of the same biopsy, two adjacent biopsies, or two adjacent pieces of tissue excised from 
a whole inferior turbinate. It was intended that data generated in this manner would 
provide an insight into how wide the distribution of related IgE' B cell clones was 
across the allergic nasal mucosa. 
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6.2 The anatomy of the nasal mucosa. 
In the following sections of this chapter the distribution of IgE+ B cells in the nasal 
mucosa of allergic rhinitis patients is considered. Sections 6.3 and 6.4 describe IHC 
experiments in which it is informative for the anatomy of the nasal mucosa. to be 
understood. In Fig. 6.2.1 the features of the nasal mucosa, including the epithelium, 
lamina propria and glandular ducts are identified at both a diagrammatic (A) and 
microscopic (B) level. The position of the cell rich sub-epithelial layer is of particular 
relevance. 
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FAd. 6.2-1. The anatomy of the nasal mucosa on the inferior turbinate. A) A diagrammatic 
representation of the nasal mucosa [adapted from Mygind et aL, 1996] illustrating the different 
layers of the nasal mucosa, the glandular ducts and the venous sinusoids. B) A typical 
unstained, 6 ýLrn frozen nasal biopsy section from an allergic rhinitis patient, in which the 
different regions of the nasal mucosa are delineated as accurately as possible and examples of 
glandular ducts and venous sinusoids are detailed. 
Venous 
sinusoids 
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6.3 The distribution of CD138+ IgE+ B cells in the nasal mucosa of 
allergic rhinitis patients, determined by immunohistochemistry. 
The presence of IgE' plasma B cells in the nasal mucosa of allergic rhinitis patients has 
been implied by the local production of IgE protein [Smurthwaite et al., 20011. 
However, IgE+ plasma cells have only been visualised in the allergic nasal mucosa by 
one group of researchers [KleinJan et al., 2000], although other researchers have 
attempted to identify them [Durham et al., 1997]. Initial IHC experiments were 
therefore designed to reproduce the chromogenic staining of CD138+ IgE+ (plasma) B 
cells in the allergic nasal mucosa previously observed by KleinJan el al. In these 
preliminary experiments a double stained cell, expressing both IgE and CD138 (a 
plasma cell producing IgE in the nasal mucosa) was detected in the nasal mucosa of an 
allergic rhinitis patient biopsied outside of the pollen season (Fig. 6.3.1). 
It was evident however that even when the colours of the chromogens were varied (data 
not shown), cells double stained with chromogen could not be un-controversially 
identified. While the PCR analysis, intended to take place subsequent to 
microdissection of the cells would have added credibility to such results, an alternative 
MC protocol was designed. Antibodies conjugated to fluorophores enabled both a 
faster and more convincing double staining of cells. In preliminary experiments this 
protocol generated evidence of another double stained IgE' CD138+ plasma B cell from 
the same patient, in which distinct surface expression of CD138 was combined with 
strong IgE expression (Fig. 6.3.2). In both Figs. 6.3.1 and 6.3.2, CD138+ plasma B 
cells, including those that were IgE+, were individually distributed throughout the 
lamina propria in the sub-epithelial layer. In contrast, IgE+ CD138- cells, likely to be 
mast cells, were also found deeper in the lamina propria. 
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AB 
CD138 negative control and anti-IgE Anti-CD138 and anti-IgE distal to the epithelium 
--- > 
Anti-CD138 and anti-IgE in the sub-epithelium 
D 
"A--, 
ouisicre or rne grass poHen season. Fuschin chromogenic substrate was used to 
immunohistochemiGally stain for the plasma B (and epithelial) cell marker CD138 (pink). DAB 
Ghromogenic substrate was used to immunohistochemiGally stain for IgE (brown). InA), C)and 
D) the epithelium is towards the left of the section. In B) the epithelium is not shown but the 
orientation of the section is the same. For details of the anatomy of the nose please refer to Fig. 6.2.1. The sections were incubated with A) mouse MOPC21 (as an isotype control for CD1 38) 
and goat anti-human IgE-biotin antibodies and in B), C) and D) mouse anti-human CD1 38 and 
goat anti-human lgE-biotin antibodies (see section 3.2.38 for full experimental details). In B) a 
lack of CD138* cells was evident in the area of the section distal to the epithelium, although IgE* 
cells were present. In C) a double stained IgE* CD138* cell, a plasma cell producing IgE is 
indicated by an arrow. In D) this double stained IgE* CD138* cell is shown at a higher 
magnification. Scale bars representing 50 ýtm are shown in A) B) and C) and 20 Itm in D). No 
isotype control for the goat anti-human IgE-biotin antibody was available at the time of this 
experiment, although in a repeat experiment goat-IgG-biotin isotype control antibody gave 
negative results as expected (data not shown, as only single positive cells were identified). In 
addition, further experiments confirmed that sections incubated without antibody were also 
negative (data notshown). 
Davao OUtANM W OMDOMW 'i no secuons presentou nere onginatea nrom the some biopsy as those In Fig. 15.3.1. The fluomphore FITC (green) was used to 
immunohistodmTkaky stain for the plasms 8 (and opithellial) cell marker CD138. The 
fluorophore Cy3 (orange) was used to Immunohislochernically stain for 19E. A) and B), C) and 
D), and E) and F) are pairs of Images taken from the some section. A), C) and E) were Imagft 
visualsed In the Cy3 spectrum and 8), D) and F) in the FITC spectrum. In all sections; the 
epithelium Is towards the left of the section. For details of the anatomy of the nose plefte few 
to Fig. 6.2.11. The sections were incubated with A) and 8) mouse MOPC21 (an isotype control 
for CD1138) and goat IgG-bWUn (an Isotype control for 19E). In C) and D) =use anti-human 
CD138 and goat anti-human 19E mouse antibodies (see section 3.2.39 for full exporimerW 
details), a double stained CD1 38* IgE* can In the sub-opftheNum Indicated by an arrow. In E) 
and F) this double stained call Is shown at higher magnification. In G) the Images from E) and 
F) are merged. Scale bars representing 50pm are shown In A), B). Q and D) and 20jAm In E), 
F) and G). A fWl complement of contmi sections were Included In this experiment, all of which 
yielded nogethe results as expected (data not shown). 
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6.4 The distribution of CD19"' B cells in the nasal mucosa of allergic 
rhinitis patients, determined by immunohistochernistry. 
While the VH-C6 transcripts from the nasal mucosa, analysed in chapters 4 and 5, may 
have originated from plasma B cells (particularly as their quantity Of VH-CH transcripts 
would be greatest), plasma cells are no longer subject to CSR and SHM. This implies 
that sequences from related B cell clones would only have been likely to have originated 
from plasma cells, if a family of related CD19+ B cell clones had undergone terminal 
differentiation, but remained in close proximity. While only a small number of sections 
were analysed, IgE' plasma cells did not appear to behave in this manner according to 
the preliminary data presented in Figs. 6.3.1 and 6.3.2. It was therefore with particular 
interest that IHC to determine the distribution of CD19+ (non-plasma) B cells in the 
nasal mucosa was carried out. 
Initial IHC staining was undertaken using a chromogenic technique (Fig. 6.4.1). These 
results were then confirmed using fluorescently labelled antibodies (Fig. 6.4.2). 
Unfortunately, while the sections depicted in both Figs. 6.4.1 and 6.4.2 were meant to 
have originated from an allergic rhinitis patient, the hospital were unable to confirm that 
the nasal biopsy had not mistakenly originated from a normal patient. 
The preliminary work did however suggest that while the CD19+ B cells were located in 
the cell rich sub-epithelium of the lamina propria, they were not as tightly associated 
with the sub-epithelium as the plasma cells had appeared to be. Importantly, in contrast 
to the plasma cells, the CD19+ B cells were evident both individually and also as 
distinct clusters. Problems with the cross-reactivity if the anti-human IgE and anti- 
human CD19 antibodies unfortunately meant that there was insufficient time to carry 
out the intended double staining of CD19+ IgE+ B cells in the allergic nasal mucosa 
during this project. 
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cnromQgen staining or E; uiv using a Itm acetone rixea 
frozen nasal biopsv sections. The allergic status of the subject was not clear. Fuschin 
chromogenicsubstrate was used to immunohistochemically stain forthe B cell marker CD1 9. In 
A), C) and E) the epithelium is towards the right of the section. [nB), D)andF)theepitheliumis 
not shown but the orientation of the sections is the same. Fordetails, of the anatomy of the nose 
please refer to Fig. 6.2.1. The frozen sections were thawed briefly before acetone fixation and 
incubation with in A) mouse MOPC21 (as an isotype control for CD1 9), or in B), C), D), E) and F) 
mouse anti-human CD19 antibody (see section 3.2.40 for full experimental details). InB)alack 
of CID1 9* B cells is evident in the area distal to the epithelium. In C) and D) large numbers of 
CD1 9* B cells are evident in the sub-epithelium and clustering of the cells is particulady evident. 
In E) and F) these dusters of cells are shown at a higher magnification. Scale bars representing 
50 ýLmare shown inA) B) C) and D) and 20 ýLrn in E) and F). 
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frozen nasal biopsy sectfons. The sections presented here originated from the same biopsy 
as those in Fig. 6.4.1. The allergic status of the subject was not dear. The fluorophore Cy3 
(orange) was used to immunohistochernically stain forthe B cell marker CD1 9. InA), B), C)and 
E) the epithelium isto the right of the section. In D) the epithelium is not shown but the orientation 
of the section is the same. For details of the anatomy of the nose please referto Fig. 6.2.1. The 
frozen sections were thawed briefly before acetone fixation and incubation with in A) mouse 
MOPC21 (as an isotype control for CID1 9 or in B), C), D) and E) mouse anti-human CIDII 9 
antibod (see section 3.2.41 for full experimental details). In B), C) and D) large numbers of 
CD19* 
Vellsaree%Adent 
inthesub-epithelium and clusteringofthe cellsis particularly evident in 
C) and D). In E) the cluster of CD1 9* B cells from C) is shown at a higher magnification. Scale 
bars representing 50 lim are shown in A) B) C) and D) and 20 pm in E). 
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6.5 Analysis Of VHCF- sequences amplified by Pfu from adjacent 
samples of the nasal mucosa from four allergic rhinitis patients. 
As an alternative experimental approach, the RT-PCR amplification Of VH-C& 
sequences by Pfu DNA polymerase from adjacent areas of the allergic nasal mucosa 
was undertaken. It was intended that this would enable how widely clonally related 
IgE+ B cell clones were distributed across the tissue. 
Adjacent samples of the nasal mucosa from four allergic rhinitis patients were analysed 
(see Table 6.5.1 for patient details). The tissue samples were of three different forms, 
adjacent halves of a nasal biopsy (SJ24, part A and B) and adjacent double biopsies, 
taken no more than 2 mm apart in the nasal mucosa, (TL25A and B and CA30A and B). 
In addition, a random piece of tissue excised from a whole inferior turbinate (obtained 
as a by-product of routine surgery) was divided in two, each resultant piece being of a 
similar size to a nasal biopsy (SLT IA and B). 
Total serum IgE Specific serum 
Patient Age Sex Status at 
samplinga 
(lu / ml) 
(Norm=3-150) 
IgE 
(lu / MI) 
Allergiesc 
)b (Norm < 0.35 
SJ24 36 F O/P 1264 HDM = 11.4 ND (severe G 58.5 eczema) 
13012 C ZU. J 
TL25 27 M I/P 304 
- 
G 13.1 G, M, T, B, 
C 3.24 C, D 
CA30 26 F O/P 1025 HDM = 0.36 G, D 
G= 101 
SLT1 38 F O/P ND ND HDM, G, B 
Table 6.5.1: Clinicai data from Daffents SA24, TL25. CA30 and SLT1. a) In-season (1), Out- 
of-season (0), Perennial (P). SL was the only patient to undergo a turbinectomy. b) 
Determined by RAST for the allergens; house dust mite (HDM), Mixed grass (G), Treeff), Cat 
(C), Dog (D). c) Determined by a skin-prick test ýt 2mm diameter for; Det7natqphagoides 
(house dust mite) (HDM), Phleum pratense (grass pollen) (G), mugwort (M), three trees M, 
silver birch (B), cat (C), dog (D), horse (H), Aspergillus fumigatus (AF), Cladosporium herbarum 
(CL), Altemaria alternata (A). ND, represents data that could not be determined. 
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Twelve, fourteen or fifteen VH-C& sequences, all containing mutations from the 
germline in the VH region were isolated from each of the eight samples of the nasal 
mucosa (Table 6.5.2). Sequence analysis demonstrated that in each of the four allergic 
rhinitis patients, none of the VH-Ce sequences isolated from one half of the nasal 
mucosa sample were either duplicated or related to that isolated from the adjacent 
sample. 
Patient Unique sequences Predicted germline % Mutation Number of identical 
isolated from nasal VH gene usage from sequences 
biopsy samples germline isolated 
C1 4-30.4 3.3* 13 
SJ24 A C3 4-30.4 3.3# 1 
C17 4-30.4 3.6 1 
C1 3-30 8.1 14 SJ24 B C14 4-61 ND 1 
C17 1-02 7.4 1 
TL25 A C13 3-23 5.2 3 
C11 3-53 5.6 11 
TL25 B C8 5-51 5.9 15 
C3 5-51 11.1 2 
C3b 5-51 13.0 1 
C4b 5-51 7.5 1 
C5 5-51 5.2 1 
C8 5-51 6.2 1 
CA30 A C11 5-51 10.5 2 
C12 5-51 6.39 1 
C16 5-51 6Y I 
C17 5-51 10.0 1 
C20 5-51 9.6 1 
C22 5-51 10.3 3 
C7 3-07 5.6 1 
C5 4-ND 8.4 7 CA30 B C8 4-30.1/4-31 3.3 2 
C19 4-30.1/4-31 9.1 4 
C4 3-11 5.6 11 SLT1 A C3 4-59 7.0 3 
SLTI B C1 1-18 14.8 12 
Table 642: Vs, oene usaue and % Vu mutoWn of Vm-Ce seauences Lsolated hon nass 
bidosies from allemic rhinitis peffents SJ24. TL2& CA30 and SLT1. SJ24A and B were halves 
of the same biopsy. Both TL25A and B and also CA30A and B were each sets of double biopsies. 
SLT1A and B were adjacent pieces of tissue, equivalent in size to a nasal biopsy, but taken from a 
whole inferior turbinate, a by-product of routine surgery. VH gene usage is detailed such that a 
gene mapped to the locus 5-51 is a VH5 gene. VH genes whose germline sequence could not be 
reliably identified were denoted ND. Sequences highlighted in red represent related B clones 
isolated from that patient. Sequences denoted # exhibited the same degree of mutation from the 
germline, although the pattern of mutation differed in each clone. 
Chapter 6 Distribution of IqE+ B cefis in the nasal mucosa 136 
A family of related IgE' B cells were isolated from part A of the nasal mucosa of 
patient SJ24 (Fig. 6.5.1). It was possible that related B cell clones had been present in 
SJ24B but that they were not effectively amplified by the PCR, for example, the 
abundance of V3-30 and V4-61 transcripts detected in SJ24B, may have resulted in 
their preferential amplification to the detriment of the amplification of other transcripts. 
Further investigation was therefore carried out to see if transcripts from B cells related 
to those identified in SJ24A could be isolated if the amplification of transcripts from 
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c1 ........... ............ ............................... ....... ............. ... ... ... ..... 
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50 60 10 so 
(a, CA400AAGGG CCTGGUnGMTTMXPTACATCtATTACA GOCAOCACCTACTArAACC MM=AAGAGTCIIAMTý TATýýýCCMOMC 
C3 .......... ............................ ........ 
T ..... ........ 
C2 .......... ......... 
7 ..... ............................ 
cl 7 .......... ................................ A .......................................... ...... .................. ............. 
'o N D- JHU 
GL C CrOTGAýýýýýGOCCOrOrATTACTGTýCAGAZAT -------- (; TATTACTATG=TCGGGGAGTTA TGRTGCTTTTClATaTCTOGOOCCAAGGGACJkAY13MChCCG"CTTCAG 
C3 C ........ ........ -- ....................... TTýý T .............. ...... - -A' ........................................ ...... 
Cl 
ýc 
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ý ................................................ 
cl 7 . C... - ... .................................... TTCGGGCG T ................. ý- -IT -A ........... 
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Fia. 6.5.1: Familv of related IaE' B cell clones isolated from the nasal mucosa of Patient 
SJ24. sample A and the V -D-_J sequences. A) VA family expressing genes mapped to the 
locus VH4-30.4, an unidentified D gene and JH3a- The closest germline homology as 
determined by VBase is depicted in a black box. Related clones are depicted as ovals. 
Mutations are detailed such that 10(2) represents a mutation at codon 10, position 2. B) The 
sequences of the related B cell clones are detailed. GL represents the closest germline gene 
homology as determined by VBase. Primer binding regions are underlined and no mutations 
occurring in these regions were included. Homology to the germline is represented by a dot, 
whereas mutations from the germline are depicted either in upper case (if causing an amino 
acid replacement), or lower case (if having a silent effect upon the amino acid). The mutations 
indicative of links between the clones are highlighted in red. The CDR regions are detailed. 
The N region constitutes non-templated nucleotide insertions. 
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Following an adapted version of the RT-PCR protocol applied in chapter 5, SJ24 B was 
subjected to nested PCRI and 2 to specifically amplify V114-CE transcripts (see section 
3.2.20 for experimental details). These PCR products were extracted from an agarose 
gel and a sample carried through into PCR3. In PCR3 a primer homologous to the 
unique V11-13 junction was used in combination with the inner CF, specific primer to 
amplify the full signature region sequence from any IgE clones present in SJ24B that 
were related to the family of IgE' clones identified in SJ24A. 
Even after multiple repeats, no VH-C6 sequences could be amplified from SJ24B that 
expressed the signature region characteristic of the family of related B cell clones 
identified in SJ24A, although such PCR products could be amplified using this protocol 
from SJ24A itself, suggesting that the efficacy of the PCR was not at fault (Fig. 6.5.2). 




Fia. 6.5.2: Aaarose ae/ electronhoresis of Vm4-C. - sicinature region PCR _products 
amplified from the allerclic nasal biopsy pieces SJ24A and B. VA-Ct: signature region 
PCR products (175 bp), specific to the family of related IgE+ B cell clones identified in SJ24A 
and amplified in PCR 3 from SJ24A and B, were subjected to agarose gel electrophoresis on a 
1% agarose gel and visualised under UV. Lane 1; 100 bp ladder (L), (500 bp indicated). Lane 
2-, VA-Cf. signature region PCR products amplified from SJ24A. Lane 3; VA-Q. signature 
region PCR products amplified from SJ24B. Lane 4; VH4-Ct- negative control (no clDNA). 
Interestingly, in the course of this experiment, the PCR to amplify VII-CF. sequences 
from SJ24A was repeated and a further fifteen sequences analysed. This Illustrated that 
while twelve of the further fifteen sequences from SJ24A were identical to that isolated 
previously, two additional, unique sequences were detected (data not shown). While 
both were still unique to SJ24A, in future, if more detailed work is carried out, the 
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analysis of PCR products from repeated PCRs, may be of use in yielding sequences 
from a wider range of clones. 
Investigation of the sequences amplified from the pair of adjacent nasal biopsies from 
CA30, A and B, was also undertaken in greater detail. Initial sequence analysis 
suggested that at least eleven distinctly different VH5 B cells were present in one of the 
two adjacent biopsies (CA30A). In contrast, no VH5 sequences were amplified from the 
adjacent biopsy (CA30B), (see Table 6.5.2). Interestingly, even when V115-Ce 
transcripts were specifically targeted for RT-PCR amplification from CA30B, in 
repeated experiments no VH5-Ce PCR products resulted (data not shown). 
6.6 Discussion. 
In this chapter, research was presented that utilized both immunohistochernical and 
PCR based techniques, in order to understand more of the distribution of B cells in the 
allergic nasal mucosa. The IHC data resulted from preliminary experiments designed to 
enable the microdissection of stained cells for subsequent PCR analysis. Unfortunately 
this was not possible in the time provided, as a fluorescence attachment for the 
microdissector was not available. Double staining with chromogen was not sufficiently 
clear for the conclusive analysis of double stained cells, particularly as the 
microdissector necessitated the use of sections that were un-coverslipped, further 
impairing the quality of the image. 
Microdissection of single IgE' B cells would have enabled the sequences of clones 
known to originate from documented areas of the nasal biopsy to be determined. 
However, the preliminary experiments carried out to optimise the IHC techniques for 
microdissection generated such interesting data that a larger, more comprehensive study 
should be carried out in the future. The IHC demonstrated that both CD19' and 
CD138+ B cells were situated in the cell rich sub-epithelial layer described in Fig. 6.2.1 
[Mygind el al., 19961. Other IgE+ non-B cells, presumably mast cells, appeared to be 
situated both in the sub-epithelial layer and also deeper in the lamina propria. This was 
presumably a reflection of the more migratory nature of such cells. 
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The IHC confirmed an earlier documentation of IgE+ plasma B cells in the allergic nasal 
mucosa. The sections used for these experiments were from a nasal biopsy taken 
outside the grass pollen season. The patient's medical details were not comprehensive 
enough to determine if they were grass pollen mono-allergic, but it is possible that a 
greater number of IgE' plasma cells (comparable with the eight IgE+ plasma cells per 
mm2 of the nasal mucosa from an in-season grass pollen allergic patient observed by 
KleinJan et al., 2000) may have been detected in a biopsy taken within the grass pollen 
season, for while continual local IgE production is maintained in the nasal mucosa 
[Smurthwaite et al., 2001], stimulation with allergen has been shown to increase the 
number of B cells undergoing e germline transcription [Durham el al., 19971. 
A more comprehensive study would be needed before any sensible estimates of 
different B cell numbers in a nasal biopsy could be made, but it is possible that there are 
relatively few IgE' plasma B cells present in the allergic nasal mucosa. Durham el al. 
suggested that relatively few IgE' B cells may terminally differentiate to become IgE' 
plasma B cells, but that these plasma cells may secrete high levels of IgE [Durham el 
al., 1997]. This would correlate with the finding that the quantity of IgE produced 
locally in the allergic nasal mucosa is sufficient to maintain the permanent sensitisation 
of local mast cells, without the contribution of any non-locally produced IgE [Gould el 
al., 2003]. 
Furthermore, while the allergic status of the subject was unclear, preliminary IHC 
demonstrated that CD19' B cells occurred in clusters as well as individually within the 
lamina propria. It would be fascinating to expand this study to determine if this 
phenomenon is reproducible in further allergic and / or normal subjects and if so, 
whether such clusters occur only in particular regions of the inferior turbinate. In the 
future, double staining of the allergic nasal mucosa for CD19+ IgE+ B cells (intended to 
be encompassed within this study) should be completed. If IgE' CD19' B cells were 
shown to occur in clusters in the nasal mucosa, this would confirm the hypothesis 
suggested in chapters 4 and 5, that the sampling of clusters of B cells in the inferior 
turbinate by biopsy resulted in the detection of families of related B cell clones in some 
patients, but not others. Furthermore, it may be that while sequences from related B cell 
clones originated from small clusters of CD19+ B cells, individual sequences may have 
included those from either CD19' IgE' or CD138+ IgE+B cells. To date, there has been 
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one further report of clusters of lymphocytes occurring in the allergic nasal mucosa., but 
the composition of these clusters was not described and no pictorial evidence was 
provided to enable comparison [Fokkens et al., 1990]. 
The identity of such clustered CD19+ cells whether memory B cells, or centrocytes such 
as those found in germinal centres for example, could also be determined by further 
H-1C. In addition, as such clusters of B cells might be associated with focal points of 
local SHM and CSF, it would be interesting to analyse what other cell types are present. 
While the clusters do not initially appear as organised as conventional germinal centres, 
the presence or absence of T cells and antigen presenting cells, even follicular dendritic 
cells, in or around these B cell clusters would be important to determine. It would also 
be of importance to determine if these cells were proliferating (by the use of the Ki67 
antibody (Dako), for example). 
Future work may also enable staining for AID, known to be required for both CSR and 
SHM (Muramatsu et al., 19991, [Muramatsu el al., 2000], [Revy el al., 2000], 
[Fagarasan el al., 2001] and whose protein expression would be expected at sites of 
local CSR and SHM (see chapter 8). This IFIC could be made easier by the use of 
paraffin sections (enabling better tissue morphology to be preserved), as 
microdissection would no longer be the ultimate goal. The expansion of this work will 
be of particular importance, as while local germinal centres have been reported in the 
synovial tissue of rheumatoid arthritis patients [Randen el al., 1995] and also after 
antigen challenge in the murine lung [Chvatchko el al., 1996], no germinal centre-like 
structures have previously been reported in the human allergic mucosa. 
In addition to the IHC, a RT-PCR approach was carried out to obtain greater knowledge 
of the distribution of clonally related IgE' B cells in the allergic nasal mucosa. 
Adjacent pieces of the allergic mucosa from four allergic rhinitis patients were 
examined to determine if VH-Cr'- sequences suggested the presence of related B cell 
clones across a wide or restricted geographical area. Comparisons were made between 
sequences from halves of the same biopsy, adjacent nasal biopsies and also adjacent 
pieces of mucosa excised from a whole inferior turbinate. 
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When the VH-C& sequences amplified from these pieces of tissue were analysed, no 
sequences isolated from one piece of tissue were either identical or related to that in the 
adjacent sample. Furthermore, in patient SJ24 aB cell clonal family comprising three 
related B cell clones was identified in one half of the nasal biopsy (A), although even 
when the opposing half of the biopsy (B) was specifically probed multiple times, by a 
PCR to amplify the signature region unique to this B cell family, no related B cell 
clones could be identified in the adjacent half Also, while sequences from eleven 
distinct VI-15 IgE+ B cells were amplified from one nasal biopsy (CA30A), even when 
specifically targeted for amplification by PCR, no VH5-C& sequences could be identified 
in the adjacent biopsy (CA30B). 
These results suggest that related IgE+ B cells exist in an extremely localised manner, 
consistent with the hypothesis that clusters of B cells exist in the nasal mucosa. 
Furthermore, as the repertoire of B cells across the inferior turbinate appears diverse, 
the families of related B cell clones will not have been a consequence of a limited 
number of progenitor B cells existing in the nasal mucosa. A ffirther detailed study of 
tissue taken systematically from a whole turbinate might strengthen these findings, 
The RT-PCR based analysis of the distribution of related IgE' B cells in the nasal 
mucosa reported here, while providing a further example of local SHM and clonal 
expansion, additionally suggests that clonally related IgE+ B cells are located within 
small geographical areas, a likely explanation of the inability to identify clonally related 
B cells from all biopsies. Furthermore, preliminary immunohistochemistry has 
demonstrated for only the second time, the presence of IgE+ plasma B cells in the 
allergic nasal mucosa and for the first time, that small clusters of B cells, possibly 
indicative of confined germinal centre-like sites of concentrated local SHM and CSR 
activity also occur in the nasal mucosa. 
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Chapter 7 
VHgene usage and the distribution of somatic mutations 
across the VHregion of IgE4B cells in allergic rhinitis 
patients. 
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7.1 Introduction 
Previous studies have revealed the importance of analysing somatic mutations in the VH 
region and also VH gene usage, in order to observe trends resulting from the selection of 
an antibody by its antigen [Betz et al., 1993], [Snow et al., 1997]. Evidence of such 
selection may manifest in the repeated selection of B cells using a particular VH gene or 
class of genes, or exhibiting particular somatic mutations. 
When a particular somatic mutation occurs frequently within the V region sequences of 
a population of cells, it can be classified either as an intrinsic or non-intrinsic hotspot of 
mutation. An intrinsic hotspot of mutation is considered to have arisen as a 
consequence of the intrinsic bias in the targeting of somatic hypermutation (SHM) 
within the V region. In the absence of antigenic selection, SHM is not random, but has 
a tendency towards transitions rather than transversions [Insel and Varade, 19941. A 
transition results in the substitution of one purine residue (A or G) with the other, or one 
pyrimidine residue (C or T) with the other, while a transversion substitutes a purine for 
a pyrimidine, or vice versa. 
Within these transitions and transversions, particular substitutions are favoured. These 
preferences been determined both by the study of mutations accumulated in passenger 
transgenes and also by those in sequences flanking the V region and then refined, to 
generate a set of values that reflect these nucleotide substitution preferences [Betz el al., 
1993b]. This compilation of data illustrated that the transition from C-T occurs most 
frequently and that the transition from G-A is also particularly highly favoured. 
In addition to bias towards particular nucleotide substitutions, Sam also intrinsically 
favours mutation at particular hotspot motifs, including the nucleotide sequences 
R. GYW, WRCY and WA (where R= A or G, Y= C or T and W= A or T) [Rogozin and 
Kolchanov, 1992]. Intrinsic hotspots of mutation do not necessarily provide an increase 
in antibody affinity, but rather may have occurred coincidentally with another mutation 
in that B cell that does confer a beneficial effect on affinity [Berek and Milstein, 1987], 
[Jolly et al., 1996]. 
In contrast, non-intrinsic hotspots of mutation are a direct consequence of selection by 
antigen because of the increase in the antibody's affinity and are therefore of particular 
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value in identifying amino acids that interact with antigen. Non-intrinsic hotspots of 
mutation are evident in a*population of B cells that have been exposed to the same 
antigen, usually as replacement mutations and are distinguished by their failure to 
comply with the expected substitution preferences of SHM. This does not mean that 
non-intrinsic hotspots of mutation do not also occur at hotspot motifs, but rather that 
they exhibit a skewed direction of mutation so that a transversion, for example, may be 
much more common than expected [Jolly et al., 1996]. 
Selection of B cells expressing antibodies of high affinity is usually dependent on the 
interaction of the antigen with the classical antigen binding site formed by the CDR 
loops of the V regions. The majority of somatic mutations that increase antigen affinity 
by replacing an amino acid therefore tend to occur in the CDRs, whereas silent 
mutations are prevalent in the FWR because of the need to maintain the structural 
integrity of the antibody. However, replacement mutations in the FWR may have an 
indirect effect upon the structure of the CDRs [Tramontano et al., 1990], [Jolly et al., 
1996], resulting in non-intrinsic hotspots of mutation occurring occasionally in the 
FWRs. Alternatively some codons, particularly in the FWRs, may be conserved 
because of the structural importance of that amino acid. 
When antigen binding does not occur across the classical antigen binding site, the 
distribution of replacement and silent mutation in selected B cells may be altered. B 
cell superantigens have affinity to the FWR of an antibody, and can be of bacterial, viral 
or endogenous origin, for example the bacterial SWhylococcus aureus protein A binds 
to the FATROf VH3 antibodies [Sasso et al., 1989]. In such instances, selection by aB 
cell superantigen may therefore result in a bias towards B cells using a particular class 
of VHgene, such asVH3 and a distorted distribution of somatic mutations, particularly 
across the FArRs. 
In chapters 4,5 and 6, VH-Cs sequence data was presented from ten patients who had 
been subjected to a nasal biopsy and one patient who had undergone an inferior 
turbinectomy. This data appeared to suggest the frequent use of the VH5 class of genes, 
usually a minor contributor to the antibody repertoire. In addition, of the four families 
of related IgE' B cell clones detailed in chapter 4,5 and 6, two comprised clones 
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expressing VH5, including the family of B cells from S016 that exhibited both related 
IgE+ and IgA' clones. 
Previous researchers have observed a bias towards increased VH5 usage in allergic 
patients (although this was disputed by Tilgner et al., 1997, who analysed PBMC from 
allergic dermatitis patients). A VH5 bias was observed in the PBMC of allergic 
dermatitis patients [Van der Stoep et al., 1993] and allergic asthmatics [Snow et al., 
1997] and also in the spleen and the lung mucosa of allergic asthmatics [Snow el al, 
1995], [Snow et al., 1999]. It was proposed that this VH5 bias in allergic patients was a 
consequence of the selection of B cells by aB cell superantigen [Snow et aL, 19971, 
[Snow et al., 1999]. 
In the following chapter the use of the different classes Of VH genes, especially Of VH5, 
by IgE' B cells has been analysed to examine whether selection by aB cell superantigen 
occurs in the nasal mucosa of allergic rhinitis patients. Particular attention has been 
given to the distribution of somatic mutations in the IgE VH region in non-VH5 
compared to VH5 IgE sequences and the presence of any apparent non-intrinsic hotspots 
of mutation. 
7.2 VH gene usage of IgE* B cells in the nasal mucosa and PBMC of 
allergic rhinitis patients. 
VH-CF- sequence data obtained from the nasal mucosa of the allergic rhinitis patients 
CD6, JB7, CMIO, HD14, S016, HD17, AP19, SJ24, TL25, CA30 and SLTI (a total of 
62 sequences, detailed in Tables 4.3.2 and 6.5.2) was pooled to enable analysis of the 
overall patternOf VHgene usage. In additionVH-CF- sequence data obtained from the 
PBMC of patients CD6, JB7, CMIO, HD14, S016, HD17 and AP19 (a total of 50 
sequences, detailed in Table 4.3.3) was pooled for comparison (Fig. 7.2.1). Sequences 
from identical or related clones were only included once in the analysis, representing a 
singleVH-D-JH recombination event. This meant that sequences isolated ftom sister 
clones present in both the nasal mucosa and PBMC were completely excluded from the 
statistical analysis, as they could not be strictly classified into either the nasal mucosa or 
PBMC data set. This is unlikely to have altered the results of the analysis however, as 
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only six sequences were affected in this manner, of which four expressed VH3, one 
expressed VH4 and one expressed VH5. 
The expected use of the different VH gene classes approximately reflects the number of 
genes in each class (see Fig. 7.2.1), such that the VH3 class of genes occurs most 
frequently, being comprised of twenty-two members. Smaller classes of genes such as 
VH5 (comprised of only two genes) occur much less frequently. As discussed in section 
4.3, no VH2 sequences were isolated from either the nasal mucosa or PBMC of any of 
the allergic rhinitis patients. While VH2 is expressed at very low levels in normal 
PBMC (2.4%) [Brezinschek et al., 2000], it is possible that the VH2 primers were less 
efficient in the PCR than those amplifying the other VH gene classes. It is not therefore 
possible to draw conclusions from the absence Of VH2 IgE' B cells in this study. 
When the VH gene usage by IgE+ B cells in the allergic nasal mucosa was compared 
with the expected VH gene usage, (based on the in-frame genomic rearrangements 
observed in PBMC from normal patients [Brezinschek el al., 2000)) the increased use of 
VH5 in the allergic nasal mucosa was highly significant (using the chi-squared test p< 
0.005), (see appendix B for details of all chi-squared calculations) with a dramatic 
increase from the expected 2.9% to the 29% usage observed in the allergic nasal 
mucosa. Furthermore the increase in VH5 usage in the allergic nasal mucosa was 
statistically significant, even when compared with that observed in the allergic PBMC 
(p<0.025). There was no significant difference between normal and allergic PBMC 
VH5 usage. The apparent decrease of VH3 usage evident in Fig. 7.2.1 was also highly 
significant when compared to normal PBMC (P<0.005), but not when compared to the 
allergic PBMC. 
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Ra. 7.2.1. VH clene usage in hclEý B cells from afferclic rhinifis patients. VH region 
sequences detected by RT-PCR from IgE' B cells were analysed in order to determine the 
percentage usage of the different classes Of VH gene. Sixty-two sequences were pooled 
together from the nasal mucosa of eleven allergic rhinitis patients (black bars) and fifty 
sequences were pooled together from the PBMC of seven allergic rhinitis patients (grey bars). 
These were compared with 421 sequences previously pooled from the in-frame B cell genomic 
rearrangements in PBMC of normal subjects [Brezinsheck et al., 20001 (white bars). 
Sequences from related or identical B cell clones were only included once in the analysis, 
representing a single VH-D-JH recombination event. 
Although the over-representation of V115 in the nasal mucosa of the allergic rhinitis 
patients was clear in Fig. 7.2.1, the chart resulted from pooled data from the cohort of 
patients (in order to be able to analyse sufficient sequences). When the origin of the 
sequences was analysed, the incidence of V115 sequences was distributed in an even 
manner across PBMC samples from different individuals (although only four V115 
sequences were detected, one in each of four out of a total of seven samples analysed). 
In contrast there was considerable variation in the incidence of V115 sequences detected 
in the different nasal biopsies (Table 7.2.1), as the eighteen V115 sequences were 
isolated from only five of the eleven patients. 
V, l V, 2 V, 3 VH4 V, 5 VH6 V,, 7 
V, gene usage 
Chapter 7 VH qene usaqe and somatic mutation 148 
VH genes amplified from the nasal mucosa 
VHI VH2 VH3 VH4 VH5 VH7 
CD6 0 0 4 0 0 1 0 
. 1137 1 0 2 1 0 0 0 
CIA10 0 0 2 0 0 0 0 
HD14 1 0 3 1 3 0 0 
S016 0 0 4 1 1 0 0 
HDI 7 1 0 1 5 0 0 0 

































































Table 7.2.1; Variation in V, 4 qene usave detected in RT-PCR amplified sequences from the 
nasal mucosa of allenqic rhinitis Datients. VH region sequences were amplified by RT-PCR 
from the cohort of eleven allergic rhinitis patients (described in detail in chapters 4 and 6). The 
class of VH gene used in each sequence (according to homology with germline determined by 
VBase) was listed. Sequences from related or identical B cell clones were only included once in 
the analysis, representing a single VH-D-JH recombination event. In SJ24, TI-25, CA30 and SLT1, 
where adjoining samples of the nasal mucosa were analysed (see chapter 6 for details), the 
sequences detected in each part, A or B, are detailed. 
In CA30A in particular, of the fifteen sequences analysed, eleven were V115 sequences 
from unrelated IgE' B cell clones. Even more remarkable, was the observation that in 
the other half of this double biopsy (CA30B), no V115 sequences were detected (detailed 
in chapter 6). When chi-squared analysis was repeated on the first seven patients (CD6, 
JB7, CM 10, HD14, SO] 6, HD17 and AP19), therefore excluding the major contribution 
of V115 sequences from CA30A, the difference in V115 gene usage between the allergic 
nasal mucosa and normal PBMC was still highly significant (p < 0.005), although the 
significance betweenVH5 usage in the allergic nasal mucosa and allergic PBMC was 
lost. 
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An over-representation of a particular VH gene class may be a consequence of the 
affinity and selection of such B cells by aB cell superantigen. As a superantigen has 
affinity with the FATR of an entire class Of VH genes, the affinity of the superantigen 
may encompass all the members of that class. There are only two functional members 
of the VH5 class, V5-51 and V5-a. Of these, only 75% of the population has one or two 
copies of V5-a [Cook and Tomlinson, 1995]. Snow et al. demonstrated that while V5- 
51 was used preferentially in IgM, IgA and IgG, in IgE sequences V5-51 and V5-a 
appeared to be used equally in the PBMC of allergic asthmatic patients with copies of 
both genes, consistent with superantigen selection (Snow et al., 1997]. In contrast, 
sixteen sequences (of the seventeen that were of good enough quality for detailed 
analysis) isolated from the nasal mucosa of the allergic rhinitis patients in this study, 
expressed V5-51. However, the genomic profile of the patients was not determined as 
only mRNA was harvested from each sample. It is therefore possible that a smaller 
than expected proportion of the patients relied solely on V5-5 1. 
7.3 The distribution of somatic mutations across the VH region of IgE+ B 
cells from allergic rhinitis patients. 
When mutations in the VH-D-JH sequences from the allergic rhinitis patients were 
analysed, all of the IgE sequences amplified from the allergic nasal mucosa and the 
majority from allergic PBMC contained mutations within the VH region (sequences CI 
and C13 isolated from the PBMC of CMIO were identical to germline, see Table 4.3.3). 
In addition, when the families of related B cell clones were analysed in Fig. 4.3.5, there 
was evidence of a low level of mutation in some clones across the D and JH region after 
VH-D-JH recombination, consistent with that observed by other researchers [Lebecque 
and Gearhart, 1990]. 
Ce region sequence analysis had demonstrated that only one mutation in approximately 
4720 bp (0.02%) was likely to have been introduced experimentally (see section 4.2), 
considerably less than the overall level of mutation observed in the VH region sequences 
(between 1.8 and 22.7% in sequences from the nasal mucosa of the cohort of seven 
allergic rhinitis patients, detailed in section 4.3), suggesting that the majority of the 
mutations were a result of somatic hypermutation. 
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As a consequence of the data in section 7.2, suggesting a bias towards the use Of VH5, 
the distribution of hotspots of mutation in the VH region was compared between VH5 
and non-VH5 IgE sequences. If, as previous researchers had suggested, the bias towards 
VH5 was a consequence of selection of the VH5 FWR by a superantigen [Snow el al., 
1997], [Snow et al., 1999], this may have been reflected in a departure from the 
conventional distribution of non-intrinsic hotspots of mutation, with increased 
replacement mutation in the FWRs, possibly at the expense of that in CDRl and 2. 
The comparison Of VH5 with non-VH5 sequences was confined to sequences isolated 
from the nasal mucosa, partly because the significant increase in VH5 usage was 
observed in the nasal mucosa, but also because insufficient VH5 sequences were isolated 
from PBMC to enable meaningful analysis. VH5 sequences from seventeen distinct B 
cells were of sufficient quality for analysis. These were isolated from the nasal mucosa 
of five different allergic rhinitis patients (HD14, S016, AP19, TL25 and CA30A) 
previously identified in chapters 4 and 6. These were compared with nineteen non-VH5 
sequences (including VH I, VH3, VA and VH6). 
In order to identify hotspots of somatic mutation within the sequences, the percentage 
variability, i. e. the percentage of sequences acquiring a mutation that changed an amino 
acid, was calculated and shown in Figs. 7.3.1 A and B. Care was taken that the analysis 
was not distorted, mutations common to related B cell clones were not included 
multiple times, but rather each different mutation from a family of clones was included 
once. Any sequences isolated from the nasal mucosa that were either identical or 
related to those from clones in the PBMC were disregarded. Mutations demonstrated in 
section 4.3 to be likely to have resulted from experimental error were also not included 
in the analysis. 
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Fin. 7.3.1: GraDhical rwmsentWon of the &sWbution of reafeceawnt mutafions across 
the VH renion seauences RT-PCR amviffied fn)tn IbE' B cell clones from the n 
mucosa of allergic rhiniffs Patients. VH region replacement mutations were pooled from A) 
seventeen VH5 sequences and B) nineteen non-VH5 sequences (including VH1, VH3, VH4 and 
VH6). The percentage variability of each codon is detailed, such that the substitution of two 
nucleotides, for example, within the same codon is represented as only one mutated codon. 
The polymorphic codons 32a, 32b, 52a, 52b, 52c, 82a, 82b and 82c are included on the codon 
axis and the percentage variability was adjusted to take account of the numbers of sequences 
that used those codons. Mutations up to and including codon 8 (the 5' primer region) were not 
included in the analysis. CDR1 incorporates codons 31-35 and CDR2 incorporates codons 50- 
65, the extents of which are both indicated on the x axis. FWRII incorporates codons 1-30, 
FWR2 codons 36-49 and FWR3 codons 66-95. Apparent hotspots of mutation are detailed with 
the amino acid (when the same in all sequences) and the codon number. 
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The polymorphic codons 31a, 31b and 52b were not used in the VH5 genes. Inaddition, 
while codon 52c is never utilised by VH5, nor was it used by any of the non-VH5 
sequences in this data set. No mutations were detected at codons 21,36,45,70 or 86 
(all in the FWR) in either the VH5 or non-VH5 sequences, suggesting that the DNA 
sequence at these sites may have been cold spots, unfavourable to mutation. 
Alternatively, mutation of those amino acids may have been detrimental to the structural 
stability of the antibody (although no silent mutations, expected in this scenario, 
occurred either). 
In the non-VH5 sequences there was evidence of more distinct mutation of the CDRs, 
particularly CDR2, typical of antigen selection (Fig. 7.3.1 B). This was not apparent to 
the same extent in the VH5 sequences in which, generally, the distinction between the 
CDRs and FWRs, particularly CDR2 and FWR3 was not as distinct (Fig. 7.3.1 A). In 
addition, while the V145 sequences exhibited a generally greater degree of variability 
than the non-VH5 sequences, variability in the FWRs, particularly FWR3 of the VH5 
sequences appeared to be notably elevated in comparison, a surprising observation 
given its potentially destabilising effect on the structure of the antibody. 
When the distribution of silent mutations across the VH region was plotted there was no 
apparent difference in their distribution in the VH5 compared to the non-VH5 sequences 
(data not shown). This implied that the distribution of replacement mutations across the 
VH region may be an important difference between VH5 and non-VH5 sequences, 
particularly as evidence of antigen selection would be expected to manifest mainly in 
the replacement mutations. 
At each potential hotspot of mutation identified in Fig. 7.3.1, the position of the 
mutations in the codon was analysed to determine the precise nucleotide that was a 
hotspot of mutation. Hotspots of somatic mutation, evident from Figs. 7.3.1 A and B, 
were then analysed in greater detail to determine if they were likely to be intrinsic or 
non-intrinsic in origin. The observed compared to the predicted direction of somatic 
mutation at each of the hotspots is detailed in Table 7.3.1. Intrinsic mutations were 
identified as conforming with the intrinsically favoured trends of nucleotide substitution 
by SHM, defined by previous data [Betz et al., 1993b] and detailed in appendix C. 
Non-intrinsic hotspots were identified as those occurring in contrast to the expected 
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nucleotide substitution preferences. The intrinsic and non-intrinsic hotspots of mutation 
are detailed in Tables 7.3.2 (VH5) and 7.3.3 (non-VH5). In any instance where there 
were not sufficient numbers of mutations for a clear conclusion to be drawn, the hotspot 
was considered to be intrinsic. 
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Hotspot From To Obs Exp Conclusion 
VHS 
Lys 23(l) AAG CAG Gin 6 2 Biased from intrinsic trends 
GAG Glu 2 4 
TAG Stop 0 2 
Gly 24(2) GGT GAT Asp 6 2 Biased from intrinsic trends 
GCT Ala 5 0 
GTT Val 1 4 
Ser 28(3) AGC AGA Arg 3 1 Adheres to intrinsic trends 
AGG Arg 2 2 
AGT Ser 4 6 
Thr 30(2) ACC AAC Asn 1 1 Biased from intrinsic trends 
AGC Ser 4 1 
ATC lie 2 5 
Ser 31(2) AGC AAC Asn 7 7 Adheres to intrinsic trends 
ACC Thr 5 4 
ATC lie 0 1 
Ser 31(3) AGC AGA Arg 1 1 Adheres to intrinsic trends 
AGG Arg 0 1 
AGT Ser 6 5 
Tyr 32(3) TAC TAA Stop 0 0 Adheres to intrinsic trends 
TAG Stop 0 1 
TAT Tyr 4 3 
Tyr 52(2) TAT TCT Ser 1 1 Biased from intrinsic trends 
TGT Cys 1 4 
TTT Phe 5 2 
Asp 53(3) GAT GAA Glu 4 2 Likely to be intrinsic 
GAC Asp 2 4 
GAG Glu 1 1 1 
Ser 57(3) AGC AGA Arg 0 1 Adheres to intrinsic trends 
AGG Arg 0 1 
AGT Ser 7 5 
Ala 71(2) GCC GAC Asp 0 1 Adheres to intrinsic trends 
GGC Gly 0 1 
GTC Val 6 4 
Ser 76(2) AGC AAC Asn 6 4 Adheres to intrinsic trends 
ACC Thr 1 2 
ATC lie 0 1 
Met 89(3) ATG ATA lie 4 3 Although all substitutions would 
ATC Ile 0 2 result in Ile, likely to be intrinsic 
ATT lie 1 0 
Non-VHS 
Ser 31(2) AGC AAC Asn 5 3 Adheres to intrinsic trends 
ACC Thr 0 2 
ATC lie 0 0 
Table 7.3.1. The direction of muWdon at the hotspots of mWadon identffled in the VH25 
and non-Vjj5 hcIE sequences from allemic rhiniffs patients deterynined their intrinsic or 
non-intrinsk orhain. The replacement mutations in seventeen distinct VH5 sequences and 
nineteen non-VH5 sequences were analysed (Fig. 7.3.1A and B). Hotspots of mutation were 
defined either as intrinsic (conforming to the expected direction of mutation), or non-intrinsic 
(highlighted in red and biased from the expected direction of mutation). The expected direction 
of mutation was determined on the basis of previous studies [Betz et al., 1993b]. Observed 
values were denoted Obs and expected, Exp. 
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Hotspot Type Reason 
Lys 23(1) Non- Although at WA, all mutations replaced Lys, 67% gave an 
FWR1 intrinsic A->C transversion to unexpectedly generate GIn, instead of a 
AAG transition to Glu (Observed previously in VHS but not IgE 
[Snow et aL, 19971). 
Gly 24(2) Non- Although at RGYW, all mutations replaced Gly with a G-*C 
FWR1 intrinsic (83%), or a G-+T (17%) transversion, to unexpectedly 
GGT generate Ala or Val, instead of a transition to Asp (Observed 
previously in VHS sequences of all isotypes [Snow et al., 
1997]). 
Ser 28(3) Intrinsic Mutations at WIRCY followed that expected by the intrinsic bias of 
AGC SHM. 
Thr 30(2) Non- Although at WIRCY, all mutations replaced Thr, the majority 
FWR1 intrinsic by a C-*G transversion to unexpectedly generate Ser, instead 
ACC of a transition to lie (Observed previously in VHS, but not IgE 
sequences [Snow et al., 1997]) 
Ser 31(2) Intrinsic Mutations at RGYW followed that expected by the intrinsic bias of 
AGC SHM. 
Ser 31(3) Intrinsic Mutations at WIRCY followed that expected by the intrinsic bias of 
AGC SHM. 
Tyr 32(3) Intrinsic Mutations at WIRCY followed that expected by the intrinsic bias of 
TAC SHM. 
Tyr 52(2) Non- Although at WA, all mutations replaced Tyr, the majority by 
CDR2 intrinsic an A-->T transversion to unexpectedly generate Phe, instead 
TAT of a transition to Cys (Observed previously in VHS sequences 
of all isotypes [Snow et al., 1997]). 
Asp 56(3) Intrinsic Hotspot likely to result from the intrinsic bias of SHM, but analysis 
GAT of more mutations would make this more certain. 
Ser 60(3) Intrinsic Mutations at WIRCY followed that expected by the intrinsic bias of 
AGC SHM. (Identified previously as non-intrinsic in VHS, but not IgE 
sequences [Snow et al., 1997]). 
Mutations at WIRCY followed that expected by the intrinsic bias of 
Ala 71(2) Intrinsic SHM. (Although previously identified as non-intrinsic in VHS IgE 
GCC sequences [Snow et al., 19971). 
Ser 76(2) Intrinsic Mutations at RGYW followed that expected by the intrinsic bias of 
AGC SHM. 
Met 89(3) Intrinsic Hotspot likely to be intrinsic, although not possible to determine 
ATG with certainty as all possible mutations have a silent effect. 
Table 7.3.2. Intrinsic and non-intdnsk hotspots of mutaffon identified in 16-& IgE seguences 
from alleruic rhinitis patients. The replacement mutations in seventeen distinct VH5 sequences 
were analysed (Fig. 7.3.1A). Hotspots of mutation identified from this analysis were defined as 
either of intrinsic or non-intrinsic origin according to the criteria detailed in the text. R=A or G, Y=C 
or T and W=A or T in the hotspot motifs. Non-intrinsic hotspots are highlighted in red. The 
corresponding findings of previously identified non-intrinsic hotspots in allergic patients are detailed. 
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Hotspot Type Reason 
Ser 31(2) 
AGC 
Intrinsic Mutations at RGYW followed that expected by the intrinsic bias of 
SHM. 
Table 7.3.3: Intrinsic hotspot of mutation identiffed in non-W5 IbE seauences from allervic 
rhinids Dadents. The replacement mutations in nineteen distinct non-VH5 sequences were 
analysed (Fig. 7.3.1 B). Hotspots of mutation identified from this analysis were defined as either of 
intrinsic or non-intrinsic origin according to the criteria detailed in the text. No non-intrinsic hotspots 
were identified from these sequences. R=A or G, Y--C or T and W--A or T. 
The hotspots at both Met 40 and Tyr 59 in the VH5 sequences and codon 52a, 56 and 84 
in the non-VH5 sequences (identified in Fig. 7.3.1), were not regarded as genuine 
hotspots as the mutations were evenly spread across each codon and were not 
significant as hotspots at the individual positions within each codon. Furthermore, the 
mutations had very different effects on the codons and were therefore unlikely to have 
been selected by antigen. In addition, the apparent hotspots of mutation at codons 52b 
and 82a in the non-VH5 sequences were also dismissed. Mutations at codon 52b 
occuffed in both of only two sequences that used the polymorphic codon and mutations 
at 82a were divided between Asn and Ser residues so that there were not sufficient 
mutations at each to determine reliably the direction of mutation. 
Importantly, four potential non-intrinsic hotspots of mutation were identified by this 
analysis, all were evident only in the VH5 sequences, consistent with the VH5 sequences 
originating from B cells with affinity for a limited number of antigens, in comparison 
with the non-VH5 sequences that would be expected to demonstrate affinity for a 
broader repertoire of antigens. Of these non-intrinsic hotspots, three occurred in FWR I 
(Lys 23(l), Gly 24(2) and Thr 30(2)) and only one in a CDR (Tyr 52(2) in CDR2). This 
was in contrast to the expected effect of conventional antigen selection across the 
CDRs. 
Interestingly, the four non-intrinsic hotspots identified in this study correlate with those 
previously identified in allergic asthmatic patients. Both Gly 24(2), and Tyr 52(2) were 
observed to be non-intrinsic hotspots in VH5 sequences from all antibody isotypes in 
the PBMC of allergic asthmatic patients, whereas Lys 23(2) had only previously been 
identified as a hotspot in VH5 sequences from IgA sequences in these allergic PBMC. 
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Thr 30(2) had also only previously been identified as a non-intrinsic hotspot in IgG and 
IgA VH5 sequences from the allergic PBMC [Snow et al., 19971. However, the hotspot 
at Ala 71(2), identified previously from VH5 IgE sequences as non-intrinsic [Snow et 
al., 1997], was identified as a hotspot and displayed a similar direction of mutation in 
this study, but in this study was considered to be consistent with the intrinsic bias of 
SHM. In contrast, the two non-intrinsic hotspots identified from VH5 IgE sequences 
isolated from allergic dermatitis patients [Van der Stoep et al., 1993 ] at Gly 35 and Thr 
95 [Betz et al., 1993b] did not correlate with the findings of the present study. 
Fig. 7.3.1 depicted the percentage variability of each VH codon in the VH5 and non-VH5 
IgE sequences. Analysis of the total percentage mutation of each codon (including 
silent mutations) did not demonstrate any further non-intrinsic hotspots (such as the 
unexpected repeat occurrence of a silent mutation, for example, data not shown). In 
addition, no further non-intrinsic hotspots were detected in either the VH5 or non-VH5 
sequences when the percentage variability of each nucleotide was analysed (data not 
shown). 
7.4 The distribution of replacement and silent mutations in the CDR and 
FWROf VH region sequences isolated from lgE" B cells from the nasal 
mucosa of allergic rhinitis patients. 
Analysis of R/S values (replacement / silent mutations) can provide a more detailed 
insight into the distribution of somatic mutations. Such analysis was therefore applied 
to the CDR and FWR to investigate further the apparent difference in the distribution of 
replacement mutations across the VH5 and non-VH5 VH-CS sequences in the nasal 
mucosa of allergic rhinitis patients. The same sequence data utilised in sections 7.2 and 
7.3 was used for this analysis. CDR data was generated from mutations in CDRI and 2. 
FWR data was generated from mutations in FWRI, 2 and 3. 
In the absence of antigen selection the inherently more mutable CDRs exhibit a R/S 
value of 2.9, compared to the less mutable FWRs in which an R/S value of 1.5 would be 
expected. Conventional antigen selection results in an increase in the R/S value of the 
CDRs to >2.9 [Shlomchlik et al., 19871, [Chang and Casali., 1994]. The non-VH5 
sequences exhibited R/S values consistent with conventional antigen selection (Table 
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7.4.1) displaying a significant difference between the CDR and FWR (p < 0.025 when 
the chi-squared test with Yates correction for continuity was applied). In contrast, there 
was no significant difference between the R/S values in the CDR and FWR of the VH5 
sequences (Table 7.4.1), implying a lack of antigen selection across the CDR and 
increased replacement mutations selected in the FV*TR. 
R/S value and (actual numbers of mutations) 
VHS Non-VH5 
CDR 2.38 (76 / 32) 3.46 (83 / 24) 
FWR 2.06 (146 / 71) 1.67 (107 / 64) 
Table 7.4.1. Replacement / silent amino acid mutedon (RIS) values in the CDR and FWR 
of V ýH5 and non-YA sequences from lur B ceMs from the naW mucosa of affera 
rhinids Dadents. Seventeen VH5 and nineteen non-VH5 sequences were each pooled and the 
R/S values for the CDR and FWR of each data set calculated. A significant difference between 
the CDR and FWR R/S value was found in the non-VH5 sequences (p < 0.025 as determined by 
chi-squared analysis with Yates' correction for continuity). There was no significant difference 
between the R/S value in the CDR compared to the FWR of the VH5 sequences. The CDR 
category includes mutations from the germline as determined by the VBase database in CDR1 
and 2 and the FWFR category, mutations in FWRI, 2 and 3. 
The R/S values detailed in Table 7.4.1 were generated by pooling all the mutations 
observed in the sequences belonging to each data set. Analysis of the R/S values in the 
individual sequences was also carried out. This demonstrated that both the VH5 and 
non-VH5 data sets were comprised of sequences with widely ranging individual R/S 
values, (Table 7.4.2) even in sequences from the same patient in which B cells would 
have been broadly exposed to the same repertoire of antigens. 
When the individual sequences were categorised. on the basis of their CDR and FWR 
R/S values, it was evident that while a greater percentage of non-VH5 sequences showed 
evidence of conventional antigen selection (50.0%) (in which the CDR R/S value was 
>2.9 but a lower R/S value was observed in the FWR); 41.2% Of VH5 sequences also 
displayed such a trait. Furthermore, while 23.5% Of VH5 sequences exhibited a reversal 
in values, such that the FWR had a greater R/S value than the CDR, this was also 
observed in 16.7% of the non-VH5 sequences. 
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HD14 C7 6.0 2.0 CD6 C1 
S016 C11 6.0 2.5 CD6 C13 7.0 2.5 
CA30A C12 >6.0 2.0 HD14 C2 >5.0 2.7 
CA30A C11 6.0 2.4 
Ag 
HD14 C4 4.0 1.0 
CA30A C16 4.0 1.5 HD14 C11 3.0 1.5 Ag 
CA30A C22 5.0 0.5 HD14 C16 5.0 1.0 
CA30A C4b >4.0 1.6 S016 C13 5.0 2.0 
HD14 C12 0.3 1.7 CA30B C7 >5.0 1.7 
TL25B C8 2.0 2.0 TL25 A C17 3.5 1.7 
CA30A C8 3.5 3.0 CD6 C12 1.0 2.3 
CA30A C 17 3.0 2.5 ND CD6 C2 1.5 1.4 
CA30A C3 0.6 0.9 HD14 C9 2.3 1.2 
ND 
CA30A C20 1.7 2.4 AP19 C16 1.0 <1.0 
HD14 C19 1.5 >6.0 CA30B C8 >1.0 0.6 
AP19 C2 0.5 3.7 
SAg 
CA30B C19 1.7 2.5 
CA30A 5 >4.0 - 5.0 CD6 C5 3.0 5.0 
CA30A C3b 1.3 5.0 AP19 C3 >2.0 4.0 SAg 
AP19 C6 1.5 3.5 
Table 7.4-2: Regiacement / silent (RfS) values in the CDR and FWR of YA and non-yA 
secuences from IaE' 8 celks from the nasal mucose of alieraic rhinids-vationts. The CDR 
included mutations in CDR1 and 2. The FWR included mutations in FWR1,2 and 3. 
Sequences were categorised according to the type of antigenic selection most likely to have 
occurred where conventional antigen selection (Ag) induced a CDR R/S >2.9 and a difference 
between the CDR and FWR R/S values of at least 1.0. When antigen selection could not be 
determined (ND), either the sequence did not exhibit a CDR or FWR R/S value >2.9 or the 
difference between the values was less than 1.0. Superantigen selection (SAg) was proposed 
when the FWR >2.9, greater than that in the CDR and there was a difference between the CDR 
and FWR R/S values of at least 1.0. Where a R/S value is preceded by >, there were no silent 
mutations and where preceded by <, no replacement mutations. 
There was no correlation in general between sequences that demonstrated R/S values 
suggesting superantigen. selection and those that exhibited the non-intrinsic mutations 
identified in section 7.3. Most sequences exhibited one or two of the non-intrinsic 
hotspots, two exhibited three of these hotspots, while one sequence (CA30A C20) had 
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accumulated all four of the mutations thought to be non-intrinsic. The R/S values in 
CA30A C20 did not clearly suggest superantigen selection, although the R/S values 
were higher in the FWR than the CDR (2.4 and 1.7 respectively). The family Of VH5 
IgE' B cell clones identified from the nasal mucosa of patient S016 (represented by 
S016 CII) did not contain any of the non-intrinsic mutations, consistent with 
conventional antigen selection. However, the family Of VH5 IgE' B cell clones 
identified in the nasal mucosa of AP19 (represented by AP19 C2), exhibited two of the 
non-intrinsic mutations, in addition to R/S values consistent with superantigen selection. 
7.5 Analysis of replacement and silent mutations in the individual 
FWRs Of VHS sequences from the nasal mucosa of allergic rhinitis 
patients. 
In section 7.4, unusual R/S values in the CDR and FWR of the VH5 sequences were 
identified. The apparent decrease in the R/S value of the CDRs, and increase in the 
FV; Rs was consistent with superantigen selection, although no conclusive parallels 
could be drawn between the presence of non-intrinsic hotspots and sequences exhibiting 
particularly distorted overall R/S values. As a superantigen need not have contact with 
all the FWRs, the R/S values in the individual FWRs 1,2 and 3 of the VH5 sequences 
were therefore examined to determine if closer analysis indicated any correlation (see 
appendix D for data). 
The combined R/S value in FV*FR1 was 2.16, slightly higher than overall VH5 FWR R/S 
of 2.06. The combined R/S in FWR2 was however only 1.06, exhibiting the low 
variability expected of a FATR. In contrast, the combined R/S of FWR3 was 2.61. This 
suggested that the skewed R/S values observed in the overall FWR of the V115 
sequences were likely to have resulted from the unusually high variability of FWRI and 
FWR3. The particularly high R/S value of the VH5 FWR3 did not seem to be a 
consequence of FWR3 being generally more mutable, as the R/S value of FWR3 in the 
non-VH5 sequences was consistent with that expected (1.57). All of the sequences 
classified in Table 7.4.2 as subject to superantigen selection exhibited more replacement 
than silent mutations in FWR3, although this was also observed in some of the 
antibodies thought to have been selected by conventional antigen, (data not shown). 
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Although elevated FWRI R/S values were also not solely confined to sequences 
selected by superantigen, interestingly the sequence with the most skewed overall R/S 
values, CA30A Ob, also exhibited the highest individual R/S value in FAFRI (R/S = 
7.0), but not in FWR3. Those sequences with the highest individual FWRI R/S values 
also included two of the other three sequences classified as superantigen selected (AP 19 
C2 and CA30A C5). In addition, CA30A C20 exhibited all four of the non-intrinsic 
mutations and a high FAIRI R/S value of 5.0, but a low FWR3 R/S value. (Details of 
the numbers of replacement and silent mutations used in calculating all R/S values are 
detailed in appendix D). 
7.6 Discussion 
In this chapter a detailed analysis of the usage of the different VH gene classes and the 
distribution of somatic mutations across the VH gene in allergic rhinitis patients was 
presented. Previous researchers had reported a bias towards the increased use of the 
VH5 gene class in IgE+ B cells in the PBMC of allergic dermatitis patients [Van der 
Stoep et al., 1993] and in both the PBMC, spleen and lung mucosa of allergic asthmatic 
patients [Snow et aL, 1997], [Snow et al., 1995], [Snow et al., 1999]. In addition, an 
unusual distribution of replacement and silent mutations across the CDR and FWR of 
the VH5-CF- VH5 sequences was observed in many of these studies [Van der Stoep el al., 
1993], [Snow et al., 1995], [Snow et al., 1999]. These observations led to the 
suggestion that antigen selection by aB cell superantigen with affinity for the FWR of 
VH5 may have occurred in these allergic patients [Snow et al., 1995], [Snow et al., 
1999]. It was therefore of interest to determine whether such trends were observed in 
VH-CF- sequences RT-PCR amplified from the nasal mucosa and PBMC of allergic 
rhinitis patients. 
Superantigens have long been known to activate T cells by simultaneously binding to 
both the T cell receptor and also to MHC class II on antigen presenting cells outside of 
the conventional peptide-binding groove [reviewed by Proft and Fraser, 2003]. More 
recently however, the interaction of superantigens with B cells via the conserved VH 
region FWRs has been observed, resulting in biased usage of the VH gene classes. Such 
B cell superantigens are of similar origins to T cell superantigens, from bacterial, viral 
and endogenous sources. They include protein A from SWhylococcus aureus (SpA, 
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specific to VH3) [Sasso et al., 1989], protein L from Peptostreptococcus magmis 
(specific to kappa light chains) [Nilson et al., 1992], IHV gp120 (specific to VH3) 
[Berberian et al., 1993], the human protein Fv (specific to VH3 and VH6) [Silverman et 
al., 19951. 
In chapters 4,5 and 6 of this thesis, VH5 B cell clones featured prominently. Two of the 
four families of related IgE+ B cell clones (identified in chapters 4 and 6) utilised VH5, 
including the family of clones that additionally incorporated IgA' B cell clones. The 
detailed analysis Of VH-C6 sequences from the allergic rhinitis patients indicated that 
there was a highly significant difference between the VH5 gene usage in the allergic 
nasal mucosa and both that expected on the basis of the genomic rearrangement of 
functional VH regions identified in normal PBMC [Brezinschek el al., 20001 and also 
that observed in allergic PBMC. 29% of sequences isolated from the nasal mucosa used 
VH5, comparable with that observed in the allergic lung mucosa (33%) [Snow el al., 
19991. The use Of VH3 in the allergic nasal mucosa was highly significantly decreased 
compared to that in normal PBMC, possibly as a consequence of the over-use of V115, 
an observation also noted in the allergic lung [Snow et al., 1999]. 
While other researchers identified an increased usage Of VI-15 in the PBMC of allergic 
patients [Van der Stoep el al., 19931, [Snow et al., 1996], there was no significant 
difference in the use of VH5 in PBMC from allergic rhinitis patients analysed in this 
study, suggesting that in these patients increased VI-15 use was restricted to the local 
microenvironment. It is possible that the V115 bias was locally generated in the allergic 
lung mucosa also, but that the greater volume of tissue meant that cells that had 
migrated from the lung constituted a much larger percentage of those present in the 
circulation. 
Intrinsic hotspots of somatic hypermutation were identified in the VH5 and non-VO 
sequences from the nasal mucosa of the allergic rhinitis patients, reflecting the intrinsic 
bias of the SHM mechanism. Non-intrinsic mutations, characteristic of the selective 
pressures of antigen, were only identified in the VH5 sequences, consistent with these B 
cell clones having affinity with a restricted repertoire of antigens. In contrast to that 
expected as a consequence of conventional antigen selection across the CDR loops, 
three of the four non-intrinsic hotspots occurred in FWRI (Lys 23(l), Gly 24(2) and Thr 
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30(2)), while only one occurred in a CDR (Tyr 52(2) in CDR2). Although mutations in 
the FWRs occasionally have an indirect effect on the conformation of the CDRs and 
therefore on conventional interaction with antigen, it seems unlikely that all three 
hotspots would have such an effect. Interestingly, these non-intrinsic hotspots exactly 
correlated with those previously identified by analysis Of VH5 sequences from the 
PBMC of allergic asthmatics [Snow el al., 1997], although not with those observed in 
the VH5 sequences from the PBMC of allergic dermatitis patients [Van der Stoep et al., 
1993 ], [Betz et al., 1993b]. 
The observation of common non-intrinsic hotspots suggests that VH5 sequences may be 
selected in both allergic asthmatics and the nasal mucosa of allergic rhinitis patients by 
the same superantigen. A different superantigen may be responsible for the similar 
phenomena in allergic dermatitis patients. This may be a result of the distinction 
between the presence of an airborne superantigen, versus a superantigen that originates 
from bacteria that colonise the broken skin of dermatitis patients, for example. 
In order to determine if the general distribution of replacement and silent mutations 
across the VH region of the VH5 sequences differed from that expected ftom 
conventional antigen selection, the R/S values in the CDR and FWR of the VH5 and 
non-VH5 sequences were compared. The R/S values in the non-VH5 sequences reflected 
conventional antigen selection, with a significantly greater R/S value in the CDR than 
the FWR [Shlomchik et al., 1987], [Chang and Casali, 1994]. In stark contrast, there 
was no significant difference between the R/S values observed in the CDR compared to 
the FWR of the VH5 sequences. The interpretation of the data was complicated by the 
observation that individual sequences from both the VH5 and non-VH5 data sets 
exhibited a range of different R/S values, some consistent with conventional antigen 
selection, some in which no evidence of any selection was obvious, and some with 
evidence of selection across the FWRs, consistent with that of a superantigen. This was 
also observed when previous researchers analysed allergic PBMC [Snow et al., 1997], 
[Van der Stoep et al., 1993]. 
Van der Stoep suggested that such R/S values may result from chronic antigen 
stimulation, leading to the accumulation of mutations with a 'neutral' effect on the 
antibody affinity. This might skew R/S values from that expected, towards a more 
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random pattern [Van der Stoep el aL, 1993]. This would correlate with the greater 
degree of mutation observed in VH5 sequences from the nasal mucosa, but would not 
lessen the possibility that superantigen selection had occurred. It is perhaps more likely, 
however, that while a superantigen initially activates VH5 B cells, the activated B cells 
are allergen specific and therefore later acquire specific mutations. Alternatively, the 
superantigen may allow the simultaneous conventional binding of an antigen to the 
CDRs, as suggested in Staphylococcus aureus protein A (SpA) binding to VH [Graille el 
al., 2000]. In either such scenario, a blurred imprint of either superantigen or 
conventional antigen selection would result, consistent with that observed in some of 
the VH5 sequences. 
When the R/S values of the VH5 sequences in FWRI, 2 and 3 were analysed separately, 
the distortion of the overall FWR R/S value was shown to originate from particularly 
high levels of variability in FWRI and FWR3. The highest FWRI R/S values occurred 
in sequences in which the overall R/S values were most skewed, particularly CA30A 
Ob. CA30A C20 exhibited all four of the proposed non-intrinsic hotspots and also one 
of the highest FWRI R/S values. 
When the sequences representing families of related VH5 B cells were studied, the 
family Of VH5 B cells isolated from the nasal mucosa of patient S016 demonstrated 
evidence of conventional antigen selection (as suggested to be likely from the pattern of 
mutation observed in chapter 5). In contrast, the family of related VH5 B cells isolated 
from the nasal mucosa of patient AP19 demonstrated R/S values (and two non-intrinsic 
hotspots) that implied the family may have expanded in response to a superantigen. 
The research presented in this chapter demonstrates that the bias towards increased 
usage Of V115 sequences in allergic patients, previously identified in dermatits and 
asthma patients [Van der Stoep et al., 19931, [Snow et al., 1995], [Snow et al. 1999], is 
also present in the nasal mucosa of allergic rhinitis patients. In contrast to previous 
research however, the bias appears to be confined to the local nasal mucosa and is not 
significant in the PBMC. In addition, analysis of adjacent pieces of nasal mucosa 
(chapter 6) suggested that the VH5 clones appeared to be extremely locally contained, 
possibly as clusters of B cells, perhaps explaining why while no VH5 sequences were 
amplified from some nasal biopsies, VH5 was predominantly amplified from others. 
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Taken in combination, the VH5 bias in the nasal mucosa, the unconventional hotspots of 
non-intrinsic mutation and the distorted R/S values in the CDR and FWR do suggest 
that selection Of VH5 by the interaction of a superantigen with the FWR is likely to have 
occurred in the nasal mucosa of particular allergic rhinitis patients. Furthermore, it is 
possible that while such an interaction might predominantly be with FWRI, some 
contact with CDR2 and FWR3 may also occur. This model of interaction would 
correlate with that observed previously by B cell superantigens and VH. SpA, for 
example, is known to interact with FWRI, FWR3 and CDR2 [Randen el al., 1993], and 
FWR3 has previously been suggested to act as an alternative antigen binding site 
[Kirkham et al., 1992]. 
Identifying a superantigen with affinity for the FWR Of VH5 in the nasal mucosa of 
allergic rhinitis patients would make a major contribution towards understanding the 
aggravated symptoms of allergy observed in some individuals. The superantigen may 
be bacterial in origin, for example IgE antibodies directed against Slaphylococcus 
aureus enterotoxins (SAE) in nasal polyps were linked with an increased severity of 
asthma [Bachert et al., 2003]. (Preliminary investigation of SAE IgE' nasal polyp 
samples did not suggest a VH5 bias (data not shown), although the allergic rhinitis 
patients detailed in this chapter were not screened for such infections). 
It is also possible that a superantigen could be of viral, endogenous or allergenic origin. 
Of all of the patients in this study, CA30 was most likely to have had exposure to a 
superantigen; sequence CA30A C20 contained all four of the proposed non-intrinsic 
VH5 hotspots of mutation, sequence CA30A C3b demonstrated R/S values that were the 
most highly skewed towards superantigen selection and eleven distinct VH5 sequences 
were amplified from the nasal mucosa of patients CA30. Patient CA30 was allergic to 
both grass and house dust mite, implying that either could be a candidate allergen to act 
as a superantigen. 
HDM was previously suggested as a potential superantigen [Snow el al., 19951, 
although there was no general correlation between the amplification Of VH5 sequences 
fi7om the nasal mucosa and sensitivity to HDK in the present study. However, all of 
the patients from whom VH5 sequences were isolated, were allergic to grass pollen. 
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Four of the five patients from which VH5 sequences were amplified were biopsied 
within the grass pollen season, whereas four of the six patients from whom no VH5 
sequences were amplified from the nasal mucosa (all both grass pollen and perennial 
sufferers) were biopsied outside the grass pollen season. In previous research in which 
a VH5 bias was demonstrated in well-characterised allergic patients, the subjects have 
exhibited multiple allergies including grass pollen [Snow et al., 1997], [Snow el al., 
1999]. It is therefore possible that grass pollen acts as a superantigen and that although 
patient CA30 was biopsied outside the pollen season, the VH5 sequences originated 
from B cells stimulated earlier in the year. 
It is also possible that multiple allergens could act as different superantigens in different 
allergic disorders. For example, a VHl bias and lack of conventional antigen selection 
has been observed in peanut allergic patients [Janezic et aL, 1998] and in allergic 
dermatitis the non-intrinsic hotspots in the over-represented VH5 sequences do not 
correlate with those observed in allergic asthma and rhinitis. 
Superantigen binding to the VH5 FAIR of the B cell receptor would enable non-specific 
activation and subsequent clonal. expansion of allergen specific B cells. In addition, 
cross-linking of IgE on the surface of mast cells would non-specifically instigate cell 
degranulation, releasing mediators such as HA with a consequent increase in allergen 
specific IgE and exacerbation of the allergic response. For example, the superantigen 
protein Fv is endogenous to normal liver but is released in the gut as a consequence of 
viral hepatitis. Some symptoms of viral hepatitis have been suggested to result from the 
degranulation of basophils and mast cells by the non-specific binding of protein Fv to 
IgE in just such a manner [Patella et al., 1993]. The non-specific binding of Protein L 
to IgE light chains has also been shown to stimulate the secretion of IIL-4 and IL-13 
from basophils [Genovese et al., 20031 
It is likely that similarly, in the allergic nasal mucosa the superantigen binds to the FWR 
Of VH5 IgE on the surface of mast cells, stimulating their degranulation, prolonging and 
exacerbating allergic symptoms by the positive feedback of EL4, stimulating TH2 cells 
and further switching of B cells to express IgE. The bias towards V115 is likely to result 
from the non-specific activation of B cells expressing a VH5 antibody on the B cell 
surface. 
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The work presented in this chapter has provided many more questions to be addressed. 
While normal, non-allergic nasal biopsies do not contain sufficient IgE for analysis, RT- 
PCR amplification Of VH-CS sequences from the PBMC or the whole inferior turbinate 
of non-allergic patients may be possible from carefully selected subjects and would 
provide more accurate 'expected' values Of VH gene usage than those from the 
productive genomic rearrangement used for comparison in this study (determined by 
[Brezinschek el al., 2000]). A further study Of VH5 sequences from normal subjects 
may also enable the non-intrinsic hotspots identified in this study to be clearly 
confirmed and distinguished from mutations intrinsic to the VH5 sequence itself 
It would then be of interest to compare the VH gene usage in other antibody isotypes 
from the nasal mucosa of both normal and allergic rhinitis patients. A bias towards VH5 
should be evident in all isotypes as a superantigen has affinity for the FWR. Previous 
analysis of IgM in allergic lung was however unable to demonstrate a VH5 bias [Snow 
et al., 1999] and some of the non-intrinsic hotspots previously identified in the PBMC 
of allergic asthmatics, were only evident in VH5 antibodies of particular isotypes [Snow 
et al., 1997]. It is possible that IgM B cells activated by superantigen switch promptly 
to another antibody isotype, so that VH usage by IgG or IgA antibodies in the allergic 
nasal mucosa might be more revealing. It would also be of interest to extend the 
analysis Of VH gene usage throughout the inferior turbinate, as it is possible that if the 
whole of the inferior turbinate were analysed a bias towards VH5 usage would be 
evident in all or a particular sub-set of allergic rhinitis patients, a feature that may be 
disguised by the varying cellular contents of individual biopsies. 
The area of particular interest for future work however would be to explore further the 
identity of the proposed superantigen and its manner of interaction with VH5. This 
could be determined by the construction of a combinatorial Fab library Of VH5 
antibodies, ideally amplified from the nasal mucosa of an allergic rhinitis patient, such 
as CA30, from whom evidence of local superantigen selection of B cell clones is 
strongest. This would enable not only the affinity Of VH5 antibodies for a variety of 
potential superantigens to be determined, but also the eventual crystallisation of high 
affinity complexes, so that the interaction of the superantigen with VH5 and in particular 
with the proposed non-intrinsic hotspots, could be identified. 
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In conclusion, while the overall antibody response in the allergic nasal mucosa would 
appear to be the consequence of a multi-clonal response to multiple epitopes and 
antigens, the research presented in this chapter suggests that the predominance of 
families of related VH5 B cells, the biased usage Of VA increased replacement 
mutations in the FWR Of VH5 sequences and unusual non-intrinsic mutations in VA 
support the hypothesis of superantigen selection of B cells expressing VH5 antibodies in 
the nasal mucosa of allergic rhinitis patients. 
169 
Chapter 8 
Local expression of mRNA transcripts encoding activation- 
induced cytidine deaminase in the nasal mucosa of allergic 
rhinitis patients. 
ChaDter 8 Locad exDression of AID 170 
8.1 Introduction. 
Activation-induced cytidine deaminase (AID) expression by active CD19+ B cells has 
been shown to be essential in enabling class switch recombination and somatic 
hypermutation to take place in both murine [Muramatsu et al., 1999], [Muramatsu el al., 
2000], [Fagarasan et al., 200 1] and human [Revy et al., 2000] systems. 
In humans, hyper IgM syndrome has been shown to result in some cases from the 
deficiency of functional AID protein (IUGM2). Investigation of AID expression in 
different human tissues suggested that AID mRNA was expressed in the human lymph 
nodes, tonsil and spleen. In addition however, AID expression was detected at a much 
lower level in most of the other human tissues tested from a panel of commercial cDNA 
samples, including the kidney, pancreas, and very weakly in the lung [Muto el al., 
2000]. As investigation of the murine gut mucosa revealed that local expression of AID 
corresponded with local CSR to IgA [Fagarasan et al., 2001], it seemed important to 
determine if AID mRNA was present in the nasal mucosa of allergic rhinitis patients. 
Local AID expression in the nasal mucosa would be assumed to be necessary in order to 
support local CSR and SHM. 
Time-course studies of AID mRNA expression stimulated in normal PBMC by in vitro 
incubation with anti-CD40 and IL-4 (stimuli for AID expression and CSR) were carried 
out in order to determine the potential value of AID mRNA as a marker for local CSR 
and SHM. Further RT-PCR and Southern blot analysis investigated whether AID 
mRNA transcripts were expressed in the nasal mucosa of allergic rhinitis patients. 
8.2 Time-course analysis of AID expression in stimulated PBMC. 
Previous research demonstrated that expression of AID mRNA transcripts could be 
induced in normal PBMC by in vitro incubation with anti-CD40 and IIL-4 (mimicking B 
cell interaction with and stimulation, by T cells) [Revy et al., 2000]. In these normal 
subjects, AID mRNA expression (undetectable at day zero) was evident after five days 
of incubation. Revy et al. also determined that AID expression remained detectable 
after eight or twelve days incubation, although the strength of this expression was not 
commented upon. 
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The work by Revy et aL was repeated and extended in this study to determine the exact 
time taken for AID transcripts to be generated from normal PBMC and the length of 
time for which the transcripts remained when constantly stimulated by IL-4 and anti- 
CD40 (as would also occur in the allergic nasal mucosa as a consequence of chronic 
antigen exposure). RT-PCR analysis of the stimulated PBMC demonstrated weak AID 
expression after in vitro incubation for just one day, although an up-regulation of All) 
mRNA occurred after five days in some cultures (data not shown) and considerable up- 
regulation was always evident at six and seven days (Fig. 8.2.1). This correlated with 
other work conducted by our group, suggesting that under the same conditions, 
evidence of CSR was detectable by switch circle transcript (SCT) analysis after six 
or seven days incubation (unpublished observations by P. Takhar). 
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Fiog. 8.2.1, Agarose gel electrophoresis of AID PCR Droducts arnDlified from normal PBMC 
stimulated in vitro with anti-CD40 and IL-4 as a time-course exDeriment. AID PCR 
products (647 bp) were subjected to agarose gel electrophoresis on a 1% agarose gel and 
visualised under UV. Lane 1: day 0. Lane 2: day 1. Lane 3; day 2. Lane 4ý day 3. Lane 6; 
day 4. Lane 6; day 5. Lane 7; day 6. Lane 8; day 7. Lane 9: AID negative control (no cDNA). 
Lane 10; 100 bp ladder (L), (500 bp indicated). 
Additional time-course experiments demonstrated that when the cDN A from each of the 
stimulated PBMC samples was normalised. to the expression of the GAPDII 
housekeeping gene (and proportional amounts of cDNA included in the PCR), AID 
mRNA expression was reduced, but still evident after ten days incubation (Fig. 8.2.2). 
After fourteen days, no AID expression was evident when the samples were nornialised 
to GAPDH, although when 5 ýd of undiluted cDNA was PCR amplified a low level of 
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expression was evident, indicating that AID expression, while considerable down- 
regulated, had not completely ceased (data not shown). 
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Fiq. 8.2.2; A-Qarose mel electrophoresis of AID PCR products normalised to GAPD 
expression and amplified from normal PBMC stimulated in vitro with anti-CD40 and ILA 
as a time course experiment AID PCR products (647 bp) were subjected to agarose gel 
electrophoresis on a1% agarose gel and visualised under UV. Lane 1 -1 100 bp ladder (L) (500 
bp indicated). Lane 2; day 0. Lane 3, day 7. Lane 4, day 10. Lane 5; day 14. Lane 6, AID 
negative control (no cDNA). The quantity of cDNA included in each AID PCR reaction was 
normalised to the intensity of GAPDH expression (393 bp PCR product shown below the main 
panel for each sample). 
While the PBMC used in these experiments were from normal patients, it is likely that 
the results may be similar to that in the allergic nasal mucosa in which chronic B cell 
stimulation by T cells occurs. The decrease in AID expression observed over time in 
the PBMC system is likely to have resulted from anti-CD40 mediated maturation of the 
B cells to the non-AID expressing plasma cell type [Muramatsu el 411., 1999]. In 
contrast, migration of CD19' B cells into the nasal mucosa must occur, 
It is therefore likely that if AID expression were detected in the allergic nasal mucosa as 
a consequence of the T cell population, It could not be used as a direct and accurate 
marker of recent, local CSR and SHM because persistence of the signal for at least 
fourteen days would have to be assumed. The presence of AID mRNA would however 
strengthen evidence suggesting that B cells present in the nasal mucosa of allergic 
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rhinitis patients exist in local microenvironment in which all the known prerequisites for 
CSR and SHM exist. 
8.3 AID rnRNA splice variants. 
Experiments with both stimulated PBMC and also the RAMOS cell line (used as a 
positive control) generated bands indicative of multiple PCR products. In addition to 
the expected AID PCR product at 647 bp, a particularly distinct DNA band was evident 
at 950 bp and much fainter bands at approximately 550 bp and 1400 bp (Fig. 8.3.1). 
Fiq. 8.3.1; Agarose c ted from the RAMOS iel electrophoresis of AID PCR products amplif 
ceH line demonstrating the presence of different mRNA splice variants. AID PCR products 
were subjected to agarose gel eiectrophoresis on a 1% agarose gel and visualised under UV. 
Lane 1; 100 bp ladder (L) (500 bp indicated). Lane 2; AID PCR products amplified from 
RAMOS were evident at approximately 532 bp, 647bp (as expected), 950 bp and 1400 bp. 
Lane 3; AID negative control (no cDNA). 
Attempts were made to clone and sequence the unexpected 950 and 550 bp PCR 
products to establish their identity. Sequence analysis showed the approximately 550 
bp PCR product to actually be 532 bp and while exhibiting homology with part of the 
AID sequence, was truncated as a consequence of the complete deletion of exon four 
(Fig. 8.3.2). This resulted in the consequent introduction of a stop codon in the amino 
acid sequence at the 5' end of exon five. Although the cytidine deaminase motif, 
thought to be the active site is encoded by exon three [Muto el al., 2000], the 
conformational change to the AID protein as a result of the deletion of exon four and 
five must be so substantial as to render this variant inactive. This is particularly likely 
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given the detrimental effect of mutations observed in exon four of AID in patients 
suffering from HIGM2 [Revy ef aL, 20001. 
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Fia. 8.3.2. Alionment of the 532 bD AID splice variant with the full-lencith AID secuence 
and the generation of a truncated amino acid sequence. A) The truncated 532 bp AID PCR 
product RT-PCR amplified from the RAMOS cell line was aligned with the full-length 647 bp AID 
sequence (accession no. A13040431). Primer regions are underlined. B) Translation of the 532 
bp splice variant in reading frame two demonstrated the effect of truncating the amino acid 
sequence by the creation of a premature stop codon (*). The positions of exons 1-5 in the 
coding region only are marked on the full-length sequence in A) and B). 
Unfortunately, the identity of the 950 bp band could not be determined in the time 
available, as the DNA appeared to be spliced to the correct size of 647 bp when cloned 
into the readily available strains ofE. coli. It would seem sensible to assume however 
that the product contains intronic sequence. Within the PCR amplified region, only the 
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intron between exons three and four is of appropriate size (294 bp), making it a likely 
candidate for the additional sequence included within the 950 bp PCR product. The 
weak PCR product at approximately 1400 bp was also not investigated because of time 
constraints, but it would appear likely that it might correspond to a splice variant in 
which both the intron between exons three and four (294 bp) and also between exon 
four and five (470 bp) had not been excised. 
8.4 Local expression of AID mRNA transcripts in the nasal mucosa of 
allergic rhinitis patients compared to normal subjects. 
As discussed in the introduction, it was important to determine whether AID mRNA 
expression occurred in the nasal mucosa of allergic rhinitis, patients as its presence is 
crucial at sites of CSR and SHM [Muramatsu el aL, 1999], [Muto el aL, 20001, 
[Fagarasan el aL, 2001]. Conventional PCR amplification of AID (see section 3.2.24) 
was attempted from the cDNA of a range of nasal biopsy samples, including the cohort 
of eleven patients detailed in chapters 4 and 6 (where the quantity of RNA remaining 
allowed). From only one of these samples were AID PCR products detected, in the 
nasal biopsy from allergic rhinitis patient DR20 (see section 3.2.2 for patient details), 
full-length AID mRNA was clearly and repeatedly amplified (P'ig. 8.4.1). The identity 
of the PCR product was confirmed to be AID by sequence analysis (data not shown). 




Ra. 8.4.1. Aoarose (yel electrophoresis of AID PCR products amWified from the nasal 
mucosa of allergic rhinitis patient DR20. AID PCR products (647 bp) were subjected to 
agarose gel electrophoresis on a 1% agarose gel and visualised under UV. Lane 1; 100 bp 
ladder (L) (500 bp indicated). Lane 2; DR20 nasal biopsy sample (NM). Lane 3; DR20 PBMC 
sample (PB). Lane 4-1 AID negative control (no cDNA). Lane 5, AID positive control (RAMOS 
cell line). 
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As it was possible that the limited sensitivity of the PCR prevented the detection of AID 
in the nasal biopsy samples, the PCR protocol was modified to utillse a nested approach 
(see section 3.2.24 for details). When AID mRNA expression in the nasal biopsies 
samples was re-analysed in this manner, PCR products were amplified from many of 
the samples. Preliminary results suggested that this nested PCR increased the 
sensitivity such that AID mRNA was evident in some, but not all, unstimulated normal 
and allergic PBMC samples (data not shown). However, presumably as a consequence 
of the greater sensitivity of the PCR, results from each sample were not always 
consistent when experiments were repeated. Therefore, only samples from which a 
PCR product was obtained in at least two out of four repeat experiments was classified 
as positive. 
Of the seven allergic rhinitis patients in which sufficient nasal biopsy sample remained 
for repeated analysis, AID PCR products were definitely amplified from five (Fig. 
8.4.2). These results were confirmed by Southern blot analysis using a probe that 
spanned the junction of exon three and four (data not shown). 





Fhq. 8.4.2. Amarose c jet electroj3horesis of AID PCR products amplified bv a nested PCR 
from the nasal mucosa of five out of seven affergic rhinitis patients. AID PCIR products 
(335 bp) were subjected to agarose gel electrophoresis on a 1% agarose gel and visualised 
under UV. Lane I1 100 bp ladder (L) (500 bp indicated). Lane 2; CM1 0. Lane 3; AP1 9. Lane 
4; DR20. Lane 5; JH23. Lane 6; SJ24A. Lane 7; TL25A. Lane 8; ZC27B. Lane 9; AID 
negative control (no cDNA). P denotes a biopsy taken from a patient with perennial allergies. I 
denotes a biopsy taken in-season from a patient allergic to grass pollen and MI a monoallergic 
grass pollen allergic. 
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Interestingly, expression of AID mRNA was detected from the nasal mucosa of CM 10, 
fi7om which no related B cell clones were detected but was not detected in the nasal 
mucosa of AP19, from which evidence of related B cell clones was detected (chapter 4). 
In three of the seven patients in which local AID mRNA expression was analysed, 
multiple biopsies were taken (two half biopsies from SJ24, and double biopsies from 
both TL25 and ZC27). No AID mRNA could be definitely detected in either half of the 
biopsy from SJ24 (A or B), even though a family of clonally related B cells were 
detected from SJ24A (see chapter 6). In both TL25 and ZC27 however, although the 
double biopsies were adjacent pieces of tissue, different results were obtained, AID 
mRNA was clearly evident in TL25A and ZC27B, but not in TL25B and ZC27A (data 
not shown, but also confirmed by Southern blot analysis). 
All of the biopsies detailed in Fig. 8.4.2 were either taken from grass pollen allergics in 
the grass pollen season, or from perennial allergic rhinitis sufferers. There was no 
correlation between AID mRNA expression and the season in which the tissue samples 
were taken, or whether the patients were monoallergic or multiallergic. Nor was there 
any apparent difference in DR20, in whom AID expression was evident without the 
nested PCR, compared to the other patients. However, when AID mRNA expression 
was analysed in the nasal mucosa of normal subjects, the expression was different from 
that in the allergic rhinitis patients. Even after multiple repeats of the nested AID PCR, 
there was no definite evidence of AID mRNA in any of the six normal nasal biopsy 
samples, (see section 3.2.2 for subject details), including the non-atopic GJ29 who 
exhibited an extremely elevated serum IgE titre (Fig. 8.4.3). In two samples (JF and 
ST) AID mRNA was detected in one of the three PCR repeats only by Southern blot 
analysis and even then, very faintly in ST (data not shown). 
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Fia. 8.4.3: Aaarose ciel electrophoresis of AID PCR products amplified by a nested PCR 
from the nasal mucosa of six normal subjects. AID PCR products (335 bp) amplified from 
nasal biopsy samples were subjected to agarose gel electrophoresis on a 1% agarose gel and 
visualised under UV. Lane 1; 100 bp ladder (L), (500 bp indicated). Lane 2-1 subject JF. Lane 
3; subject JM. Lane 4; subject VC. Lane 5; subject ST. Lane 6-1 subject TI-22. Lane 7, 
subject GJ29. Lane 8-1 AID positive control (RAMOS cell line). Lane 9; AID negative control (no 
cDNA). 
In order to determine whether expression of AID could be induced in the nasal mucosa, 
nasal biopsies ftom four normal subjects were incubated in Oiro for six days with IL-4 
and anti-CD40. No evidence of AID expression was detected by RT-PCR from any of 
these samples, although GAPDH could be successfully amplified from each (data not 
shown). As the conditions for in vitro incubation of nasal biopsies had not been 
thoroughly optimised (a lengthy experiment currently being carried out in our group), a 
further experiment was designed in which in vivo allergen challenge with grass pollen 
extract was administered to six grass-pollen allergic rhinitis patients, outside of the 
grass pollen season. Nasal biopsies were taken five, six or seven days after allergen 
challenge. However, while GAPDH transcripts could again be amplified successfully 
from the samples, there was no evidence of AID expression, even by amplification with 
the nested PCR, although as no SCT's could be detected either (P. Takhar, personal 
communication) it is quite possible that the challenges were again unsuccessful for a 
technical reason. 
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8.5 Discussion. 
As a consequence of recent research to elucidate the mechanisms of CSR and SFM, 
AID was identified as central to both processes [Muramatsu el aL, 1999], [Muramatsu 
et al., 2000]. It was therefore of importance to determine whether AID was present in 
the nasal mucosa of allergic rhinitis patients, an occurrence that would be assumed to be 
essential for the feasibility of local CSR and SIHM. Expression of AH) m. RNA was 
analysed rather than the presence of the AID protein because of the lack of a 
commercially available anti-human AID antibody at that time. The possibility that the 
full length mRNA detected in this study was not translated into functional protein must, 
while unlikely, be acknowledged. 
Initial investigations were carried out to determine the timescale of the induction and 
maintenance of AID mRNA expression in the presence of EL-4 and anti-CD40, 
necessary not only for the induction of AID but also for CSR to IgE [Revy et al., 2000], 
[Armitage et al., 1993]. These experiments were carried out in vitro using normal 
PBMC and supported previously findings suggesting that AID mRNA expression was 
strongly expressed after incubation for five (or six) days and was still detectable after 
eight and twelve days [Revy el al., 2000]. The results in this study more specifically 
determined that AID mRNA expression peaked after seven days of incubation and that 
while minimal AJOD expression was evident after fourteen days, it was much reduced by 
day ten. 
While the initial up-regulation in the expression of AID mRNA coincided with the 
detection of SCTs, it was apparent that SCTs were the most accurate marker of recent 
CSR, as AID expression was maintained for a longer period of time (SCTs only being 
detected at days 6 and 7) (P. Takhar, unpublished observations). Results from the 
in vitro system implied however that in an environment in which UL4 and anti-CD40 
signals were plentiful (such as the allergic mucosa) [Ying et al., 1994], ADD expression 
might be stimulated, or previous stimulation of AID might be maintained. Indeed, 
recent research has demonstrated that in humans, IIL-4 is sufficient to induce AID 
expression in both primary B cells and B cell lines, although in combination with 
CD40L, such expression was even further increased [Zhou el al., 2003]. Expression of 
AID may only have been limited in the in vitro PBMC system by the differentiation of 
CD19+ B cells into plasma cells. It would be interesting to determine if, as would be 
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expected, stimulation of allergic PBMC with IIL-4 and anti-CD40 results in the same 
AID mRNA expression profile within a time-course experiment. 
It was noted with interest that AID mRNA was detected for the first time in the allergic 
nasal mucosa, supporting the concept of local CSR and SRM. When RT-PCR was 
employed to amplify AID mRNA from nasal biopsy samples, initial results suggested 
the presence of AID in only one sample (DR20). When a nested PCR was employed 
however, it was evident that AID mRNA was present in the nasal mucosa of five out of 
seven allergic rhinitis patients at a lower, but indisputable level. In DR20 it is possible 
that the strong AID mRNA expression, evident even without nested PCR amplification, 
was a consequence of cellular stimulation five to seven days previously and that the B 
cells(s) were at the peak of their AID mRNA expression and therefore again a 
consequence of sampling. 
This may mean that AID mRNA expression by nasal mucosal B cells was initially 
induced in the lymphoid tissue, but that migration of the B cell(s) to the nasal mucosa 
enabled the expression to be maintained as a consequence of the local IL4 rich 
environment. It is also possible that the local microenvironment alone is sufficient to 
induce AID expression in B cells in the nasal mucosa. More research to determine the 
length of time of stimulation with EL-4 and anti-CD40 necessary to initiate and maintain 
AID mRNA expression needs to be carried out to elucidate which of these is the most 
likely. Further work to investigate the expression of AID within a single cell, rather 
than a population of cells would also contribute to understanding this. Optimisation of 
the in vitro incubation of nasal biopsies (unsuccessful in this study) to determine both 
the length of time that AID mRNA expression is maintained in tissue and also whether 
AID expression can be stimulated in vitro by allergen-challenge will also be of 
importance. 
As with the investigation of local SHM and the spacial distribution of related cells, the 
presence or absence of AID reinforced the concept of the nasal mucosa consisting of 
confined areas of activity. Definite evidence of AID m. RNA expression was detected 
from one part of a double biopsy but not the other, in biopsies from patients TL25 and 
ZC27. Immunohistochemistry to detect AID in the nasal mucosa of allergic rhinitis 
patients would be of particular interest to determine both the presence of the AID 
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protein and also the distribution of AID expression across the inferior turbinate, 
especially in comparison with the distribution of CD 19+ B cell clusters (see chapter 6). 
It was interesting that of the nasal biopsies from the two allergic rhinitis patients in 
which VH-CF- expression had previously been analysed (CM 10 and AP 19 in chapter 4), 
AID expression was evident in CMIO from which no reliable evidence of related B cell 
clones was detected, but was absent from AP19 from which a family of related IgE B 
cell clones had been detected. This suggests again that sampling may be of key 
importance; if the same biopsy had been taken from CMIO a day later for example, 
evidence of local CSR and SHM in the form of clonally related B cells may have been 
detected. The lack of AID mRNA expression in AP19 may indicate that the related B 
cell clones resulted from earlier SEM and clonal expansion. Detection of the clones 
may even have been facilitated by their maturation into plasma cells and the consequent 
increase in VH-CS mRNA available for PCR amplification. 
There was no apparent correlation between the time of year at which the allergic 
patients were biopsied and the presence or absence of AID mRNA expression. 
Furthermore, although no AID mRNA was amplified from the unsuccessful in vivo 
grass pollen challenge of out of season patients (as might have been expected if AID 
mRNA expression was maintained in the absence of allergen), future work should be 
carried out to determine whether expression is maintained throughout the year in 
seasonal allergic rhinitis patients. 
No clear expression of AID mRNA could be detected from the nasal biopsies of six 
normal subjects. This correlated with the high IL4 and T cell rich environment being 
peculiar to the allergic mucosa [Varney et al., 1992], [Ying et al., 1994] and necessary 
to induce (or possibly maintain) AIOD expression in nasal B cells. In two of the normal 
subjects faint AID expression, evident by Southern blot analysis was detected in one of 
the repeat experiments, but was not reproducible. It is possible, if genuine, that this 
expression was a consequence of residual low-level AID mRNA expression by aB cell 
that had been stimulated previously in the lymphoid tissue. It is also always possible 
that a 'normal' patient may be allergic to an allergen not included on the skin-prick test 
panel. 
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In the course of the experimental investigation into AID mRNA expression, it became 
evident that splice variants of AID were detected in PBMC and the RAMOS cell line 
(there was no apparent evidence of this in the nasal biopsy samples). Initially, there 
were no published reports of AID mRNA splice variants. However, in 2001 their 
existence was confirmed by a publication that also documented linkage between 
inherited AID polymorphisms and asthma [Noguchi et aL, 2001]. In the study 
presented in this chapter, a splice variant characterised by the complete deletion of exon 
four was detected (532 bp). Noguchi et al. also detected this variant and also concluded 
that it was unlikely to have any activity given the distortion of the protein by the 
deletion of exons four and five in the amino acid sequence. Furthermore, Noguchi et al. 
were able to confirm that the truncated transcript was a mRNA splice variant by 
comparison with their patients' genomic AID sequence [Noguchi et al., 2001]. In 
addition they also described a splice variant in which just 30 bp were deleted from exon 
four, which was not isolated in this study. 
Noguchi el al. did not however comment upon the suggested AID splice variants 
detected in this study at approximately 950 bp and 1400 bp, hypothesized to be a 
consequence of the ineffective removal of the introns between exon three and four, or 
three, four and five respectively. While it is interesting to note the apparent inefficiency 
of the splicing of AID mRNA, this data highlights the importance of ensuring that AID 
mRNA amplification products are from viable, full-length mRNA transcripts. Noguchi 
et al. determined that there was no association between the presence of the AID splice 
variants and the presence of an AID polymorphism that they detected in exon four 
(7888C/T). However, this polymorphism was demonstrated to have an association with 
asthma and raised total serum IgE levels. It may therefore be interesting in the future to 
sequence all the PCR products amplified from the nasal biopsy samples in this study to 
analyse the presence of the 7888C/T polymorphism and determine whether such an 
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9.1 Final discussion. 
Local production of allergen specific IgE protein had previously been shown to occur in 
the nasal mucosa of allergic rhinitis patients [Smurthwaite el al, 2001] and the presence 
of both IgE' CD19' B cells and also IgE+ CD138+ plasma B cells identified in the 
allergic nasal mucosa [KleinJan et al., 2000]. In addition, local production of IgE was 
shown to occur even in biopsies taken from grass pollen allergic patients outside of the 
pollen season, suggesting that the allergic mucosa was continuously primed to respond 
to allergen with immediate hypersensitivity. Furthermore, the production of allergen 
specific IgE from the allergic nasal mucosa correlated more closely with the patient's 
skin-prick test results and medical history than with the allergen specific IgE detected in 
the patient's serum [Smurthwaite el al., 2001], [L. Smurthwaite, personal 
communication]. 
Other researchers demonstrated that when biopsies were taken from grass pollen 
allergic rhinitis patients after challenge with grass pollen allergen out of season, 
exposure to allergen correlated with an induction of EL4 m. RNA and e germline 
transcripts [Durham et al., 1997]. An increased number of cells expressing UL4 m. RNA 
and e germline transcripts was also observed in allergic asthmatic patients, compared to 
controls [Ying et al., 2001]. This suggested that the local microenvironment of the 
allergic mucosa was such that local class switch recombination to IgE might occur 
locally, consistent with the need for an immediate response to allergen. Support for this 
hypothesis was provided by analysis of VH-Ce sequences amplified from the lung 
mucosa of an allergic asthmatic, which, on the basis of sequences from clonally related 
B cells, suggested that in addition to local class switch recombination, local somatic 
hypermutation and clonal expansion of B cells also occurred [Snow et al., 19991. 
In the previous five chapters, research undertaken to understand the molecular 
mechanisms of allergic rhinitis has been presented. This work has encompassed 
investigation to determine whether local somatic hypermutation and clonal expansion, 
local class switch recombination and also the local production of activation-induced 
cytidine deaminase occurs in the allergic nasal mucosa. In addition, the distribution of 
clonally related B cells and preliminary work to investigate the geographical 
distribution of B cells in the nasal mucosa was carried out. 
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In chapter 4, analysis Of VH-C& sequences RT-PCR amplified from the nasal mucosa, 
and for comparison, the PBMC of seven allergic rhinitis patients was undertaken. 
Sequences were deemed to have resulted from clonally related IgE' B cell clones if they 
exhibited a clonal signature region that resulted ftorn the same VH-D-JH recombination 
event in a shared progenitor cell. In addition, these sequences exhibited both shared and 
unique somatic mutations acquired in a step-wise fashion as a consequence of the 
diversification of the B cell clonal family. Three distinct families of clonally related 
IgE+ B cell clones were isolated from the nasal mucosa of two of the seven allergic 
rhinitis patients. Each family of related B cell clones consisted of two or three closely 
related members. 
In contrast, only one family of related B cell clones was isolated from the PBMC 
samples provided by the seven allergic rhinitis patients. This family comprised two 
members that were more distantly related than any observed in the nasal mucosa, 
differing by many more mutations. Sequence analysis also suggested that while 
identical sister clones were present in both the nasal mucosa. and PBMC of each of three 
of the patients, in one patient a clone was identified in the PBMC, that appeared to have 
diverged at an earlier stage in the evolution of a family of IgE' B cell clones isolated 
fi7om that patient's nasal mucosa. 
These results suggested that successive cycles of somatic hypermutation and clonal 
expansion had indeed occurred locally in the allergic nasal mucosa of at least two of the 
seven allergic rhinitis patients, resulting in the presence of closely related sister B cell 
clones in close proximity within the inferior turbinate. The alternative, that the cells 
had migrated individually from the lymphoid tissue to the same 2.5 min 3 of the nasal 
mucosa from which the biopsy was taken, seemed too unlikely to be feasible, 
particularly as later work confirmed that the B cell repertoire of the allergic nasal 
mucosa was diverse and that related B cells from the same clonal family did not appear 
to be spread throughout the tissue. No VH-CE sequences could be amplified from the 
nasal mucosa of a healthy, non-atopic subject who exhibited an extremely high level of 
total serum IgE, suggesting that the local occurrence of such IgE' B cells was a feature 
of the local microenvironment of the nose in allergic rhinitis and not simply a result of 
the elevated serum IgE levels observed in those patients. 
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In chapter 5, a RT-PCR approach was utilised to determine from the amplification of 
VH-CH sequences from B cells expressing IgK IgA or IgG, whether evidence of local 
class switch recombination was present in the allergic nasal mucosa. In one patient, five 
IgA' B cell clones were identified from the nasal mucosa that were further members of 
an IgE' B cell clonal family, previously identified in the same nasal biopsy. This data 
strengthened previous observations that local somatic mutation had occurred, but 
importantly it also suggested that switching had occurred locally. Again, it was unlikely 
that related IgA and IgE B cells, resulting from class switch recombination in the 
lymphoid tissue would have migrated to exactly the same area of the nasal mucosa. 
This observation has subsequently been supported by the detection of local switch circle 
transcripts in the nasal mucosa of allergic rhinitis patients [Takhar el al., manuscript in 
preparation]. Interestingly, while the direction of the switch event, from an upstream 
isotype to both IgE and IgA or from IgE to IgA(2) for example, was not determined, 
previous researchers had only isolated IgM and IgG sequences from B cells related to 
IgE+ sister clones from the allergic lung mucosa [Snow el al., 1999]. 
As the results of these experiments supported the hypothesis of local somatic 
hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis 
patients, it was of obvious importance to identify whether activation-induced cytidine 
deaminase (AlD) was also present locally (chapter 8), (see publication included in 
appendix E). AED has been shown to be required for both class switch recombination 
and somatic hypermutation [Muramatsu et al., 1999], [Muramatsu el al., 2000], [Revy 
et al., 2000], [Fagarasan et al., 2001 ]. Its presence would therefore be expected to be 
necessary to support such a hypothesis of local events in the allergic nasal mucosa. The 
presence of mRNA encoding the full length AID transcript was indeed detected in five 
of the seven allergic rhinitis patients analysed. Furthermore, expression of AED mRNA 
was not evident in the nasal mucosa of the majority of normal subjects. Therefore, not 
only does the presence of AID support the hypothesis of local class switch 
recombination and somatic hypermutation in the allergic nasal mucosa, but its apparent 
absence from the nasal mucosa of normal subjects implies that the environment of the 
normal nasal mucosa, at least in times of health, is not suitable for switching or somatic 
mutation, even though this would perhaps be a sensible attribute. 
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In respect of both somatic hypermutation, class switch recombination and AID 
expression, only samples from some allergic rhinitis patients yielded positive results. 
As there was no apparent difference between patients from whom positive compared to 
negative results were obtained, it was suggested that the sampling of the inferior 
turbinate might be responsible. The consistency of the cellular content of the inferior 
turbinate has not been investigated and it was proposed that if clonally related B cells 
were present in small groups or clusters that such clusters might be randomly excluded 
from the biopsy of one patient, but included in another. 
When VH-Cs sequences were analysed from adjacent pieces of tissue (chapter 6) it was 
evident that there was both a wide repertoire of IgE+ B cells in the allergic nasal mucosa 
and also that the related IgE+ B cell clones appeared to be concentrated in a small 
geographical area, as there was no evidence either of related or identical sister clones 
being present in adjacent pieces of tissue, even when the two halves of a nasal biopsy 
were examined. Furthermore, preliminary IHC (chapter 6) identified clusters of CD19+ 
B cells in the nasal mucosa for the first time, while IgE+ CD 138+ plasma cells appeared 
to occur individually. 
Detailed analysis of VH-Ce sequences isolated from the allergic rhinitis patients also 
supported the concept of the allergic nasal mucosa as a unique microenvironment. 
There was a highly significant difference in the usage Of VH5 in the allergic nasal 
mucosa compared to both that expected on the basis of the normal, rearranged genomic 
repertoire of the PBMC and also, importantly, that observed in the allergic PBMC. 
Even this biased use Of VH5 was not observed in all patients, or even in adjacent 
biopsies from the same patient, again suggestive of extreme local differences in the B 
cell clonal composition of the inferior turbinate. 
When the VH5 sequences from the nasal mucosa of the allergic rhinitis patients were 
analysed in greater detail, they exhibited an unusual distribution of somatic mutations 
across the VH region. There was evidence of four potential non-intrinsic hotspots of 
mutation in the VH5 sequences, suggesting that the VH5 sequences were targeted 
towards a restricted repertoire of antigens. Unusually however, three of the non- 
intrinsic hotspots of mutation were situated in FWRL The fourth non-intrinsic hotspot 
occurred in CDR2. Significantly, these non-intrinsic hotspots had all been previously 
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identified in VH5 sequences amplified from the PBMC of allergic asthmatic patients 
[Snow el al., 1997) 
When the R/S values in the CDRs and FWRs were compared between the VH5 and non- 
V115 sequences, the FWRs were shown to be subject to a greater degree of mutation in 
the VH5 sequences and the normally significant difference observed between the FWR 
and CDR R/S values was abolished. In combination, the VH5 bias, the unusual non- 
intrinsic hotspots of mutation and the unusual R/S values in the VH5 sequences, 
suggested that in some patients, antigen selection by aB cell superantigen had occurred 
in the allergic nasal mucosa, consistent with that concluded by previous researchers in 
the allergic lung mucosa [Snow et al., 1999] and the spleen of an allergic asthmatic 
[Snow el al., 1995]. However, results from this study suggested that the effect of the 
superantigen was locally confined, in contrast to asthma and allergic dermatitis, in 
which similar trends were identified in the patient's PBMC [Snow et al., 1997], [Van 
der Stoep et al., 1993]. In this study a further hypothesis was proposed, that the B cell 
superantigen was likely to interact writh FWRI of VH5 and also possibly CDR2 and 
FWR3. 
Therefore, while the data presented in this thesis is largely circumstantial, it strongly 
supports the hypothesis that local class switch recombination, somatic hypermutation 
and clonal expansion occur locally in allergic rhinitis patients. This would appear to be 
coordinated by the local activity of activation-induced cytidine deaminase and as a 
consequence of the unique microenvironment of the allergic nasal mucosa. Exposure to 
allergenic antigens and possibly a superantigen(s) predispose and exacerbate the 
symptoms of allergic disease. Understanding fully the molecular mechanisms 
responsible for such allergy is of vital importance for the progression of therapies 
which, as a consequence of this and others research may now be targeted in a local 
fashion, thus enabling a much wider range of drugs, to treat the bacterial source of a 
superantigen, or to inhibit AID for example, to be contemplated. 
Further work is being carried out by a subsequent PhD student to try to elucidate many 
of the interesting questions that have arisen as a result of the research presented in this 
thesis. In particular, further work has been targeted towards understanding the cellular 
composition of the nasal mucosa, especially with respect to clusters of CD19+ B cells. 
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A greater number of well-characterised allergic and normal mucosa samples need to be 
analysed. From these samples it will be important to determine how frequently such 
CD19' B cell clusters occur and whether they are associated with the allergic state. In 
addition, it will be important to optimise both the IgE' CD19, - double staining protocol 
to determine the distribution of such cells in the nasal mucosa and also to identify 
whether other cell types such as T cells or dendritic cells, for example, are present 
within, or close to, the clusters of CD19' B cells. Whilst the presence of AID mRNA in 
the allergic nasal mucosa has been identified in this study, it would also be of interest to 
utilise immunohistochernistry to confirm the presence of the AID protein and to identify 
if it is expressed by B cells associated with particular areas within the mucosa, such as 
the CD19' B cell clusters. It will also be of importance to determine whether such 
CD19 +B cell clusters are associated with local SHNt clonal expansion and CSR and 
whether they resemble germinal centre B cells. 
The other major area of research to be pursued ffirther, is to identify the significance of 
the increased VH5 use by B cells within the allergic nasal mucosa. Initially, work has 
progressed to study somatic mutations acquired in out-of-frame VH5 sequences from 
normal subjects. As antigen selection can have placed no pressure upon the acquisition 
of these mutations, this should provide a more comprehensive picture of the intrinsic 
pattern of somatic mutation acquired by VH5 sequences and is therefore of importance 
in confirming whether the non-intrinsic hotspots of mutation identified in chapter 7 are 
indeed likely to be antigen dependent. The use Of VH5 by other antibody isotypes in the 
allergic nasal mucosa is also to be investigated. 
Future work has also been directed towards identifying the putative superantigen, 
proposed on the basis both of the increased use Of VH5 in the allergic nasal mucosa and 
the unusual non-intrinsic mutations that were identified from those sequences. It is 
hoped that this may be achieved by the amplification, cloning and expression of Fabs, 
isolated from singleVH5 IgE+ B cells, FACS sorted from the allergic inferior turbinate. 
To date, there are no crystal structures of any VH5 molecule. In the interim, molecular 
modelling may enable the positions of the potential non-intrinsic mutations to be 
studied, but ultimately, it is hoped that this work may generate a crystal structure of 
VH5. It is also anticipated that screening of these VH5 Fabs may enable the 
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Appendix A- DNA polymerase error rates. 
In chapter 4 the difference in the experimental error rate when Taq and Pfu DNA 
polymerase were used was compared. The experimental error rates of Taq DNA 
polymerase (Fig. A. 1) and Pfu DNA polymerase (Fig. A. 2) were calculated as the 
number of mutations / number of base pairs amplified / number of cycles of PCR 
amplification. This was determined from analysis of the mutations introduced into Ce 
amplified in theVH-CE RT-PCR. The contribution of errors from other sources such as 
the reverse transcriptase step were not analysed separately from this overall error rate. 

































FIG. A. 1: Alignment of Cc sequences ampiffled by VxCe RTýPCR emipfiffcaWn with 
DNA Dolymerase. Thirty-two Cc sequences amplified from the nasal biopsy and PBMC 
samples of patient SI-5 by Taq DNA polymerase, are aligned to the germline Cc sequence at the 
top of the figure. Sequences highlighted in red include a mutation from this germline Cc 
sequence and were used to calculate the experimental error rate. 
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Four mutations were evident in the 1888 bp of Ce sequence amplified by T2q DNA 
polymerase, an error rate of, 
no. of mutations / no. of base pairs amplified / no. of cycles of PCR amplification 
(4 / 1888) / 60 = 3.53 x 10-5 inut bp-1 dup-1 
This equates to one mutation being erroneously incorporated in experimental conditions 
including Taq DNA polymerase in approximately every 2 VH regions analysed (each VH 
region being approximately 282 bp). 
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Fid. A. 2: Alionment of Cc seouences ampiffled by VcC. - RT-PCR amvifflcation wfth 
DNA PoNmerese. The thirty-two CE sequences amplified from the nasal biopsy and PBMC 
samples of seven patients (CD6, JB7, CM10, HD14, S016, HD17 and AP19) by Pfu DNA 
polymerase are aligned to the germline Cr, sequence at the top of the figure. Sequences 
highlighted in red include a mutation from this germline Cc sequence and were used to calculate 
the experimental erTor rate. 
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Two mutations were evident in the 9440 bp of Cc sequence amplified by Pfii DNA 
polymerase, an error rate of, 
no. of mutations / no. of base pairs amplified / no. of cycles of PCR amplification 
(2 / (9440) / 60 = 3.53 x 10-6 mut bp-1 dup-1 
This equates to one mutation being erroneously incorporated in experimental conditions 
including Pfu DNA polymerase in approximately every 17 VH regions analysed (each 
VH region being approximately 282 bp). 
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Appendix B- Chi-squared data. 
In appendix B the data used to determine statistical significance according to the chi 
squared test is detailed. 
The equation applied to the data was as follows; 
([observed-expected] - 0.5)2 / expected 
This includes Yates' Correction for Continuity, which demands the subtraction of 0.5 
from the [observed-expected]. This consequently results in a more conservative 
calculation of significance and is advisable when 'expected' values are less than 10. 
Chi-squared analysis was used in chapter 7 to demonstrate the significance between the 
VH gene usage in the allergic nasal mucosa compared to that expected. Expected values 
were based on the in-frame genomic rearrangements in normal PBMC observed by 
Brezinschek et al., 2000. 
Comparison of VH5 usage in the nasal mucosa of allergic rhinitis gatients and 
normal PBMC. 
Raw data - observed number of sequences from eleven allergic rhinitis patients 
(detailed in Table 7.2.1) and an undefined number of normal patients [Brezinschek el 
2000] 
VHS Non-VH5 Total 
Allergic nasal mucosa 18 44 62 
Normal PBMC 12 409 421 
Total 30 453 483 
Expected values - ((column total x row total grand total) 
VH5 Non-VH5 
Allergic nasal mucosa 3.85 58.14 
Normal PBMC 26.14 394.85 
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Chi-4uared values - ([observed-expected] - 0.5) 
2/ expected) 
VH5 Non-VH5 
Allergic nasal mucosa 48.3955 3.2000 
Normal PBMC 7.1174 0.4719 
Total chi-squared value = 59.1848 
The critical values for chi-squared distribution [Fentem, 1996] with one degree of 
freedom are; 
p value 0.99 0.975 0.95 0.9 0.1 0.05 0.025 0.01 0.005 
Chi-squared 0.000 0.001 0.004 0.016 2.706 3.841 5.024 6.635 7.879 
The chi squared value therefore equates with ap value of 0.05 - 0.025 
When p<0.05 = the difference is significant, when p<0.01 the difference is highly 
significant. 
The difference between VH5 gene usage in allergic rhinitis patients and normal 
PBMC is therefore highly significant. 
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Comparison Of VH5 gene usage in the nasal mucosa of allergic rhinitis patients and 
normal PBMC. 
Raw data - observed number of sequences from seven allergic rhinitis patients 
(excluding the major VH5 contributor CA30, as detailed in chapter 7) and an undefined 
number of normal patients [Brezinschek et al., 2000]. 
VH5 Non-VH: 5 Total 
Allergic nasal mucosa 6 31 37 
Normal PBMC 12 409 421 
Total 18 440 458 
ENpected values - ((column total x row total )/ grand total) 
VH5 Non-VH5 
Allergic nasal mucosa 1.45 35.55 
Normal PBMC 16.55 404.45 
Chi-squared values - ([observed-expected] - 0.5)2 / expected) 
V115 Non-VH5 
Allergic nasal mucosa 11.3121 0.4614 
Normal PBMC 0.9911 0.0406 
Total chi-squared value = 12.8052 
The difference between VH5 usage in the allergic rhinitis patients (excluding CA30) 
and normal PBMC is therefore still highly significant. 
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Comvarison Of VH5 gene usage in aflergic and normal PBMC. 
Raw data - observed number of sequences from seven allergic rhinitis patients (detailed 
in Table 7.2.1) and an undefined number of normal patients [Brezinschek el al., 2000]. 
VH5 NOn-VH5 Total 
Allergic PBMC 4 46 50 
Normal PBMC 12 409 421 
Total 16 455 471 
Expected values - ((column total x row total )/ grand total) 
VH5 NOn-VH5 
Allergic PBMC 1.70 48.30 
Normal PBMC 14.30 406.70 
Chi-squared values - ([observed-expected] - 0.5)2 / expected) 
VH5 non-VH5 
Allergic PBMC 1.9059 0.0671 
Normal PBMC 0.2266 0.0080 
Total chi-squared value =2.2076 
The difference between VH5 usage in allergic and normal PBMC is not therefore 
significant. 
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ComRarison of V115 gene usage in the nasal mucosa and PBMC of allerizic rhinitis 
vatients. 
Raw data - observed number of sequences from the nasal mucosa of eleven allergic 
rhinitis patients (detailed in Table 7.2.1) and from the PBMC of seven allergic rhinitis 
patients. 
VH5 Non-VH5 Total 
Allergic nasal mucosa 18 44 62 
Allergic PBMC 4 46 50 
Total 22 90 112 
Expected values - ((column total x row total )/ grand total) 
VH5 Non-VH5 
Allergic nasal mucosa 12.18 49.82 
Allergic PBMC 9.82 40.18 
Chi-squared values - ([observed-expected] - 0.5)2 / expected) 
VH5 Non-VH5 
Allergic nasal mucosa 2.3237 0.5681 
Allergic PBMC 2.8821 0.7044 
Total chi-4uared value = 6.4783 
The difference between VH5 usage in the allergic nasal mucosa and allergic PBMC 
is therefore of significance. 
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Comparison Of VH5 gene usage in the nasal mucosa and PBMC of allergic rhinitis 
patients. 
Raw data - observed number of sequences from seven allergic rhinitis patients 
(excluding the major VH5 contributor CA30, as detailed in chapter 7) and from the 
PBMC of seven allergic rhinitis patients. 
VH5 Non-VH5 Total 
Allergic nasal mucosa 6 31 37 
Allergic PBMC 4 46 50 
Total 10 77 87 
Expected values - ((column total x row total )/ grand total) 
VH5 Non-VH5 
Allergic nasal mucosa 4.25 32.75 
Allergic PBMC 5.75 44.25 
Chi-4uared values - ([observed-expected] - 0.5)2 / expected) 
VH5 Non-VH5 
Allergic nasal mucosa 0.3676 0.0477 
Allergic PBMC 0.2717 0.0353 
Total chi-squared value = 0.7223 
The difference between VH5 usage in the allergic nasal mucosa and allergic PBMC 
(excluding CA30) is not therefore of significance. 
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Comparison of VH3 usage in the nasal mucosa of allel: gic rhinitis patients and 
normal PBMC. 
Raw data - observed number of sequences from eleven allergic rhinitis patients 
(detailed in Table 7.2.1) and an undefined number of normal patients [Brezinschek el 
al., 2000]. 
VH3 Non-VH3 
Allergic nasal mucosa 21 41 
Normal PBMC 232 189 
Total 253 230 
ENpected values - ((column total x row total grand total) 
VH3 Non-VH3 
Allergic nasal mucosa 32.48 29.52 
Normal PBMC 220.52 200.48 
Chi-squared values - ([observed-expected] _ 0.5)2 / expected) 
VH3 Non-V, 13 
Allergic nasal mucosa 3.7118 4.0840 
Normal PBMC 0.5467 0.6014 





The difference between VH3 gene usage in allergic rhinitis patients and normal 
PBMC is therefore highly significant. 
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Comparison of VH3 gene usage in allergic and normal PBMC. 
Raw dat - observed number of sequences from seven allergic rhinitis patients (detailed 
in Table 7.2.1) and an undefined number of normal patients [Brezinschek et al., 2000]. 
VH3 Non-V, 13 Total 
Allergic PBMC 25 25 50 
Normal PBMC 232 189 421 
Total 257 214 471 
Expected values - ((column total x row total )/ grand total) 
VH3 Non-VH3 
Allergic PBMC 27.28 22.72 
Normal PBMC 229.72 191.28 
Chi-aguared values - ([observed-expected] - 0.5)' / expected) 
ViE[3 non-VH3 
Allergic PBMC 0.1161 0.1395 
Normal PBMC 0.0138 0.0166 
Total chi-aquared value --0.286 
The difference between VH3 usage in allergic and normal PBMC is not therefore 
significant. 
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ComDarison of Vjj3 gene usage in the nasal mucosa and PBMC of allergic rhinitis 
lRatients. 
Raw dat - observed number of sequences from the nasal mucosa of eleven allergic 
rhinitis patients (detailed in Table 7.2.1) and from the PBMC of seven allergic rhinitis 
patients. 
VH3 Non-VH3 Total 
Allergic nasal mucosa 21 41 62 
Allergic PBMC 25 25 50 
Total 46 66 112 
Enected values - ((column total x row total )/ grand total) 
VH3 Non-VH3 
Allergic nasal mucosa 25.46 36.54 
Allergic PBMC 20.54 29.46 
Chi-Nuared values - ([observed-expected] - 
0.5)2 / expected) 
VH3 Non-V113 
Allergic nasal mucosa 0.6159 0.4292 
Allergic PBMC 0.7635 0.5323 
Total chi-squared value = 2.3409 
The difference between VH3 usage in the allergic nasal mucosa and allergic PBMC 
is not therefore significant. 
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Chi-squared analysis was also used to analyse the difference between the observed and 
expected R/S values in the FWRs compared to the CDRs in VH5 and non-VH5 
sequences (chapter 7). 
ComDarison of R/S values in the CDR and FWR of VH5 seguences from allergic 
rhinitis Datients (seventeen seauences). 
Raw data 
CDR FWR Total 
Replacement mutations 76 146 222 
Silent mutations 32 71 103 
Total 108 217 325 
Expected values - ((column total x row total )/ grand total) 
CDR FWR 
Replacement mutations 73.77 148.23 
Silent mutations 34.23 68.77 
Chi-Nuared values - ([observed-expected] - 0.5)2 / expected) 
CDR FWR 
Replacement mutations 0.0406 0.0202 
Silent mutations 0.0874 0.0435 
Total chi-Nuared value = 0.1917 
The difference between the R/S values in the CDR and FWR of the VH5 sequences 
from the allergic nasal mucosa is not therefore significant. 
ADDendix B 226 
ComiDarison of R/S values in the CDR and FWR of non-VH5 seguences from 
allergic rhinitis patients (nineteen seguences). 
Raw data 
CDR FWR Total 
Replacement mutations 83 107 190 
Silent mutations 24 64 88 
Total 107 171 278 
Expected values - ((column total x row total )/ grand total) 
CDR FWR 
Replacement mutations 73.13 116.87 
Silent mutations 33.87 54.13 
Chi-Nuared values - ([observed-expected] - 0.5)2 
/ expected) 
CDR FWR 
Replacement mutations 1.2006 0.7512 
Silent mutations 2.5922 1.6220 
Total chi-squared value = 6.166 
The difference between the R/S values in the CDR and FWR of the non-VH5 
sequences from the allergic nasal mucosa is therefore significant. 
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Appendix C- Directionality of somatic hypermutation. 
In chapter 7 the expected direction of somatic mutation, predicted on the basis of the 
intrinsic bias of SIHM, was calculated and compared to the number of mutations 
observed at hotspots in theVH5 and non-VH5 data sets. A departure from the expected 
values indicated that the mutation was likely to be a non-intrinsic hotspot, selected by 
antigen. The expected direction of mutation was predicted on the basis of the 
preferences of SEM that were determined by Betz el al., 1993b, detailed below. 
To T c A G 
From 
T 0.52 0.31 0.17 
c 0.74 - 0.09 0.17 
A 0.29 0.19 - 0.52 
G 0.09 0.32 0.59 - 
Table C. 1. The subs"on mWtmces of sonodc hvperynutaWn [Betz et at.. 1993bl. 
Therefore, if ten mutations occurred at a hotspot substituting X the predicted direction 
of mutation would be; 
2 (0.19 x 10) 
5 (0.52 x 10) 
3 (0.29 x 10) 
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Appendix D- R/S values. 
In chapter 7, the distribution of replacement and silent mutations were analysed by 
comparing the R/S values in different data sets. Replacement mutations generated a 
change in the amino acid, while silent mutations had no effect on the amino acid that 
was encoded. This meant that the number of individual nucleotide mutated within a 
codon could not be taken into account. Only one sequence was used to represent a 
family of related B cells clones, however each mutation in any clone from that family 
was included once in that representative sequence. 
Initially the overall R/S values in the CDRs and FWRs were compared between the VH5 
and non-VH5 sequences (Table 7.4.1 details both the final R/S values and the raw data). 
These overall R/S values were calculated by pooling the total number of replacement 
and number of silent mutations observed in the sequences comprising each data set 
e. g. the overall R/S value in the VH5 CDR = 
total no. replacement / total no. silent mutations in the CDRs of the VH5 sequences 
76 / 32 = 2.06 
The overall R/S value of the combined FWRs and also the combined CDRs was also 
calculated for each individual sequence (Table 7.4.2). The raw data and final R/S 
values for each of these sequences is detailed below in Tables D. I and D. 2. 
In instances where there were zero silent mutations, but there were replacement 
mutations, the R/S value was preceded by >- Where there were zero replacement 
mutations, but there were silent mutations, the R/S value was preceded by <. While not 
strictly accurate this was determined to be the best way in which to distinguish such 
values. This was only an issue when individual sequences were examined and did not 
affect the overall interpretation of any of the results. 
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CDR FWR 
R s R/S R s R/S 
HD14 C7 6 1 6.0 8 4 2.0 
sols Cil 6 1 6.0 10 4 2.5 
CA30A Cl 2 6 0 >6.0 6 3 2.0 
CA30A Cl 1 6 1 6.0 12 5 2.4 
CA30A Cl 6 4 1 4.0 6 4 1.5 
CA30A C22 5 1 5.0 6 12 0.5 
CA30A C4b 4 0 >4.0 8 5 1.6 
HD14 C12 1 4 0.3 5 3 1.7 
TL25B C8 4 2 2.0 4 2 2.0 
CA30A C8 7 2 3.5 6 2 3.0 
CA30A C17 6 2 3.0 10 4 2.5 
CA30A C3 3 5 0.6 9 10 0.9 
CA30A C20 5 3 1.7 12 5 2.4 
HD14 C19 3 2 1.5 6 0 >6.0 
AN 9 C2 2 4 0.5 11 3 3.7 
CA30A CS 4 0 >4.0 5 1 5.0 
CA30A C3b 4 3 1.3 20 4 5.0 
Table D. I. The raw numbers of replacement (R) and silent (S) mutations and the 
value in the CDR and FWR of each YA sequence amgIffied from the allemic nasal 
mucosa (ordered to correspond with Table 7.4.2). 
Appendix D 230 
CDR FWR 
R s R/S R s R/S 
CD6 Cl 3 1 3.0 4 2 2.0 
CD6C13 7 1 7.0 5 2 2.5 
HD14 C2 5 0 >5.0 8 3 2.7 
HD14 C4 8 2 4.0 8 8 1.0 
HD14 Cl 1 3 1 3.0 6 4 1.5 
HD14 C16 5 1 5.0 5 5 1.0 
S016 C13 5 1 5.0 2 1 2.0 
CA30B C7 5 0 >5.0 5 3 1.7 
TL25A C17 7 2 3.5 5 3 1.7 
CD6 C12 2 2 1.0 7 3 2.3 
CD6 C2 3 2 1.5 7 5 1.4 
HD14 C9 7 3 2.3 7 6 1.2 
AP19CI6 2 2 1.0 0 1 <1.0 
CA30B C8 1 0 >1.0 3 5 0.6 
CA30B C19 5 3 1.7 10 4 2.5 
CD6 C5 3 1 3.0 5 1 5.0 
AP19 C3 2 0 >2.0 4 1 4.0 
AP19 C6 3 2 1.5 7 2 3.5 
Tabie D. 2: The raw numbers of replacement [R) and silent IS) mut&Vbns and the RIS 
value in the CDR and FWR of each non-YA seguence ampiffied from the allemk n&wi 
muc (ordered to correspond with Table 7.4.2). 
The R/S values of each of the FWRs, 1,2 and 3 were also determined for each 
individualVH5 sequence. The overallVH5 FV*rRl, 2 and 3 R/S values were additionally 
calculated for the combined sequences (Table D. 3). 
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FWRI FWR2 FWR3 
R s R/S R s R/S R s R/S 
HD14 C7 3 1 3.0 1 1 1.0 4 2 2.0 
S016 CII 4 1 4.0 0 2 <2.0 6 0 >6.0 
CA30A Cl 2 2 2 1.0 0 0 0.0 4 1 4.0 
CA30A Cl 1 5 1 5.0 1 1 1.0 6 3 2.0 
CA30A C16 1 1 1.0 0 2 <2.0 5 1 5.0 
CA30A C22 1 4 0.25 2 2 1.0 3 6 0.5 
CA30A CO 3 3 1.0 2 1 2.0 3 1 3.0 
HD14 C12 2 1 2.0 0 0 0.0 1 1 1.0 
TL25B C8 2 0 >2.0 1 1 1.0 1 1 1.0 
CA30A C8 4 1 4.0 0 0 0.0 2 1 2.0 
CA30A C17 2 2 1.0 2 1 2.0 6 1 6.0 
CA30A C3 3 4 0.6 0 2 <2.0 6 4 1.5 
CA30A C20 5 1 5.0 2 1 2.0 5 3 1.7 
HD14 C19 2 0 >2.0 0 0 0.0 4 0 >4.0 
AP19 C2 4 1 4.0 2 2 1.0 5 0 >5.0 
CA30A C5 4 1 4.0 2 1 2.0 2 0 >2.0 
CA30A C3b 7 1 7.0 3 0 >3.0 10 3 3.3 
Combined 54 25 2.16 17 16 1.06 73 28 2.61 
Table D. 3. The raw numbers of replacement (M and silent (S) mutabons and the RIS 
value in FWRI. 2 and 3 of each VN, 5 seguence and the combined sequences. a 
from the allegivic nasal mucossfordered to correspond vAth Table 7.4.2). 
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The FWR3 R/S values of the non-VH5 sequences was also calculated (Table D. 4). 
FWR3 
R s R/S 
CD6 Cl 4 2 2.0 
CD6CI3 4 1 4.0 
HD14 C2 6 2 3.0 
HD14 C4 6 7 0.9 
HD14 Cl 1 1 3 0.3 
HD14 C16 2 3 0.7 
S016 C13 1 1 1.0 
CA30B C7 2 3 0.7 
TL25A C17 4 3 1.3 
CD6 C12 6 2 3.0 
CD6 C2 4 2 2.0 
HD14 C9 5 4 1.3 
AP19CIS 0 1 <1.0 
CA30B C8 2 2 1.0 
CA30B CIS 6 2 3.0 
CD6 C5 5 1 5.0 
AP19 C3 3 1 3.0 
AP19 CS 5 2 2.5 
Combined 69 44 1.57 
Table DA The raw numbefs of reviacement IR) and silent (S) mutadons and the W 
value in FWR3 of each non-M seguence and the combined seguences. ampiffled fro 
the allergic nasal mucosa (ordered to correspond with Table 7.4.2). 
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Appendix E- Related publication. 
Publication in press: 
Coker, H. A., Durham, S. k, Gould, H. I Local somatic hypermutation and class 
switch recombination in the nasal mucosa of allergic rhinitis patients. 2003, J 
Immunol., 171,5602-5610. 
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Rhinitis Patients 
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Abstract 
Iminunoglobulin E is produced by nasal B cells in response to allergen. We have analyzed IgE VH region 
sequences expressed in the nasal mucosa of patients suffering from allergic rhinitis. VH region sequences 
were amplified by RT-PCR from IgE' B cells from nasal biopsies. In two out of six patients, sequence 
analysis clearly demonstrated the presence of closely related IgE' B cell clones; cells displaying identical 
'signature regions' across CDR3/FWR4, indicating a common clonal ancestry, but a mixture of shared 
and diverse somatic mutations across the VH region. Furthermore, in one of the two patients exhibiting 
related IgE' B cell clones, five IgA' B cell clones, related to the IgE' B cell family were also isolated 
from the patient's nasal mucosa. This evidence, combined with the local expression of mRNA transcripts 
encoding activation-induced cytidme deamukise, suggests that local somatic hypermutation, clonal 
expansion and class switch recombination occur within the nasal mucosa of allergic rhinitics. The 
presence of related B cells in the nasal mucosa does not appear to result from the random migration of 
IgE+ cells from the systemic pool, as analysis of a non-atopic subject with highly elevated senim IgE did 
not exhibit any detectable VH-C6 transcripts in the nasal mucosa. We have provided evidence that 
suggests for the first time that the nasal mucosa of allergic thinitics is an active site for local somatic 
hypermutation, clonal expansion and class switch recombination, making it of major significance for the 
targeting of future therapies. 
Introduction 
Allergic reactions occur mainly in the mucosal tissues of the respiratory tract, gut and sldn. Susceptibility 
at these sites is due to the presence of mast cells bearing the high-affinity inummoglobulin E (IgE) 
receptor, FccRI, sensitized by antibodies of the IgE class. Cross-linking of the receptors by allergen 
binding to IgE antibodies triggers immediate hypersensitivity. Mast cells in the nasal mucosa of patients 
with allergic rhinitis are sensitized by IgE antibodies that are produced locally by resident plastria cells 
(1). In an allergic individual, local IgE production persists for long periods in the absence of allergen, 
enabling an immediate response upon re-exposure to allergen. However, little is known about the history 
of the IgE-producing B cells, in particular when and where the precursor cells underwent class switch 
recombination (CSR)3 to IgE (involving rearrangement of the constant region genes encoding the various 
antibody classes, e. g. to C&) and affinity maturation by somatic hypermutation (SHM). 
Both SHM and CSR are stimulated by antigen in the germinal centres of lymphoid tissue (2), but it is 
becoming increasingly apparent that these processes may also occur locally at sites of chronic or recurrent 
antigen stimulation as has been clearly demonstrated for rheumatoid arthritis (3,4). In the local mucosal 
environment, signals to initiate SHM and CSR are available (5,6) as in vitro studies have demonstrated 
that, in the presence of antigart, T cells have the ability to induce SHM and CSR by the production of 
cytokines (such as EL-4) and also their interaction via CD40: CD404igand and CD80: CD28 with B cells 
(7). Evidence suggesting local CSR has been presented for IgA in the murine gut mucosa (8), for IgE in 
the human nasal mucosa of allergic rhinitics (9-11) and in the human lung mucosa in allergic asthma (12, 
13). Evidence for local SHM has been presented for IgE in the lung mucosa of an allergic asthmatic 
patient (13). We have examined the evidence for local SHM and CSR in six patients with allergic 
rhinitis. 
SHM results from the stepwise accumulation of predominantly single nucleotide substitutions into the V 
region DNA. This stepwise accumulation of mutations enables the genealogy of aB cell to be traced, 
relying on the unique complementarity determining region 3/framework region 4 (CDR3/FWR4) 'clonal 
signature' generated by the VDJ recombination of the progenitor cell. It is estimated that mutations are 
introduced at a rate of 10-4-10-3 per base pair per generation (14). A single mutation may bring about as 
much as a ten-fold increase in antibody affinity (14,15). Mutations are introduced at a high level across 
the CDRs but additionally the RGYW motif (where R=A or G, Y=C or T, W=A or T and G is mutated) or 
the reverse complement WRCY is a frequent target of mutation, particularly at the serine codons AGC 
and AGT (16). IMe molecular mechanism of SHM has not been fully elucidated, although errors are 
thought to be introduced by an activation-induced cytidine deammase (AID) and error-prone polymerase 
dependent process (17-19). Several DNA polymerases have been suggested as candidates, including 
DNA polymerasen, K, t and ý (20 - 23). AID has also been shown to be required for CSR (17,18). 
We present evidence generated by RT-PCR and DNA sequencing Of VH-C& sequences from the nasal 
mucosa of allergic rhinitis patients. Our work is the first to demonstrate in two allergic rhinitis patients 
the clear presence of related IgE' B cell clones in the nasal mucosa, B cells that exhibit shared ancestry 
Oudged by identical CDR3/FWR4 motifs) and both shared and diverse somatic mutations. In addition, 
detailed investigation enabled the detection of sequences from IgA* B cell clones from the nasal biopsy of 
one patient 7besc sequences exhibited shared ancestry and both shared and diverse somatic mutations 
with the related IgE+ B cell clones isolated from the same nasal biopsy sample. IgE VH-CH region 
amplification from the nasal mucosa of a healthy non-atopic subject with highly elevated serum IgE was 
negative, implying that the families of related clones seen in allergic patients were unlikely to have 
resulted from the random migration of IgE' B cells from a systemic pool. 
Furthermore, RT-PCR analysis demonstrated the presence of mRNA encoding AID in the nasal mucosa 
in five out of seven allergic rhinitis patients, the first reported instance of local AID expression in 
humans. We propose that local somatic hypermutation, clonal expansion and class switch recombination 
take place in the nasal mucosa of allergic rhinitis patients. We suggest that this local activity is 
fundamental to the pathogenesis of allergic disease. 
Materials and Methods 
Sampksftem aflergic rhiniMpatients 
Male and female donors between the ages of eighteen and fifty-five were recruited from the Royal 
Brompton Hospital Allergy Clinic or by advertisement in the local press. None had received 
immunotherapy and any medication was discontinued at least two weeks before nasal biopsy. Biopsies 
were performed at the Royal Brompton Hospital with the approval of the local Ethics Committee and the 
patients' written informed consent. The allergic status of the donors was assessed by medical history, 
skin-prick tests and serum allergen specific IgE (RAST). Six patients who exhibited a total IgE of over 
200 IU/ml were selected for the study Of VH-CF- transcripts. Biopsies were taken according to a previous 
detailed protocol (24) in which a 2.5 MM3 biopsy was randomly taken from the under surface of the 
inferior turbinate, behind the antenor insertion into the lateral wall of the nose and 8-10 cin distal to the 
nearest lymphoid tissue, Waldeyer's ring in the pharynx The random nature of the biopsies prevented 
the sampling of any defined cell populations from within the inferior turbinate. Biopsies were placed in 
1.5 nd Hank's balanced saline solution (GibcoBRL) and washed to remove blood before being transferred 
to a cryotube and snap frozen in liquid N2 before being stored at -70'C. 
25 in] blood was taken from each patient and PBMC isolated by Ficoll-Paque density gradient 
centrifugation. The PBMC pellet was snap-frozen and stored at -70T. The samples were treated to 
extract RNA and manufacture cDNA as for the tissue samples, with the exception that I ml RNAWIZ 
buffer was added to the PBMC pellet (ca. 4x 10' cells) and the cells resuspended by pipetting before 
dividing into four 250 0 aliquots, one of which was used for future molecular analysis. 
Sawksftom the non-oopic sst*ct 
A healthy 55 year old male was recniited with no previous medical history of any allergic symptoms and 
a negative skin-prick test and RAST for all common allergens (a slightly raised RAST of 0.71 IU/ml 
(normal <0.35 TU/n-d) was detected for Aspergillusfimigatus). No other abnormal medical conditions 
were reported although the subject's total senun IgE was 1834 IU/ml. A nasal biopsy and PBMC sample 
were taken according to the protocol above. 
Amplification of GAPDH from the samples utilised the following PCR method; 5 pl of cDNA was added 
to a 50 ýd PCR reaction, which included both a GAPDH forward and reverse primer each at I ýLM 
(GAPDH forward; 5'- AT17GGTCGTATTGGGCGCCTGGTC-3', GAPDH reverse; 5'- 
TCATACTTCTCATTGTTCACACCCATG-3'), dNTP's at 0.25 mM and included 1.26 U Pfu DNA 
polyinerase (Promega). The reaction was initially denatured at 95"C for 2 min, then subjected to 30 cycles 
of denaturation at 940C for I min, annealing at 590C for 2 min, and extension at 720C for 2 min before a 
final extension at 720C for 10 min. 
RIVA adradion 
Biopsies were transferred to an RNase-free tube and homogenized in 250 0 RNAWIZ buffer (Ambion) 
with 300 vigorous pulses using an Eppcndorf homogeniser (Anachem). Total RNA was extracted from 
each sample according to the manufacturer's protocol and re-suspended in 20 0 RNase-free water. The 
concentration of RNA was determined from the absorbance at 260 nm. 
RT-PCR of VH-Celraptscripts 
5 ýLg RNA was included in a 40 0 cDNA reaction with M-MOLV Reverse Transcriptase (Gibco BRL) 
using an ofigo dT primer (Gibco BRL). 50 of cDNA was added to a 50 0 PCR reaction, which 
included each VH leader region class-specific primer at 0.5 pM (VHIL-VH6L) and the CE I specific primer 
(C61) at 0.5 pIA dNTP's at 0.25 mM and contained 1.26 U Pfu DNA polymerase (Promega). The 
reaction was initially denatured at 951C for 2 min, then subjected to 30 cycles of denaturation at 94*C for 
I min, annealing at 56*C for 2 min, and extension at 72"C for 2 min before a final extension at 721C for 
10 min. 5 RI of the first PCR reaction was then transferred into a second nested PCR, which differed only 
in that it included VH class-specific primers homologous to FWRI (VHIF-VH6F) and an internal Cel 
primer (CE: 2). This reaction was incubated with an initial denaturation at 951C for 2 min, then 30 cycles 
of denaturation at 941C for I min, annealing at 65*C for 2 min, extension at 72*C for 2 min, then a final 
extension at 721C for 10 ' 
Tlie PCR for amplification of the separate VH classes of the V, -Ce transcripts in the PBMC of the non- 
atopic subject GJ29 employed the same conditions as above, using the appropriate VH primer in each 
reaction. 













(Based on VH region primers published previously (25,26)) 
Cs 1: 5'-TGTCCCGTrGAGGGAGCCTGT-3'; 
Cc2: 5'-GGGTCGACAGTCACGGAGGTGGCATT-3', 
(Based on Ce primers published previously (27)) 
RT-PCR of VH-CA VH-Ca and Vff-Cytranscripts 
PCR amplification of sequences from lgM+, IgG'- or IgA+ B cells was carried out as separate reactions 
based on a multiple step PCR published previously (28,29). 
PCR I 
The initial nested PCR was carried out as for the amplification of VH-Cs except that only the VH region 
primer specific to the VH class of interest was used; e. g. reaction I utilised VH51, in conjunction with each 
of the individual outer CH primers (CýLl, Ca I or Of 1). All other conditions remained the same as those 
specified above for IgE and the reaction denatured at 95*C for 2 min, followed by 30 cycles of 
denaturation at 940C for I min, annealing at 560C for 2 min, extension at 721C for 2 min and a final 
extension of 72T for 15 * 
PCR 2 
Reaction 2 of the nested PCR for amplification of sequences from IgM+, IgG+ or IgA' cells utilised an 
inner VH5 primer, VH5Fm, with each of the inner CH primers (Cp2, Coc2 or Cy2) to further amplify the 
VH5-CH sequences. All other conditions remained the same except initial denaturation was carried out at 
95'C for 2 min, fol-lowed by 30 cycles of denaturation at 941C for I min, annealing at 54*C for 2 min, 
extension at 721C for 2 min, then a final extension at 72'C for 15 min. 
The PCR products from each second PCR were subjected to electrophoresis on a 1% agarose gel and the 
DNA excised. 50 of the gel extracted PCR product was carried forward into a third, semi-nested PCR 
for each isotype. 
PCR 3 
Reaction 3 was semi-nested, utilizing the gel extracted PCR 2 products with the inner of each set Of CH 
primers and a CDR3/FWR4 primer specific for each clonal family (e. g. B16V5 specific for the SO 16 VH5 
family) to amplify from CDR3 to the 5' Of CH. The conditions for PCR 3 were as detailed above except 
the initial denaturation 951C was for 2 min, then 20 cycles of denaturation at 940C for I min, annealing at 
53'C for 2 min, extension at 720C for 2 min, and a final extension at 720C for 15 min. PCR products 
were cloned and sequenced as below before proceeding to the following stage. 
PCR 4 
In order to obtain the VH region sequences from specific IgA clones, 50 of the gel extracted PCR 2 
products was used in the semi-nested reaction 4 with conditions as for the previous reactions, except for 
the use of the VH5Fm. primer and S016A4 (specific for the D-J junction of the family) with initial 
denaturation at 950C for 2 min, then 20 cycles of denaturation at 94*C for I min, annealing at 541C for 2 
min, extension at 72"C for 2 min, and a final extension at 720C for 15 min. 
PCR 5 
An additional experiment was carried out to re-amplify the complete sequence of the VH5-IgA clone I 
from CDRI in the VH region through the D and JH region to CoL (previously only analyzed by PCR 3 and 
4 generating different Eragments of the fidl sequence). 'Me semi-nested PCR 5 included; 50 of the gel 
extracted PCR 2 products with conditions as above, except that the specific CDRI primer (Bl6V5CI) 
was used in conjunction with the inner Ca primer. The reaction was then incubated for an initial 
denaturation at 950C for 2 min, then 20 cycles of denaturation at 94'C for I rnin, annealing at 530C for 2 
min, extension at 72T for 2 min, and a final extension at 720C for 15 min 












RT-PCR ofAID transcrip& 
To amplify AID mRNA transcripts by RT-PCR, cDNA was manufactured from nasal biopsy samples 
taken from seven allergic rhinitis patients as above. 50 cDNA was added to each 25 0 PCR reaction, 
which included the forward primer AIDIP at 0.2 pM and the reverse primer AID2P at 0.2 gM, dNTP's at 
0.2 mK MgC12 at I mM and included 1.25 U Platinum Taq DNA polymerase (Invitrogen). The reaction 
was initially denatured at 94*C for 5 min, then subjected to 30 cycles of denaturation at 940C for I min, 
annealing at 56"C for I min, and extension at 72*C for 2 min before a final extension at 72*C for 5 min. 
50 of the first PCR reaction was then transferred into a second PCR, which differed only in that it 
included an inner forward primer AID3P at 0.2 pM and an inner reverse primer AID4P at 0.2 pM. This 
reaction was incubated with an initial denaturation at 94C for 5 min, then 30 cycles of denaturation at 
94'C for I min, annealing at 60"C for I min, extension at 720C for 2 min, then a final extension at 721C 
for 5 min. 
Details of the primers are as follows; 
AIDIP: 5'-GAGGCAAGAAGACACTCTGG-3' 
AID2P: 5'-GTGACATTCCTGGAAGTTGC-3' 
(Based on AID primers published previously (17)) 
AID3P: 5'-TAGACCCTGGCCGCTGCTACC-3' 
AID4P: 5'-CAAAAGGATGCGCCGAAGCTGTCTGGAG-3' 
(Based on AID primers published previously (32)) 
Cloning and sequencing of PCRproducft 
All PCR reaction mixes were subjected to electrophoresis on 1% agarose gels except for the Cý4 Qx and 
Cy PCR products from reaction 3 and the AID PCR products which were subjected to electrophoresis on 
2% or 1.5% agarose gels, respectively. Bands of the appropriate size were gel purified (Qiagen) and 
cloned using the Zero Blunt TOPO PCR Cloning Kit (Invitrogen). EcoRl digests confirmed the presence 
of the cloned insert and subsequent minipreps; were sequenced using M13F or M13R primers (Molecular 
Biology Unit, KCL, UK and ABC Sequencing Service, IC, UK). 
Identification of sequences 
Assignment of VH, D and JH genes and their somatic mutations was carried out according to their 
homology with the germline sequences detailed on the VBase database (www. mrc:: gRg. cam. ac. uk . The identity of aD gcnc given a score of less than 50 by VBase was regarded as undefined (where +5 is 
awarded for a nucleotidc match and -4 for a mismatch). Where the alignment of the VH and D gene or D 
and JH were seen to overlap, precedence was given to VH and JH so that a truncated D gene sequence was 
presented. The CDR3/FWR4 region of each sequence was used to determine clonality. Genealogical 
trees were constructed based on the premise that shared mutations were acquired early, and individual 
mutations acquired later in the evolution of the clone. Antibody isotype and AID sequence homology 
was established using the NCBI BLAST program (http: //www. ncbi. nlm. nih. gov/BLASl). 
Results 
VH sequence analysis and IgE* B cell clonaI4 
We have analyzed VH-C6 sequences from the nasal biopsy samples of six patients (five multiallergics and 
one grass pollen monoallergic), characterized by skin-prick test, RAST and a medical history of allergic 
rhinitis for at least two years (Table 1). The selected patients exhibited serum IgE levels >200 IU/n-d to 
ensure success in RT-PCR amplification of VH regions (27,33). Fifteen sequences were analyzed from 
the nasal biopsy samples of each patient 
INSERT TABLE I 
All samples were PCR amplified using Pft DNA Polymerasc, which exhibits a proof-reading ability 
resulting in a very low experimental error rate compared to other DNA polymerases. The experimental 
error rate generated in our system of nested RT-PCR amplification was determined to be approximately I 
in 4720 bp, the equivalent of I mutation introduced experimentally in approximately every 17 VH region 
sequences amplified in this manner. Experimental error rate was determined by analysis of the number of 
mutations introduced into the Cc DNA amplified by the VH-Cs PCR (data not shown). 
Initial analysis of VH-Cz sequences generated by RT-PCR demonstrated that we were able to detect all 
VH gene families with the exception of VH2, one of the most infivquendy expressed VH gene families 
(34). VH, D and J genes were assigned using the VBase database (www. mrc: M. cam. ac. uk , allowing 
mutations from the germline to be identified. 
VH-C8 sequences containing mutations from the germline that followed the expected trends of SHM were 
isolated from all nasal biopsy samples (Table H). Multiple copies of identical sequences were isolated 
from all samples. All sequences contained in-framc rearrangements, implying successful translation of 
mRNA into IgE protein. 
INSERT TABLE H 
Detailed analysis of VH region sequences sharing identical CDR3/FWR4 regions was carried out in each 
sample, allowing the construction of families of clonally related IgE' B cells (nucleotide sequences 
submitted to EMBL, accession numbers AJ491904 - AJ491915). Due to the experimental error rate in 
our system, two families (each comprising only two B cell clones) were discarded on the basis that the 
single mutations linking each of the related clones may have been experimental artefacts. When PBMC 
from each of the patients was analyzed (and three small families, again, each comprising two clones 
linked by a single nucleotide difference, were discarded) only two distantly related B cell clones were 
detected (from patient HDI7, who exhibited the highest total serum IgE of all the patients) and which 
differed by nineteen VH mutations, four D and one JH mutation while still exhibiting clear homology 
across the 'signature region' (data not shown). 
Clear evidence of clonally related IgE+ B cells, closely linked by multiple differences in their VH 
mutations, was however evident in two of the six nasal biopsy samples analyzed (patients S016 and 
AP19). Sequences suggesting two families of related IgE+ B cell clones were isolated from SO 16. One 
family of B cell clones expressed a VH3 gene and comprised three B cell clonal members (of which one 
was a hypothetical intermediate, not isolated experimentally). The other fiunily of B cell clones isolated 
from S016 expressed a VH5 gene and comprised four B cell clones, of which one was a hypothetical 
intermediate. The aligrunent of these related clones (Fig. 1) enabled the formation of 'genealogical trees', 
demonstrating the clonal relationships between the B cells (Fig. 2). In only one instance, did sequence 
data suggest the presence of an IgE+ B cell clone in the PBMC that was distantly related to B cell clones 
detected in the nasal mucosa (one clone from the PBMC of SO 16 shared five mutations and the same VH- 
D-JH rearrangement (data not shown) with the family of VH3 IgE' B cell clones depicted in Fig. 2 A). 
IdentWation of related JgE and IgA B cell clones in the nasal mucosa 
Further investigation of patients S016 and AP19 was undertaken to determine whether sequences from 
cells related to the families of IgE' B cell clones, but which expressed isotypes other than IgE could be 
detected in the nasal mucosa. A three-stage PCR approach based on that documented previously (28,29) 
was utilised to achieve this, using a nested reaction (PCR I and 2) to amplify VH3 or VH5 sequences from 
either IgM, IgG' or IgA` B cells in each sample. The third PCR reaction in each case utilised a semi- 
nested approach using a forward primer specific for the clonal 'signature region' (VH-D junction) of 
interest, combined with the inner set of primers for IgM, IgG or IgA. 
No sequences suggesting the presence of B cell clones of arty other isotype related to the VH3-Cc family 
from S016, or the VH5-Ce family from AP19, were detected. In contrast, successful amplification of a 
'signature region' from an IgA2 B cell related to the VH5 family of IgE' B cell clones was isolated from 
the nasal mucosa of patient S016 (Fig. 3A) (nucleotide sequence submitted to EMBL, accession number 
AJ491916), indicating the presence of at least one IgA2' B cell sharing a common ancestry with the 
previously isolated family of IgEý- B cells. 
Another, separate, semi-nested PCR (PCR 4) was used to amplify the ftdl VH region sequence from the 
related IgA' B cell(s) from which the signature region had been amplified in PCR 3. Sequences were 
detected from five IgA' B cell clones that were related to each other and to the IgE+ family of B cell 
clones and which exhibited a complex pattern of shared and unique somatic mutations throughout the full 
length of the VH region sequence (nucleotide sequences submitted to ENML, accession numbers 
AJ536081 - 5). These sequences were aligned and homology with the sequences from the related IgE' B 
cell clones, also isolated from the nasal mucosa of patient SO 16, could clearly be seen (Fig, 3 B). 
In order to eliminate the possibility that the IgA clones were PCR artifacts (unlikely as both the shared 
and diverse mutations were dispersed throughout the VH region), we successfully re-amplified in PCR 5 
the complete VH-D-JH-C(x2 sequence 3' of CDRI from the IgA clone CI that had previously been 
partially amplified by PCR 4 (nucleotide sequence submitted to ENML, accession number AJ536086) 
(data not shown). Both the signature region and the somatic mutations were identical to that amplified 
previously, confirming that the sequences presented here were unlikely to be PCR artifacts. 
VH-Ce sequences were not isolatedfirom the nasal mucosa of a non-atopic subject with highly elevated 
serum JgE 
In order to investigate whether random migration of IgE' B cells from the circulation to the nasal mucosa 
occurs in subjects exhibiting high systemic IgE levels (a possible explanation for the presence of related 
B cell clones seen in the nasal mucosa. of allergic rhinitis patients), a nasal biopsy was taken from non- 
atopic healthy subject GJ29 who exhibited extremely elevated senun IgE (total senim IgE = 1834 IU/nil). 
No VH-CF- sequences could be isolated from the nasal biopsy sample (Fig. 4A), although the nasal biopsy 
exhibited a strong GAPDH signal (Fig. 4C) and VH-C14 VH-Ca, and VH-Cy PCR products, corresponding 
to IgK IgA and IgG' B cells respectively, could be amplified from the sample (data not shown). In 
addition a strong IgE sigrial was obtained from PCR amplification of IgE VH regions from the subject's 
PBMC (Fig. 4A). When VH-Cc transcripts from the subject's PBMC were amplified using primers to 
amplify the different VH class in separate reactions, the subject's IgE was shown to be comprised of B 
cells expressing VHI, VH3, VH4, VH5 and VH6 (Fig. 4B), thereby demonstrating that the repertoire of IgE* 
B cells in the PBMC was diverse and that a mono / oligoclonal lymphoproliferative disorder did not 
account for the subject's raised total serum IgE. 
Local AID mRIVA tramwripts in the nasal mucosa of aHergic rhimids padents. 
In order to investigate the presence of local All) mRNA transcripts in allergic rhinitis, a nested PCR 
technique was applied to nasal biopsy samples from seven patients. Two of these samples (CMIO and 
AP19) had also been used in the VH-Cs transcript analysis (restricted sample size unfortunately prevented 
the analysis of the other five nasal biopsies on which VH-C6 analysis had been carried out). All of the 
patients in which AID analysis was studied were either biopsied within the grass pollen season or suffered 
from perennial allergic rhinitis. When the PCR products were subjected to agarose gel electrophoresis, 
AID mRNA was shown to be present in the nasal mucosa of five of the seven patients (Fig. 5). The PCR 
products were confinned by Southern blot analysis using a probe that spanned exon 3 and 4 (data not 
shown). 
Discussion 
Allergic rhinitis is increasingly prevalent in the Western world. Studies at the molecular level have 
enabled the investigation of IgE-mediated immediate hypersensitivity at specific locations. Previous 
work has demonstrated the occurrence of local IgE protein production in the nasal mucosa of patients 
suffering from allergic rhinitis (1), but no PCR based investigation has been undertaken until now to 
determine whether DNA class switch recombination to generate B cells committed to IgE synthesis and 
concurrent somatic hypermutation also occur locally in the nasal mucosa of allergic rhinitis patients (as 
has been shown for the asthmatic lung mucosa (13)). These processes are potential therapeutic targets. 
In order to investigate whether local CSR and SHM occur locally in the nasal mucosa of allergic rhinitis 
patients, we have amplified IgE' VH region sequences by RT-PCR from the nasal mucosa of six allergic 
rhinitis patients. These sequences have provided clear evidence of families of closely related IgE' B cell 
clones in the nasal mucosa of two of the six patients. This was in stark contrast both to the one instance 
in which two very distantly related IgE' B cell clones were isolated from the PBMC of one patient and 
the one instance in which an IgE' clone from the PBMC was found to be distantly related to a family of 
IgE' clones from the nasal mucosa (possibly resulting from the diffusion of related cells from lymphoid 
tissue prior to SHM and clonal expansion in the nose, or from the nasal mucosa into the circulation). 
Each family of related B cell clones originate from a common precursor B cell that proliferated and was 
subjected to differing extents of SHM. We propose that the occurrence of local SHM and subsequent 
clonal expansion is a likely explanation for the presence of these families of closely related IgE* B cell 
clones in the mucosa, rather than the migration of all members of each family of related B cell clones 
from lymphoid tissue to the same location in the nasal mucosa. 
Additional evidence supporting the theory of local events in the nasal mucosa was provided by the further 
investigation of patient SO 16. Sequences were identified from five different IgA' B cells that exhibited 
identical CDR3/FWR4 'clonal signature' regions to those from the IgE' family of related B cell clones 
also isolated from the same nasal biopsy sample. These IgA sequences exhibited a range of mutations 
shared with and also different from the IgE sequences-. - Again, it is unlikely that these IgA' cells were 
derived from CSR in lymphoid tissue and that they then homed to the same 2.5 mm3 of nasal mucosa as 
the related IgE' B cells. Detection of related IgE' and IgA' B cell clones instead implies that it is more 
likely that the different antibody isotypes were generated by local CSR as has been previously suggested 
in the lung mucosa of allergic asthmatics (13). 
Further studies were carried out in order to investigate the origin of the related B cell clones observed in 
the nasal mucosa of the allergic rhinitis patients. Analysis of a healthy non-atopic subject with highly 
elevated IgE indicated that whereas (as expected) a strong RT-PCR product resulted from the 
amplification of IgE VH regions from the subject's PBMC, no IgE VH region sequences could be isolated 
from the subject's nasal mucosa sample even though a positive GAPDH signal could be amplified and VH 
region sequences from other isotypes were detected. This suggests that a high level of sentin IgE (from 
multiple different IgE' B cell clones) does not automatically result in the random migration of IgE' cells 
to the nasal mucosa, although it is possible in allergic rhinitis patients that specific cell recruitment takes 
place. 
AID expression has been shown to be associated with both CSR and SHM (17,18). The presence of AID 
in the nasal mucosa might therefore be expected if the local microenvironment supported CSR and SHM. 
We detected AID mRNA transcripts in the nasal mucosa of five out of seven allergic rhinitis patients, 
demonstrating for the first time the presence of AID mRNA transcripts in local human tissue and 
strengthening the suggestion of local CSR and SHM in the allergic nasal mucosa. Unfortunately, 
restricted sample size meant that we were only able to analyse AID mRNA expression from two of the 
samples used for VH-C& analysis, CMIO and AP19. Interestingly, All) expression was clearly detected 
in CMIO (in which no reliable evidence of related clones was detected), but was not detected from the 
nasal biopsy AP19 from which a family of related IgE+ B cell clones was detected. It is therefore 
possible that the local activity in AP19 had ceased and that AID expression had subsequently been down- 
regulated, while the related B cell clones remained. 
This investigation is the first to demonstrate the presence of local families of closely related B cell clones 
in the nasal mucosa of allergic rhinitis patients and to provide clear molecular evidence for the occurrence 
of localized AID mRNA expression and indirectly, evidence of local SIHM, CSR and clonal expansion in 
an area of the nasal mucosa distant from lymphoid tissue. In addition, we suggest that while the presence 
of related B cell clones in two out of six nasal biopsy samples and of AID in five out of seven samples is 
of importance in itself, it is likely that the nasal biopsy samples that appeared negative for related B cell 
clonal families may have done so as a result of sample variation: It is likely that related B cell clones in 
the nasal mucosa of allergic rhinitis patients are located in clusters, as observed by immunohistochernical 
staining of CD19' B cells from nasal biopsy sections. Our preliminary analysis of adjacent halves of a 
biopsy has suggested that clonal families are highly localized within the mucosa (Coker et al., 
unpublished observations). Our inability to take more than a single biopsy at any one time from a patient 
for ethical reasons implies that such clusters may be excluded by the nature of the random sampling of 
approximately 0.1% of the inferior turbinate; each turbinate is on average 10 g, and each nasal biopsy, on 
average, 10 mg. 
While this is the first study to investigate the local environment of the nasal mucosa in this number of 
patients, a previous study being restricted to just two lung biopsies from a single asthmatic patient (13), 
we suggest that it is highly significant that in many respects a consistent pattern of results is emerging in 
comparison with that observed in the allergic asthmatic lung (13). Our results additionally describe 
analysis of the VH region repertoire of the nasal mucosa of a healthy non-atopic patient with high 
systemic levels of IgE, but no detectable local mRNA encoding IgE, suggesting that IgE' B cells do not 
randomly migrate to the nasal mucosa from the circulation. We therefore conclude that the cells in the 
nasal mucosa of allergic rhinitis patients are stimulated with allergen, undergo class switch 
recombination, somatic hyperimitation and expand locally in the presence of AID. Our data strengthen 
the argument that the mucosa acts as a microenvironment in which cells from the immune system direct, 
process and remove antigen in a localized manner and we suggest that this is fundamental to the 
pathogenesis of allergic disease. 
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Table 1: Patient's clinical and experimental data. 
NUMBER OF B CELL 
PATIENT STATUS TOTAL SPECIFIC ALLERGIESc FAMILIES (NUMBER OF NUMBER OF V REGION 
AT SERUM 19E (IU/mIf MEMBERS ISOLATED FROM SEWENCES ANALYZED 
BIOPSY a IgE (IU/ml) EACH CLONAL FAMILY) IN 
NASAL BIOPSY 
J57 o/p 236 G=9.25 HDM, G, C. D. 15 
C--11.1 CL 
cmio O/P 382 HDM-1.09 HDM, G, M, T. 15 
C>3.36 5, C, D, H, CL 
G=101 
HD14 UP 787 HDM=2.68 HDM, G 15 
G-101 
S016 I/p 514 G-101 0, T, B. D. 2(2.3) 15 
MD17 1 2745 G=101 G- 15 
AP19 UP 414 HDWI. 23 HOM, G, C, D. 1(3) 15 
C=32.10 H, CL 
G-60.20 
GJ29 Non- 1834 AF--0.71 - - 
atopic 
') In-season (1), Out-of-season (0), Perennial (P) 
b) Determined by RAST for the allergens; House dust mite (HW, Gress (G), Cut (C), Dog (D), Tree (T). A*efgMW Amnoetus (AF) 
c) House dust mite (HDPA, grm pollen (G), mugmrt M, three trees (T), silver birch (B), cut (C), dog (D), home (H), AspeWkj3 Awilgetus (AF), 
CkKbspodum herberum (CL), Alkwnatfa allernate (A), determined by sidn-prick test 
Table 11: VH region sequences isolated from IgE+ B cells in the nasal mucosa of allergic 
rhinitis patients. 
PATIENT SEQUENCE GERMLINE VH GENE WITH % MUTATION FROM NUMBER OF TIMES 
GREATEST HOMOLOGY4 GERMLINE ISOLATED 
JB7 B7C14 1-46 22.7 1 
B7C9 3-23 5.5 1 
B7Cl7 3-74 4.8 8 
B7C22 4-04 7.3 5 
cmio BlOC7 3-30 / 3-30.5 2.9 1 
BlOC13 3-30/ 3-30.5 4.4 1 
Blocl 3-66 10.9 1 
BIOC2 3-66 10.7 12 
HD14 B14C16 1-02 5.9 1 
B14C9 3-15 9.9 1 
B14C4 3-30 11.0 1 
B14C2 3-30 7.0 8 
B14Cll 4-59 6.4 1 
B14CI9 5-a 4.5 1 
B14C7 5-51 7.4 1 
BUC12 5-51 4.8 1 
S016 B16C12 3-20 3.3 2 
BIBCIS 3-23 1.8 1 
13=2ý 3-30 4.1 1 
Blace 3-30 5.2 2 
816clo 3-33 5.6 2 
Bleci 3-65 ND 1 
BlOC13 4-M 3.7 1 
B16C5 5-51 2.9 1 
B16C8* 5-51 8.5 1 
B16Cll* 5-51 7.7 1 
B16C14* 5-51 7.7 2 
HD17 B17C13 "9 4.8 1 
B17Cl 3-30 9.6 1 
B17C16 4-ND 12.1 1 
B17C9 4-30.1 / 4-31 8.4 1 
B17C37 4-30.1 / 4-31 8.8 1 
B17C15 4-30.2 7.7 5 
BI 7C31 4-30.2 8.5 3 
Bl 7C32 4-59 5.6 1 
B17C7 7-04.1 3.7 1 
AP19 B19C16 1-18 2.2 1 
BIQC6 4-04 5.2 1 
B19C3 4-30.1 / 4-31 2.5 2 
B19C2$ 5-51 7.1 8 
B19C4$ 5-51 6.4 1 
B19CS 5-51 ND 1 
B19Cl4$ 5-51 7.5 1 
') - VH gene locus detailed such that 5-51 denotes a VHS gone 
ND -Not determined 
., * and $ denote members of each IgE* B cell clonall family 
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Fig. L Alignment of VrD-J sequences amplified by RT-PCR from the nasal mucosa of allergic 
rhinitis patients S016 and AP19 indicated the prcwnCe of clonally related IgE' B cells. Sequences 
are detailed such that e. g. sequences isolated from AP19 have closest homology with the germline 
sequence of a VH gene from the VH5 family, locus 5-51 (VH5-51), the D gene DI-26 and the JH gene 
JH3b. CDR regions are indicated and PCR primer regions underlined. Mutations in the primer regions 
were not included. (Although the D1 -26 gern-dine sequence in reading frame 2 used in AP 19 encodes a 
stop codon, denoted with an asterisk, the non-temPlated insertion between the VH and D gene are such 
that rearranged sequences demonstrate an open reading frame. ) CDR regions are indicated and PCR 
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Fig. 2. Sequences isolated from related IgE+ B cell clones amplified from the nasal mucosa enabled 
the construction of genealogical trees for allergic rhinitis patients A) S016 and B) AP19. The 
closest gem-dine gene homology is depicted at the top of each tree in a box. Sequences isolated from 
clones are depicted in an oval. Hypothetical intermediates are denoted with X. Mutations are detailed 
such that 27(3) represents a single nucleotide substitution occurring at codon 27, nucleotide 3. Each 
family is detailed such that sequences isolated from AP19 have closest homology with the germline 
sequence of a VH gene from the VH5 family, locus 5-51 (VH5-51), the D gene DI-26 and the JH gene 
JH3b. 
ý3 






























i yyyy iy 
Zia aZ, Zi io ous Zia 85, U-,: maI Stsf4st 
1411410: 
sss 
Fig. 3. Alignment of the signature region and VH-D-Ji sequence RT-PCR amplified from related 
IgE+ and IgA+ B cell clones from the nasal mucosa of allergic rhinitis patient S016. The signature 
region sequence (which was joined to the 5' of the IgA2 CH region) generated by PCR 3 and also the 
corresponding VH-D-JH sequences from the related IgA clones (amplified by PCR 4) are both detailed, as 
the join to IgA was only explicit in the signature region sequence. A) An identical signature region 
sequence was amplified by PCR 3 from both IgE and IgA2 B cell clones. Sequences had greatest 
homology with the germline VH5 gene V5-51, D4-17 and JH4b (positions indicated). Primers used in 
PCR 3 are marked in bold and regions of homology between the sequences are denoted with vertical 
lines. B) The VH region sequences of the related IgA clones amplified by PCR 4 were aligned with the 
related IgE clones and exhibited both shared and unique VH region mutations. The sequences had 
greatest homology with the germline VH5 VH gene V5-51 and D4-17 (indicated). The JH gene JH4b was 
only partially amplified and was completely encompassed by the primer region. Primer regions are 
underlined. Mutations in the pruner regions were not included. 
A) 1234 












Rg. 4. VH-D-J-Ce regions were RT-PCR amplified from the PBMC but not the nasal mucosa of a 
non-atopic subject with highly elevated levels of serum IgE. A) VII-D-J-0, RT-PCR products Nýcrc 
subjected to clectrophorcsis on a 1% agarose gclI- Lane 1,100 base pair DNA ladder (500bp indicated)-, 
Lane 2, non-atopic subject GJ29 nasal mucosa, Lane 3, non-atopic subject GJ29 PBMC Lane 4, negative 
control (no DNA). B) VH-D-J-Cc RT-PCR products from the individual VI, gene classes (VIj I- V116) 
from the PBMC of non-atopic subject GJ29 were subjected to c1cctrophoresis on a I% agarosc gel -, Lane 
1.100 base pair DNA ladder (500bp indicated)-, Lane 2, VIi I PCR products, Lane 3. VH2 PCR products', 
Lane 4. VH3 PCR products-, Lane 5. V114 PCR products. Lane 6. VH5 PCR products, Lane 7. V116 PCR 
products-, Lane 8, all classes Of VH PCR products, Lane 9, negative control (no DNA). C) GAPDH RT- 
PCR products were subjected to electrophoresis on a 1% agarose gel-, Lane 1,100 base pair DNA ladder 
(500bp indicated), Lane 2. non-atopic subject GJ29 nasal mucosa, Lane 3, non-atopic subject GJ29 
PBMC, Lane 4, negative control (no DNA). 
234 
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Fig. 5. Amplification of AID mRNA transcripts by RT-PCR from the nasal mucosa of rive out of 
seven allergic rhinitis patients. AID RT-PCR products from the nasal mucosa of seven allergic rhmitis 
patients were subjected to electrophoresis on a 1.5% agarose gel, Lane 1,100 base pair DNA ladder 
(500bp indicated). Lane 2, patient CMIO; Lane 3, patient AP19, Lane 4, patient DR20, Lane 5, patient 
JH23: Lane 6, patient SJ24-, Lane 7. patient TL25, Lane 8, patient ZC27- , Lane 9, negative control (no DNA). The correct 335 bp AID RT-PCR product was observed in five of the seven samples. 
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